A feasibility study of a home-based exercise intervention for prostate cancer patients on androgen deprivation therapy by Santa Mina, Daniel
A Feasibility Study of a Home-Based Exercise Intervention for 
Prostate Cancer Patients on Androgen Deprivation Therapy 
Daniel Santa Mina (Sta-Mina) 
A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN 
PARTIAL FULFILMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
Graduate Programme in the 
School of Kinesiology and Health Sciences 
York University 
December 2012 
©Daniel Santa Mina, 2012 
Abstract 
Purpose: Androgen deprivation therapy (ADT) is an effective treatment for advanced-
stage prostate cancer. Unfortunately, ADT has several adverse effects that significantly 
impair health-related quality of life (HRQOL). In patients receiving ADT, resistance 
training has been shown to improve important physical and psychosocial outcomes. 
However, little is known about the effects of aerobic exercise in this population. This 
feasibility study compares the effects of aerobic and resistance exercise interventions on a 
panel of psychological, physical fitness, and biological outcomes related to prostate 
cancer and ADT. 
Methods: 66 men receiving ADT for prostate cancer were recruited for this prospective, 
randomized trial. Participants are assigned to either a resistance or aerobic, moderate-
intensity exercise 3-5 times per week for 30-60 minutes/session. Participants were 
provided with equipment so that they could exercise at home. The primary outcomes 
were related to feasibility for future, large-scale trials. Secondary outcomes included: 
fatigue, HRQOL, physical fitness, adipokines, insulin-like growth factor axis proteins, 
and exercise adherence. Outcomes were assessed at baseline and at 3, 6, and 12 months. 
Results: Preliminary findings are presented. 205 patients were approached for 
participation, 66 of which agreed to participate (n=34 in the resistance training group and 
32 in the aerobic training group). Over the intervention period we experienced an attrition 
rate of 33%. There were no adverse events and biweekly booster sessions were poorly 
attended (n=27 aerobic training participants and n=22 resistance training participants did 
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not attend any booster sessions). Intention-to-treat analyses showed that fatigue and 
HRQOL were not significantly different between groups; however, in a per-protocol 
analysis the resistance-training group demonstrated clinically significant improvements in 
HRQOL. Differential within-groups effects on physical fitness and biomarkers were also 
observed at various time-points. At all time-points, the aerobic training group engaged in 
significantly more physical activity than the resistance training group. 
Conclusion: Our findings suggest that both resistance and aerobic training can have 
positive effects on body composition with differential effects on psychosocial and 
biological outcomes. It appears that the aerobic exercise intervention was more effective 
at producing long-term, clinically significant increases in physical activity volume than 
resistance training. Our study has set the framework to conduct future clinical trials 
investigating the effects of exercise in men treated for prostate cancer. 
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1.0 Introduction 
Among Canadian men, prostate cancer (PCa) is the most common cancer 
diagnosis (excluding skin cancer) and the second leading cause of cancer-related death 
(1). While more than 80% of PCa diagnoses are in men aged 60 years or older (1), 
improved detection methods (e.g. prostate specific antigen testing) have progressively 
lowered the mean age of diagnosis and treatment (2, 3). Advances in PCa treatment and 
an increased survival rate (1) challenge clinicians to develop comprehensive treatment 
programs to maximize health-related quality of life (HRQOL) during lengthier 
survivorship periods. 
Many patients with locally advanced or metastatic PCa receive androgen 
deprivation therapy (ADT) because it increases survival when used alone ( 4), or 
adjuvantly with radiotherapy (5) or radical prostatectomy (6). Unfortunately, detrimental 
physical, functional and psychological effects are associated with ADT: including 
deleterious changes in haemoglobin (Hb) levels, thyroid functioning, cognitive 
functioning, body composition (decreased lean mass and bone mineral density and 
increased fat mass) (7-16) and, in some patients, cardiovascular function (17). These 
adverse effects collectively reduce HRQOL over the years of ADT, which are often the 
remaining years oflife (13, 18, 19). 
Fortunately, exercise interventions are associated with significant improvements 
in fatigue, physical fitness, and HRQOL in ADT-treated PCa patients (20-30). However, 
questions remain regarding the efficacy of different exercise modalities and program 
delivery strategies aimed at long-term exercise participation, such as: i) how to instil a 
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chronic change in exercise behaviour that overcomes the problem of discontinued 
exercise and consequential rapid loss of benefits (24, 31 ); ii) can home-based exercise 
programs be effective at improving essential elements of HRQOL given their inherent 
logistic strengths (low cost of participation, potential for long-term program adherence, 
reduced barriers to routine exercise); and iii) does aerobic exercise training (AET) confer 
equivalent effects to the more established modality of resistance exercise training (RET) 
when implemented in the home-based setting. Accordingly, the objectives of this study 
were to examine the feasibility of conducting a large-scale, adequately powered trial that 
would test the effects of six months of home-based AET versus RET in a randomized 
trial of ADT-treated PCa patients with a six-month post-intervention follow-up. 
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2.0 Background 
2.1 Overview of Prostate Cancer and Androgen Deprivation Therapy 
PCa is an androgen-dependent cancer, which means that malignant cell growth 
and proliferation relies on androgens, primarily testosterone and dihydrotestosterone 
(DHT) (32-34). Thus, the acute or chronic suppression of androgens is central to the 
management of locally advanced or metastatic PCa (35). ADT is commonly used as an 
adjuvant (and/or neo-adjuvant) therapy, in combination with radiation therapy or radical 
prostatectomy, to mitigate or respond to biochemical relapse (i.e. post-treatment increase 
in prostate-specific antigen) (5, 36, 37). ADT is increasingly used as a primary PCa 
management strategy (3 7, 3 8). Initially, orchiectomy (removal of the testes) was used as 
the primary type of ADT (39) but contemporary androgen suppression is primarily 
achieved pharmacologically through three pharmacological approaches: luteinizing 
hormone-releasing hormone (LHRH) analogues; androgen receptor blockers; and 5a-
reductase inhibitors (37, 40-42). Due to the numerous physiological roles of androgens, 
ADT has metabolic, musculoskeletal, and cardiovascular consequences (19, 43) that lead 
to an increased risk of developing diabetes, osteoporosis and cardiovascular disease ( 44-
47). 
ADT rapidly produces significant deterioration in healthy body composition by 
reducing bone and muscle, and increasing fat mass (36, 48, 49). As PCa is typically 
diagnosed in older men (often 65 years of age or older (1, 50)), ADT effects can 
accelerate and amplify age-related sarcopenia, osteoporosis, and general frailty ( 51). 
Such changes in body composition are overtly manifested as declining of physical fitness 
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and functional capacity (52, 53) to levels more comparable with men 10-20 years older 
(54). Moreover, poor cardiorespiratory and musculoskeletal fitness increases the risk of 
falls likely to produce fractures in these often-osteoporotic men (47, 55). This is of 
particular concern given the increased mortality risk of men with PCa who sustain a 
fracture ( 5 6). 
One of the more evident and distressing psychological/physical manifestations of 
ADT-related changes in physiology is fatigue (57-61). Stone et al (61) found that fatigue 
severity increased in almost 70% of patients 3 months after starting ADT, 14% of whom 
had severe fatigue. ADT-related fatigue is not well understood but may have several 
underlying physiological mechanisms, including anemia, reduced psychological 
vigor/vitality, and impaired functional capacity (36, 48, 61 ). Fatigue in ADT patients 
interferes with daily tasks and recreational activity that ultimately adds to the HRQOL 
reductions associated with PCa and its medical management. To optimize HRQOL in 
PCa patients receiving ADT, new strategies to maintain physical and mental capacity and 
to combat fatigue are needed. Exercise is an intervention with many demonstrated 
physical and psychosocial benefits in cancer survivors during and after therapy, including 
improvement in fatigue (62, 63). Recent evidence indicates that exercise is acutely (i.e. 
during the intervention period) effective in improving many facets of the ADT sequelae 
and enhancing overall HRQOL (20-25, 64-67). Research is specifically needed to assess 
which modalities are most effective and how exercise behaviour can be sustained to 
ensure that the acute benefits can be extended throughout the course of ADT and into 
post-treatment survivorship. 
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2.2 Exercise and Prostate Cancer 
2.2.1 Exercise, Physical Activity and Prostate Cancer Prevention 
The etiology of PCa is multifaceted and largely unexplained, but both modifiable 
and non-modifiable risk factors have been identified that alter disease progression. The 
most common non-modifiable risk factors are age, ethnicity, and family history (68, 69), 
while modifiable lifestyle risk factors include diet and obesity (70, 71 ), smoking (72), 
alcohol consumption (73), and sexual activity (74). A growing body of recent research 
has examined the influence of physical activity in PCa incidence that has demonstrated 
mixed results. To date, 22 cohort studies (75-95) and 10 case-control studies (96-105) 
have examined the relationship between PCa incidence and physical activity. Fifteen of 
these studies found a protective effect based on aerobic fitness (86), occupational 
physical activity (80, 85, 97, 98, 102, 106), recreational physical activity (76, 77, 82, 88, 
94, 105, 107), and both occupational and recreational physical activity (78). However, 15 
other studies have found no association between physical activity and PCa incidence (7 5, 
79, 81, 83, 84, 87, 90-93, 95, 96, 99, 102, 104) and four studies have found either an 
increase or possible increase in PCa risk with physical activity (89, 100, 101, 103). This 
inconsistency led the World Cancer Research Fund and American Institute for Cancer 
Research to conclude that a formal judgment on the relationship between physical 
activity and PCa cannot be made based on the current available research (108). 
Nevertheless, there appears to be a role for research that examines the effect of an 
exercise-based primary prevention strategy in this population. 
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Several criticisms of the epidemiological (pre-diagnosis/primary prevention) 
literature have been articulated; namely, that i) selection bias might be influential in much 
of this research since physically active men are more likely to be screened for, and thus 
diagnosed with, PCa (106, 109); and ii) given the latency and insidious nature of PCa, 
many men will die with, rather than from, PCa undermining some estimates of 
association between physical activity volume and PCa incidence as the subclinical 
diagnoses made at autopsy (if conducted) have not been included in these estimates 
(109). 
In terms of secondary prevention, only one study has assessed the relationship 
between physical activity and PCa survival. Kenfield et al (110) recently examined the 
effect of post-diagnosis physical activity on PCa-specific, and overall, survival in 2, 705 
men with non-metastatic PCa from 1990-2008 in the Health Professionals Follow-Up 
Study. In that study, the researchers collected self-reported physical activity information 
every two years and then reviewed diagnosis and cause of death information in patients 
who had survived for at least four years after recruitment into the study. The results 
demonstrated: i) a 51 % reduction in all-cause mortality with more than 10 hours of 
vigorous exercise per week versus less than one hour per week of non-vigorous activity; 
ii) a 3 6% reduction in all-cause mortality for those who walked more than seven hours 
per week versus less than 20 minutes per week, with additional risk reduction with brisk 
walking; and iii) a 49% reduction in all-cause mortality and 61 % reduction in PCa-
specific mortality for those vigorously active for more than three hours per week when 
compared with less than one hour per week. It is also worth noting that the authors of 
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this study indicate that for those men with~ 9 MET-hrs/wk compared to< 9 MET-hrs/wk 
had a hazard ratio of 0.65 (95% CI = 0.43 - 1.0). Thus a change of 9 MET-hrs/wk 
appears to be a reasonable estimate of clinical significance in this population. 
Furthermore, these effects were independent of pre-diagnosis physical activity volume 
suggesting that physical activity interventions following diagnosis may have a significant 
influence on life-expectancy for men with PCa. 
Proposed biological mechanisms for the decreased risk and/or attenuated 
progression of PCa with physical activity include a reduced exposure to circulating 
androgens, lower body fat and associated adipokines, improved immune system function, 
and improved antioxidant availability and function (111, 112). A series of studies 
investigating the effects of a low-fat diet and/or regular physical activity have suggested 
these healthy lifestyle modifications can elicit serum changes in vivo that can reduce in 
vitro cancer cell proliferation and increase the apoptosis of androgen-dependent cell lines 
(i.e. PCa cells that are responsive to ADT) (113-117). The protective effects of these 
studies are likely due to reductions in insulin and insulin-like growth factors (e.g. IGF-1) 
and anti-apoptotic proteins (Bcl-2), amidst concomitant increases in sex-hormone binding 
globulin, insulin-like growth factor binding protein-1 (IGFBP-1 ), and apoptotic proteins 
(p53 and p21) (116, 118, 119). Theoretical concerns of accelerating tumour growth due 
to transient increases in serum testosterone levels have not been borne out in exercise 
studies with PCa patients (21, 23, 120, 121). 
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2.2.2 Exercise during Treatment for Prostate Cancer 
Several studies have investigated the effect of exercise during PCa treatment (21, 
23, 24, 26-28, 30, 65, 66, 120-123) with additional publications pertaining to study 
protocols describing ongoing research (123-128). Table 1 shows a summary of exercise 
and physical activity trials in men after a PCa diagnosis. The first examination of 
exercise as a HRQOL and health optimizing strategy for PCa patients was conducted in 
2003 in response to observations of the numerous physical and psychosocial detriments 
associated with treatment (120). To date, several reviews of exercise interventions for 
PCa patients have been conducted (54, 129, 130). Thus far, exercise interventions have 
been essentially limited to PCa patients undergoing external beam radiation and/or 
androgen suppression (as detailed in subsequent sections). There is a noticeable dearth in 
the literature regarding the effects of exercise during other treatments for PCa, namely 
radical prostatectomy and chemotherapy. Only one trial has examined the role of 
exercise in 10 post-prostatectomy patients that were between 8-169 months post-surgery 
(27). In fact, postoperative exercise may be less appropriate to mitigate the effects of 
surgery than is preoperative exercise training, known as prehabilitation which has been 
shown to be effective in lung cancer (131, 132) and colon cancer patients (133). The 
investigation of exercise during chemotherapy is also particularly important because of 
the severe deconditioning effect on patients and long-lasting adverse effects of 
chemotherapy ( 134 ). Whether these elder patients on intensive chemotherapy regimens 
can endure routine exercise is still in question, but a growing body of literature suggests 
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that exercise is tolerable and beneficial during chemotherapy in several other cancers 
(135-142). The next two sections will focus on the literature that describes the effects of 
exercise on external beam radiation therapy and ADT. 
2.2.2.1 Exercise during Radiation for Prostate Cancer 
There have been three published trials investigating the effect of exercise on PCa 
patients undergoing external beam radiation. Windsor and colleagues ( 66) conducted a 
randomized controlled trial (RCT) that focused on the effects of a home-based, moderate-
intensity, walking program on PCa patients (n = 66) over four weeks of their radiation 
therapy. The intervention group exercised three times weekly for 30 minutes at 60-70% 
of the maximum heart rate. At the end of the intervention period, control participants 
reported increases in fatigue compared to baseline (p = 0.013), whereas fatigue scores 
remained unchanged for the exercise group (p = 0.203). Exercise improved physical 
functioning as measured by a modified IO-meter walking shuttle test (p = 0.0025). A 
100% self-reported adherence rate was noted; all patients in the exercise group reported 
at least 90 minutes per week of aerobic exercise. This excellent adherence rate is 
promising, but further studies with objective measures of physical activity participation 
(e.g. accelerometry) and longer-term follow-ups are required to demonstrate 
reproducibility and sustainability. 
Monga et al (65) conducted a RCT to examine the effects of an eight-week 
aerobic exercise program for PCa patients undergoing external beam radiation. 
Intervention participants (n = 11) were required to participate in supervised aerobic 
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exercise three times weekly, prior to treatment while control participants (n = 10) did not 
undergo any exercise. The exercise protocol consisted of 30 minutes of moderate-
intensity treadmill walking. Pre- to post-intervention improvements were observed in 
cardiovascular fitness (p < 0.001), lower extremity strength (p < 0.001), flexibility (p = 
0.006), depression (p = 0.02), fatigue (p = 0.02), physical wellbeing (p = 0.002), social 
wellbeing (p = 0.02), and overall HRQOL (p = 0.04). Compared to controls, exercising 
participants showed improvements in cardiovascular fitness (p = 0.006), lower extremity 
strength (p < 0.001), flexibility (p < 0.01), and reported less fatigue (p = 0.001), and 
better physical wellbeing (p = 0.001), social wellbeing (p = 0.002), functional wellbeing 
(p = 0.04), and overall HRQOL (p = 0.006). This was the first study to demonstrate 
improvements in fatigue and HRQOL with a supervised, aerobic exercise program for 
PCa patients undergoing radiation. Caution is required in interpreting results because of 
small sample size, potential for selection bias, and retention difficulties (approximately 
20% attrition). Intervention adherence was not reported. 
Segal et al (21) conducted a three-arm RCT of 121 radiation-treated PCa patients 
(74 of whom were receiving adjuvant ADT) that examined supervised 24-week RET or 
AET interventions versus wait-list controls. The AET group engaged in 15 to 45 minutes 
of moderate-intensity stationary cycling, treadmill, or elliptical machine exercise three 
times weekly. RET consisted of nine weight-training exercises using machines and free-
weights for one to two sets of 8-12 repetitions at 60% of the subject's one-repetition 
maximum ( 1 RM or the maximal weight or load that can be lifted once) three times 
weekly. Participants were instructed to increase their exercise load by five pounds when 
10 
they were able to complete more than 12 repetitions. An improvement in fatigue from 
baseline to 12 weeks was observed for both exercise groups compared to controls, but 
only the RET group showed less fatigue compared to the control group at 24 weeks 
(RET: p = 0.002; AET: p = 0.08). From baseline to post-test, the RET group showed 
improved aerobic fitness (p = 0.03 7) and upper/lower body strength (p < 0.001 ), while 
participants in the AET group demonstrated improved upper body strength (p = 0.006). 
A recruitment rate of 3 7% was noted for all eligible participants and the median 
adherence to the exercise program was 85.5% (as calculated by number of sessions 
attended/prescribed). In this trial three adverse events related to exercise were reported, 
one of which was serious (myocardial infarction) in the AET group following a training 
session on the third day of the program. The participant made a full recovery but did not 
complete the intervention. 
This group of authors continued their study of this cohort of participants by 
conducting two supplemental analyses. In the first (published as online additional 
content to the original paper), the authors examined the effect of the exercise 
interventions at 24 weeks, stratified by treatment (radiation ± ADT). Compared to 
control participants, the RET group on radiation only (n = 23) demonstrated 
improvements in fatigue (p = 0.004); cancer-related and disease-specific HRQOL (p = 
0.002 and p = 0.02, respectively), V02 peak (p = 0.037), and upper and lower body 
strength (p < 0.001 ). The AET group receiving radiation only (n = 25) only showed 
improvements in disease-specific HRQOL (p = 0.023). In participants receiving adjuvant 
ADT, RET (n = 17) showed improved upper and lower body strength (p < 0.001), and 
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reductions in body fat percentage (p = 0.005), whereas AET (n = 15) only improved in 
upper body strength (p = 0.02) when compared to controls. Although this analysis was 
exploratory and lacked adequate statistical power, the findings suggest that RET may be 
more beneficial than AET for men treated with radiation with and without ADT. These 
findings were confirmed in the authors' second ancillary analysis (separately published 
by Alberga et al (143)), in which they further stratified patients receiving ADT into age 
groups of :S 65 years ('younger') versus> 65 years ('older'). In this analysis, the authors 
found that younger men had significantly greater improvements in muscular fitness 
compared to control or AET participants, but no difference in body composition. 
Similarly, older men benefitted more from RET since they were the only group to 
improve body composition and muscular fitness over the course of the intervention. 
Most importantly, for men receiving radiation and ADT, only RET showed improved 
body composition and muscular fitness compared to controls. In men undergoing 
radiation only, only RET showed improved aerobic and muscular fitness. 
These findings from the Segal et al analyses (21, 143) underscore the importance 
of incorporating RET into a lifestyle/wellness program. However, there were 
acknowledged limitations to the analyses and interpretations. First, the authors noted the 
subgroup analyses were underpowered and that there was considerable variance within 
the sample in the duration of hormone suppression in ADT patients. This is important 
since previous research has shown that ADT duration for more than six months is 
associated with lower physical function and higher body fat percentage than PCa patients 
not receiving ADT or short term ADT (less than 6 months) (53). Second, although the 
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baseline differences were not statistically significantly different, there was a large 
difference in terms of lower baseline muscular strength for the RET group, particularly in 
lower extremity strength, compared to AET and controls (upper extremity strength (kg): 
RET = 49.5 ± 13.3, AET = 55.2 ± 13.3, Control= 53.4 ±J2.1; lower extremity strength 
(kg): RET = 104.7 ± 37.7, AET = 125.6 ± 55.8, Control = 117.4 ± 53.5). These 
differences were not observed for aerobic fitness (V02 peak (ml02/kg/min): RET = 28.19 
± 6.94, AET = 29.42 ± 6.5, Control = 28.78 ± 5.08) and may have been a factor that 
contributed to the lack of a significant between group effects in aerobic fitness observed. 
These findings are noteworthy for two potential reasons. First, RET participants who 
started with a lower level of muscular strength had a greater capacity for improvement 
(i.e. floor effect). Second, the novel nature of RET may make it a modality in which 
participants invest more time, focus, and energy during training. Together, these may 
explain why greater improvements observed in muscular fitness and body composition 
and the comparative absence of difference in aerobic fitness in the RET group. 
Unfortunately, only between-group comparisons of change from baseline, and not 
absolute values for post-test outcomes, were reported. 
2.2.2.2 Exercise during ADT for Prostate Cancer 
Despite the growth of exercise research in the primary/curative treatment setting 
for PCa, the majority of exercise intervention research has been predominantly conducted 
in patients with locally advanced, hormone-sensitive metastatic disease treated with ADT 
(20-25, 67). Given the detrimental effects of ADT on physical function and fatigue from 
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prolonged hypogonadism (described earlier), it is fortunate that exercise appears to 
mitigate ADT-related adverse effects. The typical chronic duration of hormone ablation 
necessitates the incorporation of acute and, ideally, long-term exercise interventions that 
provide relief and often reversal of the various physical, functional, and ADT adverse 
effects. 
Segal et al (20) conducted the first investigation into the effects of exercise on 
ADT-treated PCa patients in a study that met high-quality methodological criteria (144, 
145). In that study, 155 men were randomly assigned to a 12-week supervised RET 
group (n = 82) or to a wait list control group (n = 73). The RET program consisted of 
nine exercises targeting upper and lower body muscle groups, performed three times 
weekly, at 60-70% of 1 RM, for two sets of 10-12 repetitions. Participants increased the 
resistance of an exercise by five pounds when able to complete more than 12 repetitions. 
Results indicated that at the end of the intervention, compared with controls, intervention 
participants reported less fatigue (p = 0.002), higher levels of HRQOL (p = 0.001), and 
better scores on measures of upper (p = 0.009) and lower (p < 0.001) body muscular 
fitness. In fact, at the end of the study, control participants reported increases in fatigue 
and declines in HRQOL as well as upper and lower body muscular fitness. This study 
had a 30.6% participation rate, with a program-adherence rate of 79%, which 
demonstrated initial evidence of the willingness and motivation to register and comply 
with exercise intervention parameters in a meaningfully sized proportion of PCa patients. 
This landmark study provided two salient findings for patients on ADT: 1) clinically 
important improvements in physical function, fatigue, and HRQOL, are attainable within 
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a relatively short duration of exercise programming; and, 2) treatment as usual was 
associated with physical function declines that likely increased fatigue and reduced 
HRQOL. The authors recommended that future studies follow patients for a longer 
duration (beyond 12 weeks) to determine whether additional benefits are achieved by a 
more sophisticated body composition analysis, as well as assess different modes of 
exercise, such as AET. 
Galvao et al (121) examined the effects of a 20-week supervised, progressive 
RET program in 10 men undergoing ADT for localized PCa. Patients were required to be 
on ADT for a minimum of two months with at least five months of subsequent treatment 
planned. In small groups (n = 1 - 4) and under direct supervision, participants were 
required to complete 12 upper and lower body exercises. All exercise sessions were one 
hour in duration, including flexibility training and warm-up. The intervention improved 
upper body strength and endurance (p < 0.001), functional performance (p < 0.05), and 
quadriceps muscle thickness (p < 0.05). No differences were found in lean mass, fat 
mass, body fat percentage, whole body bone mineral content, or BMD, Hb, or cortisol. 
PSA level, testosterone, and growth hormone levels were unchanged suggesting no 
exacerbation of the disease. Weaknesses of the study were that it was non-randomized, 
not controlled (i.e., no control group), and recruited a small sample size. However, the 
authors used several additional objective measures of functional performance and, as 
advocated by Segal and colleagues ( 120), sophisticated measures of body composition 
and serological outcomes (e.g. hormones and Hb ). Furthermore, the study employed an 
intense/strenuous RET protocol (6-12 RM using hydraulic and isotonic strength training 
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machines for two to four sets over 20 weeks) and reported no adverse events, which 
demonstrated the safety of high-intensity training in this relatively fragile population. 
Carmack-Taylor et al (30) conducted a three-arm RCT named the Active for Life 
After Cancer Trial that evaluated the impact of a group-based lifestyle physical activity 
program (Lifestyle Program) or educational support program versus standard care in PCa 
patients undergoing ADT (for a minimum of one year). Participants in the lifestyle and 
educational support programs were required to attend small, 90-minute group meetings 
for six months (16 weekly meetings plus four 'biweekly' meeting). Specifically, 
participants in the Lifestyle Program (n = 46) were taught cognitive-behavioural 
strategies derived from the Transtheoretical Model (146, 14 7) and Social Cognitive 
Theory (148, 149) to increase physical activity adherence to 30 minutes at a moderate 
intensity on most days of the week (which meets Health Canada and American College of 
Sports Medicine recommendations). Although physical activity instruction was not 
provided, patients were occasionally engaged in five-minute periods of walking, an 
information session regarding injury prevention and stretching, and a facilitated 
discussion on a variety of PCa-related topics. Participants in the educational support 
program (n = 51) discussed PCa-specific issues, including diet, treatment side effects and 
sexuality. Seventy percent and 82% of the participants attended at least half of the 
lifestyle and educational sessions, respectively. Significant differences were not found 
for HRQOL, body composition, endurance, seven-day physical activity volume, caloric 
expenditure, or social support in any intervention arm. 
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In discussing the negative results, the authors suggested that the lack of efficacy 
may be a result of the relatively healthy status (e.g. low levels of anxiety, depression, and 
pain) of patients at baseline (i.e. a ceiling effect). Furthermore, the authors noted that the 
sample size was insufficiently powered, due to the onerous and costly nature of 
conducting a three-arm RCT with strict eligibility criteria (more than 1, 100 patients were 
approached). Although the intervention was relatively well received with similar 
adherence rates as previous trials, the authors recommended formal physical activity 
skills training in conjunction with cognitive-behavioural training to improve the benefits 
of, and adherence to, a physical activity program. The results also raise the possibility 
that professional supervision may be an important component of physical activity 
interventions in this group of patients, but this has not been directly tested in a RCT. 
Culos-Reed et al (24) examined the effects of 12-week home-based physical 
activity intervention on 31 PCa patients treated with ADT in a single arm, prospective 
trial. A group-based, introductory session familiarized participants with various 
exercises, consisting primarily of walking, stretching, and light RET. Resistance bands 
and exercise balls were provided to participants to support adherence to the exercise 
prescription of three to five times per week. Group-based "booster sessions" that 
incorporated exercise and discussion, were held every two weeks to encourage social 
support, adherence to the program, and measurement of compliance with the program 
parameters. Results showed that 81 % of participants attended at least five of the six 
booster sessions, with post-test differences in volumes of strenuous and total physical 
activity (p < 0.01), functional capacity (p < 0.01), resting heart rate (p = 0.03), BMI (p < 
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0.01) and fatigue (p = 0.05). A subgroup (n = 18), which was followed for four months 
post-intervention, revealed decreases in strenuous physical activity participation (p = 
0.01) and global HRQOL (p = 0.04) compared to post-treatment results. The authors 
noted that reductions in global HRQOL at the 4-month follow-up may be a result of a 
failure to maintain intervention levels of physical activity, which echoed previous 
findings suggesting that the benefits of exercise are sustained for only as long as the 
routine exercise is maintained (31 ). 
More recently, Culos-Reed et al (25) tested their intervention using a RCT design 
over 16 weeks in 100 patients scheduled to receive ADT for at least six months. 
Exercising participants demonstrated increased physical activity volume (p = 0.004), and 
smaller waist circumference (p = 0.044) and neck girth (p = 0.019) compared to controls. 
A significant difference between controls and exercisers was not observed for HRQOL, 
depression, or fatigue. Participants attended 78% of the weekly booster sessions; 
however, the drop-out rate over the 16 weeks was 34%. The authors reported that no 
adverse events occurred in either of these trials. The results of the two studies by Culos-
Reed et al suggest that home-based physical activity interventions are safe, but require 
strategies to minimize attrition. Moreover, the lack of effect on HRQOL outcomes and 
some measures of physical fitness indicated that the intervention may have lacked 
sufficient intensity and/or exercise prescription compliance required for physical 
adaptation. The investigators are currently monitoring long-term adherence and benefits 
in a study subgroup. 
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A pilot study by Hansen et al (27) of supervised, progressive eccentric RET in 
men with PCa was conducted to determine whether patients receiving ADT had a blunted 
response to RET versus PCa patients that are not receiving ADT. Sixteen men were 
enrolled in this study; however, six participants withdrew (four from the ADT group) 
leaving five in each of the two groups. All patients underwent radical prostatectomy for 
primary treatment, except for one that elected active surveillance. Two participants also 
underwent adjuvant radiation therapy after surgery, both in the ADT group. All 
participants engaged in 12 weeks of high-force eccentric ergometer training on three days 
per week 1• Eccentric training was incorporated into this protocol likely because it allows 
for a greater amount of force to be applied to the muscle group and produces the greatest 
structural and functional muscle adaptation while incurring a low metabolic 
(caloric/cardiovascular) cost when compared to conventional concentric training (150-
154). All participants completed the 36 sessions of training and there were no adverse 
events associated with training. After the intervention, ADT patients showed improved 
performance on the six-minute walk test (p = 0.01) and isometric knee strength (p<0.05). 
And, although not statistically significant, these participants also demonstrated a 
clinically important improvement in HRQOL (as measured by the Functional Assessment 
of Cancer Therapy - Prostate; mean change of 8.2 points, p-value and 95% confidence 
interval not reported). The non-ADT group improved in the physical subscale of the 
HRQOL (p = 0.03) and left quadriceps muscle volume (p = 0.04). Significant within-
1 Eccentric loading occurs when resistance is applied to a muscle while it is lengthening, and in this 
particular case the resistance is applied to the quadriceps using a cycle-like device that loads or 'pushes' the 
knee back causing the quadriceps to lengthen and the knee to flex. 
19 
group improvements were not found for the timed-up and go test or fatigue (via the 
Functional Assessment of Cancer Therapy - Fatigue); nor were there any between-group 
differences. Limited by a small sample, non-controlled design, large attrition rate 
(especially in the ADT group), and unmatched baseline characteristics between groups, 
these findings must be interpreted cautiously. Yet it is important to underscore the 
importance of RET, and particularly eccentric RET, as a training modality that appears to 
be efficacious at maintaining functional capacity despite ADT. It is also worth noting 
that the authors reported significant difficulty with recruitment, stating that attendance at 
a university-based program was a contributing factor to non-participation. However, the 
program adherence of those that did attend was 100%. The authors recommend using a 
more convenient location for the program such as the individual's home, to improve 
program participation. 
Galvao and colleagues (23) examined the effects of a 12-week combined AET + 
RET intervention in a RCT of 57 patients receiving ADT. Treatment group participants 
completed eight RET exercises at 6-12 RM (moderate to strenuous RET) for 2-4 sets per 
exercise. The AET component consisted of 15-20 minutes of cycling, walking, or 
jogging at 65-80% of maximum heart rate or 11-13 out of 20 on the Rating of Perceived 
Exertion (Borg) Scale (155). Participants completed exercises in a facility-based, 
supervised setting in small groups of one to five participants. Primary outcomes were 
whole body and regional lean mass measured by dual energy x-ray absorptiometry 
(DEXA). At the end of 12 weeks, the exercising participants demonstrated significantly 
greater lean mass, muscle strength, and functional capacity than controls. Over the 
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course of the trial, exercising participants also showed improved HRQOL scores and, 
reduced fatigue, and reduced C-reactive protein, an inflammatory marker that is 
associated with poor function, diabetes and obesity, mortality, and some cancers 
including PCa (156-163). This was the first trial to demonstrate a reversal in muscle loss 
in androgen suppressed PCa patients and demonstrated significant HRQOL, fatigue, and 
muscle strength outcomes with a mixed-modality exercise intervention. 
The most recent published exercise trial in ADT has been conducted by our 
research team. We investigated differences in performance outcomes and HRQOL 
associated with training in a one-on-one versus group setting with an exercise instructor 
(26). In this pilot study, 10 men undergoing ADT for PCa were randomized to eight 
weeks of group-based exercise or personal training for three one-hour sessions per week. 
To examine the role of facility location on participation and adherence, sessions were 
held on alternate weeks at either the University Health Network (downtown Toronto) or 
the University of Guelph-Humber (suburban Toronto). Each session was mixed-modality 
(i.e. AET + RET) at a moderate to vigorous intensity. The mean attendance rate for the 
personal training and group exercise sessions was comparable (91 % and 88%, 
respectively; p = 0.645). Participants attended sessions at each site with a similar 
frequency (94% to the hospital-based setting versus 83% to the university-based setting, 
p = 0.582). From baseline to post-test, there were no statistically significant within- or 
between-group differences in HRQOL (FACT-P) or fatigue (FACT-F); however, the 
personal training group had a clinically important improvement in fatigue that trended 
towards significance (p = 0.09). In terms of physical outcomes, the personal training 
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group demonstrated improvements from baseline in resting systolic blood pressure (p = 
0.033), body fat percentage (p = 0.001), and maximal lower body strength (p = 0.002). 
Group comparisons indicated that the personal training group had greater lower body 
strength improvements (p = 0.038), whereas the group-based exercise participants had 
better upper body strength improvements (p = 0.013). There were no within or between 
group differences for aerobic fitness, balance, BMD (as measured by quantitative 
ultrasound), grip strength, or body composition. All participants declared that the 
program was a positive experience that was beneficial to their HRQOL, whereas 60% of 
the sample preferred to do personal training rather than group exercise. Although this 
was the first study to compare delivery models of exercise for PCa survivors, it was 
limited by sample size and lack of a long-term follow-up. Despite these limitations, the 
pilot nature of this work was important to provide estimates of effect size that have been 
used for subsequent research proposals to examine delivery modalities and cost-
effecti veness. 
2.3 HRQOL and Prostate Cancer Survivors Undergoing ADT 
Patients and healthcare practitioners must consider therapeutic options for life-
threatening medical conditions by weighing survival in terms both the number of years of 
survival and the overall quality of life of those years. Consequently, HRQOL has 
evolved to broadly encompass the general aspects of global wellbeing, including 
psychological/emotional, social, functional and physical health (164). In the cancer-
specific model proposed by Courneya et al (165), HRQOL outcomes represent the state 
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of happiness and satisfaction with life, that is affected by symptom occurrence, 
interference, and distress. Courneya and colleagues further suggest that fatigue is the 
root psychophysical contributor to overall HRQOL that pervades each aspect of symptom 
status (i.e. occurrence, interference and distress). This perspective is corroborated by 
research that indicates that fatigue is the most common and distressing adverse effect of 
cancer treatment, affecting 70-90% of all cancer survivors (140). Cancer-related fatigue 
can persist for several years after cancer treatment terminates, negatively impacting 
HRQOL and interfering with activities of daily living (166). Therefore, strategies that 
specifically address this fundamental aspect of HRQOL are sorely needed. 
For men with PCa HRQOL is compromised from many angles despite knowledge 
that current curative approaches to disease management confer a 90% 15-year survival 
rate (2, 167). Common radical therapies, such as radiation and prostatectomy, are nearly 
always associated with adverse effects, such as urinary and/or bowel incontinence (UI) 
and sexual dysfunction (SD), that profoundly impair HRQOL (168-170). Irrespective of 
primary treatment, ADT is indicated for approximately half of all men with PCa for 
biochemical relapse or as a palliative approach when the cancer is diagnosed in the 
extracapsular or metastatic stages (37, 38, 171). This is problematic for HRQOL because 
ADT further compounds deleterious changes physical and psychosocial wellbeing by 
diminishing physical fitness (including detrimental changes to body composition), 
energy/vigor, sexual interest, and cognitive function (36, 48, 170). Moreover, ADT has 
been correlated with increased incidence of diabetes and cardiovascular morbidity that 
additionally exacerbate physical and psychosocial wellbeing (44-46). Accordingly, 
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urologists and scientists have advocated broadening the metrics of therapeutic success 
beyond simply disease-free survival to include overall HRQOL (2, 172-175). 
Given that the PCa and treatment sequelae are unique and profound, measurement 
of HRQOL in PCa is complex. These specific psychological and physical adverse effects 
have yielded the development of PCa-specific HRQOL measurements, such as the 
Functional Assessment of Cancer Therapy - Prostate (FACT-P) (176), the Patient-
Oriented Prostate Utility Scale (PORPUS) (177), and the Expanded Prostate Cancer 
Index Composite (EPIC) (178), aimed at capturing the true essence of living with the 
disease. The advantage of using a disease-specific measure is that, in addition to 
providing insight on overall HRQOL, there is an assessment of distinct PCa outcomes; 
such as, genitourinary symptoms, sexual interest/satisfaction, fatigue, and emotional 
health. These measures are often able to distinguish between a distinct set of deficits in 
the localized versus locally advanced/metastatic disease setting. 
Across all cancer diagnoses, exercise has been an effective ameliorative therapy 
positively influencing several psychosocial and physical adverse effects of cancer and 
associated therapies. The roots of cancer-exercise literature are founded firmly in 
psychosocial oncology with a vast majority of studies reporting on some component of 
HRQOL. This emphasis stems from a coping model within cancer survivorship, as 
exercise has traditionally been regarded as an adjuvant therapy to mitigate the effects of 
the disease and/or its treatment (165). Ultimately, it appears that exercise can positively 
influence global wellbeing and HRQOL via multiple pathways, providing benefits at the 
molecular/biologic levels that improve disease management and treatment tolerance, 
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while improving the negative impact of the disease on patients' psychological wellbeing 
(165). More recently, exercise intervention literature has approached cancer survivorship 
with a quasi-curative, rather than simply palliative approach, as findings continue to 
emerge that suggest exercise has anti-tumourigenic effects (114-117). Evidence of 
disease control can further improve HRQOL by enhancing optimism and personal control 
with respect to cancer ( 1 79). In aggregate, the body of literature in cancer and exercise 
now represents a more comprehensive, or biopsychosocial approach, with benefits 
described across all domains HRQOL. In response to the multilevel benefits of exercise, 
it is prudent, and arguably essential, that exercise be examined in a biopsychosocial 
context, using outcomes measures that reflect all physical wellbeing, psychosocial 
wellbeing, and disease control markers. 
2.3.1 The Effect of Exercise on HRQOL for Prostate Cancer Survivors Undergoing 
ADT 
The prevalence of ADT-related declines in HRQOL and the general benefits 
ascribed to exercise make them virtually inseparable in the research. This is evidenced 
by the fact that all but two ( 121) exercise studies have incorporated some measure of 
general or PCa-specific HRQOL measurements. Unfortunately, the effects of exercise do 
not appear universal across trials that appear to be related to intervention delivery 
strategies despite heterogeneity in HRQOL measurement usage. 
The most commonly used measure of HRQOL among ADT-treated PCa patients 
is the FACT-P which has been employed in five of the 10 existing studies (21, 27, 28, 
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120, 180). The first research in this population conducted by Segal et al (120) used the 
F ACT-P and found that scores were improved with RET compared to controls in all 
sample stratifications (e.g. all participants, men treated with curative or palliative intent, 
and men receiving ADT for greater than or less than one year; p = 0.001 top= 0.02). In 
Segal et al' s second RCT in PCa patients receiving radiation ± ADT (21 ), significant 
worsening was found in the PCa-specific symptoms subscale of the F ACT-P from 
baseline to 12 weeks in both the AET (mean tJ. = -3.17, 95% CI: -4.98 to 1.37, p < 0.001) 
and RET (mean tJ. = -1.91, 95% CI: -3.79 to 0.02, p = 0.047) groups, as well as in the 
usual care group (mean ti= -4.17, 95% CI: -5.97 to 2.38, p < 0.001) although the usual 
care controls experienced the greatest reduction in HRQOL (mean tJ. = -4.17, 95% CI: -
5.97 to -2.38, p < 0.001). Significant differences between groups were not found, nor did 
any group sustain these changes to 24 weeks. With respect to generalized cancer-related 
HRQOL (FACT-General component of FACT-P), RET was associated with a clinically 
significant improvement in HRQOL from baseline to 24 weeks (mean tJ. = 4.17, 95% CI: 
-4.98 to 1.37, p < 0.001), as was AET, although this finding was only borderline 
significant (mean tJ. =2.35, 95% CI: -0.06 to 4.77, p = 0.055). Between-groups 
comparisons found that RET improved cancer-specific HRQOL compared to usual care 
at 12 and 24 weeks (p = 0.017 and p = 0.015, respectively). 
Likely inspired by Segal' s initial work in the field, several other research groups 
have employed the FACT-P to assess HRQOL changes associated with exercise. Bourke 
et al (28) found within-group improvements, and exercise versus control group 
differences in total F ACT-P scores that approached clinical significance but were 
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underpowered to produce statistical significance (p = 0.21 ). Hansen et al (27) reported a 
within-group improvement in the physical subscale of FACT-P for exercising PCa 
patients not receiving ADT, but not in exercising patients who were receiving ADT. 
Additional pre-post or between-group differences were not observed. In their single-arm 
trial, Serda et al (180) found a clinically and statistically significant improvements in total 
FACT-P scores after 24-weeks of RET (mean~= 9.4, p = 0.003). In the most recent 
trial, our group found the largest improvement in FACT-P scores over the course of an 8-
week personal training intervention but the small (underpowered) sample undermined 
statistical significance (mean fl.= 12.3, SEM = 7.0, p = 0.136). In summary, the FACT-P 
has demonstrated sensitivity to changes in cancer-specific, PCa-specific, and other 
HRQOL elements in each study that has employed the measure. Interestingly, the FACT-
p has not been the primary outcome of a study and it has been used exclusively in 
facility-based exercise trials and not home-based exercise studies. The F ACT-P should 
be considered among the most appropriate choices for exercise interventions given the 
prevalence of usage in this field of study, and should be integrated in home-based 
exercise trials in order to effectively compare the HRQOL benefits across intervention 
delivery settings. 
Beyond the FACT-P, PCa-specific HRQOL responses to exercise have also been 
assessed using the PORPUS (26) and the EPIC (Expanded Prostate Cancer Index 
Composite) (122). In our recent study (26), we observed an approximate clinically-
significant change in total PORPUS scores from baseline to 8 weeks for participants 
engaging in group-based exercise, but this was not statistically significant (mean fl.= 7.9, 
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SEM = 5.3, p = 0.374) (26). Culos-Reed et al (24) observed a marginally significant 
improvement in hormone symptoms compared to controls after 16 weeks of home-based 
exercise (122) as assessed by the EPIC. 
Other studies have elected more general cancer-based HRQOL scales. Three 
studies used the European Organization for the Research and Treatment of Cancer -
Quality of Life Questionnaire (EORTC-QLQ) to assess cancer specific HRQOL (23, 24, 
122). Using the EORTC-QLQ, Galvao et al (23) found improvements in role function (p 
< 0.001), cognition (p = 0.007), nausea (p = 0.025) and dyspnea (p = 0.017), but not 
global HRQOL (95% CI: -4.3 to 12.2, p-value not reported) when mixed-modality 
exercisers were compared to controls over 20 weeks of training. In Culos-Reed et al' s 
(24) first study of PCa patients receiving ADT, the physical function role dimension of 
the EORTC-QLQ improved (p = 0.03) but not global HRQOL (p = 0.13) with 12-weeks 
of home-based exercise. However, global HRQOL declined four months post-
intervention (p = 0.04) which was concomitant with declines in strenuous physical 
activity volume (p = 0.01). This is noteworthy because there was also a trend towards 
significance for a relationship between general physical activity volume and global 
HRQOL in the post-program period (r = 0.34, p < 0.1 ). In their second home-based 
exercise study, an RCT, Culos-Reed et al (122) observed that exercisers and controls 
were similar in EORTC-QLQ scores after the 16-week intervention period. They 
addressed this unique finding through suggestions that the EORTC-QLQ lacked 
sensitivity to detect changes in global HRQOL for PCa patients participating in an 
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exercise program or that there was a potential ceiling effect of their sample due to the 
relatively high baseline values of HRQOL. 
Two studies used generic HRQOL measures to assess exercise-related changes in 
men undergoing ADT for PCa. The Short Form - 36 Health Survey (SF-36) is designed 
to capture changes in HRQOL across eight dimensions, including: physical functioning; 
role limitations resulting from physical health problems; bodily pain; general health; 
vitality (energy/fatigue); social functioning; role limitations resulting from emotional 
problems; and mental health (psychological distress and psychological wellbeing) (181, 
182). The SF-36 is frequently used in physical activity research across clinical 
populations (e.g. (183-188)). Carmack-Taylor et al (30) found that the SF-36 or its 
subscales remained unchanged from baseline following their lifestyle intervention that 
incorporated 30-minutes of home-based physical activity on most days per week over 6 
months. However, in a facility-based, mixed-modality exercise trial over 12 weeks, 
Galvao et al (23) observed improvements in the SF-36 subscales of general health (p = 
0.022); vitality (p = 0.019); and physical health composite scores (p = 0.02). 
To summarize the effect of exercise on HRQOL in PCa patients undergoing ADT, 
among the six facility-based trials that measured HRQOL, three studies (21, 23, 120) 
demonstrated statistically significant improvements in HRQOL while two others (26, 28) 
reported clinically significant improvements but lacked sample size to achieve statistical 
significance. Only one facility-based trial found that exercise had no effect on HRQOL 
for ADT patients (27). In contrast, the effects of exercise programming for ADT-patients 
in the home-based setting has been less impressive; none of the three studies with 
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HRQOL outcomes observed improvements in global HRQOL or in a majority of 
subscales. In each of Culos-Reed et al's trials only one subscale of HRQOL was 
improved (24, 122). The stronger HRQOL benefits observed in facility-based trials, 
compared to home-based trials, may be due to one or more of the following factors: 
social interaction with peers and training staff, greater programmatic adherence through 
motivation and external motivation (responsibility to training staff/partners/group), 
enhanced physical fitness benefits via more intensive, more supervised training. Non-
intervention-related reasons for this discrepancy may be the different measures used in 
the home-based and facility-based trials as the FACT-P and the EORTC-QLQ have 
almost exclusively been used in the former and latter, respectively. Bourke et al (28) 
utilized the FACT-P to assess the effect of a hybrid delivery model (i.e. combined facility 
and home-based) of a lifestyle intervention on disease-specific HRQOL. Utilizing the 
F ACT-P in a strictly home-based intervention, as well as providing routine support from 
training staff and peers, will provide the most appropriate comparison for HRQOL 
benefits across delivery settings. 
2.4 Fatigue and Prostate Cancer Survivors Undergoing ADT 
As previously described, cancer-related fatigue appears to be an essential 
component of the negative effects of PCa and ADT on HRQOL. Cancer-related fatigue 
is a unique type of fatigue characterized as a 'subjective feeling of tiredness, weakness or 
lack of energy' (189) that interferes with normal functioning and is not relieved by rest 
or sleep (190). Fatigue's profound effect on HRQOL forcing cancer patients to abandon 
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their usual activities and social roles (191). A 59 year old stage IV PCa patient described 
cancer fatigue as "a crushing, all-encompassing, incapacitating fatigue that is 
indescribable other than to say that its completely draining" (192). Unfortunately, 
cancer-related fatigue is the most prevalent adverse effect impacting nearly every cancer 
patient (140). With an increase in the frequency of multi-modal, high-intensity cancer 
treatment protocols, the burden of cancer-related fatigue continues to rise (193). 
The experience of cancer-related fatigue spans the disease continuum, with 
approximately 40% of people reporting abnormal fatigue at cancer diagnosis ( 193, 194) 
and a continual burden for years after systemic treatment ( 19 5, 196). Specifically for 
PCa patients, ADT worsens fatigue and is reported as being the most highly problematic 
adverse effect associated with this treatment ( 48, 61 ). Stone et al ( 61) found that 66% of 
ADT-treated patients reported an increase in fatigue severity after initiating therapy, with 
14% reporting significant/severe fatigue. Joly et al (197) found that fatigue severity was 
significantly worse in non-metastatic PCa patients compared to healthy, age-matched 
controls. Herr et al (198) found that PCa patients that were receiving ADT had more 
fatigue than patients not receiving therapy or that underwent localized treatment. Thus, 
while it is clear that cancer and primary therapies are inherently associated with increased 
fatigue, ADT patients are particularly vulnerable to experience significantly worse 
fatigue. Management of fatigue in ADT is, therefore, of great importance given the 
chronic nature of this treatment and HRQOL-compromising nature of this adverse effect. 
Despite its prevalence and highly distressing nature, researchers have yet to 
comprehensively describe the etiology of cancer-related fatigue, although it is generally 
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accepted that cancer-related fatigue is a multi-factorial concept with biological and 
psychosocial determinants (190, 199-201). This has ultimately hampered approaches to 
an effective resolution. Potential causes of general cancer-related fatigue include: altered 
metabolic function, hormonal dysregulation/changes, chronic stress response 
(sympathetic activation), general anxiety and/or depression, anemia, and disrupted sleep 
patterns (190, 202). In addition to these, ADT patients may have worsened fatigue 
directly related to the absence of testosterone as this hormone protects against fatigue in 
healthy men (203) and, conversely, hormonal replacement therapy has been shown to 
improve fatigue in females (204 ). 
To date, pharmacological management strategies to address cancer and ADT -
related fatigue have provided limited benefit to patients. To address anemia-related 
fatigue, exogenous erythropoiesis-stimulating drugs; such as erythropoietin and 
darbopoietin, have demonstrated some efficacy at reducing fatigue, but the benefits are 
only modest (205, 206). Exogenous erythropoiesis-stimulating drugs do not adequately 
address the severity of overall and idiopathic cancer fatigue (207). Moreover, there are 
concerns regarding increased risk of venous thromboembolism and mortality with these 
drugs (208). Ritalin (methylphenidate ), a mild central nervous system stimulant 
commonly used in children with attention-deficit hyperactivity disorder, has shown some 
promise in improving fatigue in melanoma patients undergoing interferon therapy. A 
randomized, double-blind, placebo controlled trial at the Princess Margaret Hospital in 
Toronto is currently investigating the effect of Ritalin in the management of fatigue in 
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PCa patients undergoing ADT and should provide intriguing information regarding this 
potential treatment (ClinicalTrials.gov identifier: NCT00593853). 
Psychosocial interventions for cancer-related fatigue were reviewed in two meta-
analyses (209, 210). Jacobsen et al (209) included 18 trials that used psychological 
interventions, such as cognitive, behavioural, or coping skills, and found a modest, but 
statistically significant effect on cancer-related fatigue. The effect of relaxation-based 
fatigue management strategies were assessed across 15 RCTs by Luebbert et al (210), 
finding that relaxation was associated with significant benefits in numerous psychosocial 
and physical symptoms, such as blood pressures, heart rate, nausea, pain, depression, 
tension, anxiety, mood and hostility. Unfortunately, fatigue was not among the 
symptoms that improved with relaxation. A limitation to the literature has been that few 
studies have actually screened for severe fatigue, suggesting that the samples may not be 
representative of those patients who are most affected (209). 
The positive effects on mental and physical wellbeing that exercise produces have 
made exercise a popular intervention for fatigue management among cancer researchers 
and clinicians. A recent Cochrane review by Cramp and Daniel identified 22 studies that 
assessed exercise interventions for the management of cancer-related fatigue in over 2000 
cancer survivors during and after treatment (211 ). The results of the meta-analysis 
demonstrated that exercise improved fatigue compared to usual care during and after 
cancer treatment (211). It should be noted, however, that (1) the effect sizes were rather 
modest (standardized mean difference during therapy = -0.18; 95% CI = -0.32 to -0.05; 
standardized mean difference after therapy = -0.37; 95% CI = -0.55 to -0.18), (2) a 
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majority of the trials were among breast cancer patients (n = 16), and (3) few studies 
assessed fatigue as a primary endpoint. Despite these limitations, major cancer 
organizations have eagerly and enthusiastically endorsed exercise as an important 
fatigue-combating lifestyle approach (193). 
2.4.1 Exercise and Fatigue in Prostate Cancer Survivors Undergoing ADT 
For PCa patients undergoing ADT, the effect of exercise on fatigue has been 
mixed. This may, in part, be due to variability in the methodological quality of the studies 
and differences in the measurement instruments used to assess fatigue. Although most 
studies have been randomized trials (k = 7 out of 10), methodological quality has been 
undermined by the use of small sample sizes; only 2 of the 10 studies assessing fatigue 
powered their studies for this outcome measure (21, 120). In terms of fatigue 
measurement, five studies used the F ACT-F (21, 26-28, 120); two used the Fatigue 
Severity Scale (24, 122), and one study used the Brief Fatigue Inventory (66). Two other 
studies used a subscale of a general HRQOL measure to assess fatigue symptoms (23, 
30). Similar to the effects of exercise on HRQOL in ADT-treated PCa patients, the 
impact of exercise on fatigue in participants undergoing facility-based versus home-based 
exercise programs has been equivocal. 
In the four home-based, unsupervised exercise trials that assessed fatigue (24, 30, 
66, 122), only one found that fatigue was significantly improved (24). In contrast, four of 
the six facility-based trials noted statistically significant improvements in fatigue in 
exercising participants (21, 23, 28, 120) and one study noted a clinically significant 
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improvement with personal training (and not group-based exercise), but was 
underpowered to detect statistical significance (26). This pattern of fatigue improvement 
in facility-based trials compared to home-based trials is consistent in PCa patients who 
were not undergoing ADT as Windsor et al ( 66) observed no change in fatigue symptoms 
during their 4-week home-based exercise program while Monga et al (65) found a 
reduction in fatigue after 8 weeks of supervised, facility-based AET. 
The multi-factorial nature of fatigue challenges the exercise researcher to 
determine the most effective pathway(s) towards ameliorating fatigue. On one hand, the 
diverse facets of cancer-related fatigue provide multiple paths for exercise to exert a 
beneficial influence. On the other hand, disentangling the effects of exercise on those 
avenues is extremely difficult, and researchers generally resort to measuring the 
aggregate effects of exercise on fatigue. Further, to this latter point, while the overall 
experience of disabling fatigue is of utmost importance and should be the primary 
objective, tailoring an exercise intervention to obtain the greatest effect is impossible 
without determining which aspects of fatigue are best addressed by certain types of 
exercise. The current state of literature on exercise for fatigue in ADT patients provides 
preliminary clues as to which types of interventions improve fatigue, which appear to be 
facility-based. The lack of success in reducing fatigue across home-based exercise 
programs is currently unexplained and there is limited evidence to support the idea that 
any specific modality of exercise (i.e. AET versus RET) has any distinct benefit on 
fatigue. Only Segal et al (21) investigated modality-specific effects and found, in a 
secondary analysis of men undergoing both radiation and ADT, fatigue was improved in 
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the AET group compared to controls but this subanalysis was underpowered to detect a 
statistically significant difference (fatigue measured by the FACT-F in n = 74, mean 
between groups b.. = 3.3, 95% CI: -0.4 to 7.0, p = 0.082). This is in contrast to Segal et 
al's (120)earlier work showing that fatigue was less intense after RET than after standard 
care (mean between groups b.. = 3.0, p = 0.002). In light of these discrepant findings and 
inconsistency across delivery settings, examining AET compared to RET in the home-
based setting will add important insight to the question of exercise efficacy for fatigue. 
2.5 Physical Fitness and Body Composition in Prostate Cancer Survivors 
Undergoing ADT 
Men undergoing ADT have immediate and profound changes to their body 
composition and physical fitness related to suppression of testosterone which is reduces 
muscle mass and bone mass while increasing fat mass (212). In healthy men with age-
related hypogonadism (i.e. lowered testosterone), androgen replacement therapy 
increases muscle mass (213) but its effect on adiposity is unclear (213-215). ADT, on the 
other hand, unequivocally worsens body composition and these effects occur shortly after 
the onset of treatment and steadily progress over the course of ADT (216). Luteinizing 
hormone-releasing hormone analogues (LHRHa) have been associated with significant 
increases in total weight and fat mass and concomitant decreases in muscle mass and 
bone mineral density in men with locally advanced or metastatic PCa (11, 49, 217-219). 
In a single arm, prospective trial, Smith et al ( 11) examined the effect of a 
standard regimen of a LHRHa (leuprolide 3-month depot 22.5 mg intramuscular every 12 
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weeks for 48 weeks) on body composition outcomes using dual energy x-ray 
absorptiometry (DEXA) and bioelectrical impedance analysis (BIA) in 32 men with 
locally advanced (lymph node-positive or biochemical relapse), non-metastatic PCa. In 
that study, clinical effectiveness of androgen ablation via LHRHa was demonstrated as 
serum testosterone was reduced by 96.3% (p < 0.001), prostate-specific antigen (PSA) 
decreased by 88.4% (p < 0.001), and sex-hormone binding globulin remained unchanged 
over the 48-week period. Over this period, mean body mass index (BMI) and weight 
each increased by 2.4% (p = 0.005) and body fat percentage increased by 9.4% (p < 
0.001). The increased fat mass was primarily due to increases in subcutaneous fat 
(increase of 11.1 %, p = 0.003) rather than intra-abdominal (visceral) fat (no change from 
baseline to post-test). These changes in body composition were accompanied by 
increases in serum total cholesterol (9.0%, p < 0.001), low-density lipoprotein (LDL) 
cholesterol (7.3%, p < 0.001), and triglycerides (26.5%, p = 0.01) (interestingly, high-
density lipoprotein (HDL), the 'good cholesterol' also improved by 11.3%, p < 0.001). 
In addition to these serum markers, fasting glucose and Hb A 1 c levels have been examined 
which have shown to be increased in association with ADT (218, 220). 
With respect to muscular fitness, ADT alters the androgen receptor complex 
which compromises muscular development and consequently force production capacity 
(221). Total body lean mass has been shown to be reduced by 2.0% to 2.7% over 36 to 
52 weeks of ADT (10, 11, 49). ADT-related changes in muscle maintenance and 
adaptation to training stimulus have been attributed to a decrease in the number of 
androgen receptors on skeletal muscle, the neuromuscular junction via acety le ho line 
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receptor desensitization as well as reductions in insulin like growth factor-1 (I GF-1) 
(221 ). These physiological changes are directly related to the proportion of muscular 
volume and capacity that routine tasks require and the subsequent recovery from 
muscular exertion. ADT-related reductions in muscle mass are clinically significant 
because they accelerate the rate at which elder men approach minimum functional 
thresholds for independent living and HRQOL (221, 222). 
Essentially, the clinical relevance of decreased muscle is reduced physical 
strength. Basaria et al (223) found that upper body strength (but not lower body strength) 
was reduced in men on ADT (average duration of ADT = 45 months) compared to age-
matched controls. Soyupek et al (224) compared 20 patients with locally advanced PCa 
on ADT to healthy aged-matched controls and found that grip strength and hand dexterity 
was worse in ADT users. Clay et al (53) found that compared to controls, men on 
chronic ADT had significantly slower walking speed and lower extremity function, which 
was worse in men on long term treatment (> 6 months of ADT). In a RCT of RET 
compared to standard care controls, Segal et al (120) found significant reductions in 
upper and lower body muscular endurance over the 12 week intervention period in the 
control participants. These fitness declines may be more overtly manifested in reductions 
in overall activity as Galvao et al ( 49) found a significant reduction in physical activity 
volume over 36 weeks of ADT. However, not all studies have shown significant declines 
in functional fitness. Stone et al (225) found that grip strength, a predictor of upper 
extremity strength and mortality in older adults ( 61, 226), was unaffected after three 
months of ADT. Potosky et al (227) observed no difference in limitations to daily 
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activities in 661 PCa patients receiving ADT versus no PCa-treatment. Collectively, 
these findings suggest that maximal physical capacity is likely reduced (as demonstrated 
by consistent findings regarding decrements in fitness tests) whereas functional fitness 
may be less impaired (as demonstrated by mixed findings regarding ability to adequately 
complete daily tasks and grip strength measurements). 
The effects on fitness are not limited to musculoskeletal parameters, but extended 
to cardiorespiratory aspects of physical capacity. Reduced haemoglobin (Hb) resulting 
from ADT is widely established, and although the exact mechanisms lack definitive 
description, anaemia likely results from inhibition of erythropoeisis through androgen 
suppression (13). Strum and colleagues (8) reported that rapid declines in Hb in 133 
patients as early as one month after the initiation of combined hormone blockade and 
reaches nadir at six months with an average decline of 25.5 g/L in 133 patients. Chandler 
et al ( 14) also reported average reductions in Hb of 10 .1 g/L over 16 months in a 
population of 69 ADT patients, with nadir reached at 4 months. The negative effect of 
ADT on erythropoiesis is a plausible explanation given the recovery of Hb concentrations 
among ADT patients when treatment is discontinued (along with recovery of testosterone 
levels) or concurrent recombinant human erythropoietin administration (8, 13, 14). 
Moreover, the anaemic state of cancer patients may also be attributed to reduced 
erythrocyte production from bones at metastatic sites (vertebral bodies, pelvis, and long 
bones) or iron deficiency from poor dietary intake ( 10, 11 ). 
In men, circulating androgens and estrogens play fundamental roles in the 
maintenance of BMD (228, 229). The effects of ADT on bone health have been widely 
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examined with osteoporosis noted as a common adverse effect of treatment that often 
motivates pharmacological intervention (9, 13, 15, 16, 42, 223, 230-239). In the most 
definitive epidemiological study conducted to date, Shahinian et al ( 42) examined the 
records of 50,613 PCa patients from the Surveillance, Epidemiology, and End Results 
(SEER) database and found that men who survived for five years or more post-diagnosis 
had a fracture risk of 19.4% if they received ADT versus 12.6% for men that did not 
receive ADT. Moreover, fracture risk was associated with reduced survival in a 
prospective cohort study of 195 men receiving ADT (235). Contributing to the fracture 
risk is an increased risk of falls due to poor musculoskeletal and aerobic fitness ( 4 7, 240) 
Another distressing adverse effect of ADT is gynecomastia, i.e. an enlargement of 
the glandular tissue of the breast in men (241). For ADT patients, gynecomastia is 
caused by an imbalance in the bioavailable androgens and estrogens, stimulating the 
development of subareolar fat (241, 242). The early stages of gynecomastia are 
characterized by proliferation of breast glandular ducts, epithelial hyperplasia, expansion 
of the stroma, increased vascular tissue, and periductal edema (243). Over approximately 
one year, proliferation subsides and hyalinisation and fibrosis of the stroma occur which 
are typically irreversible (243, 244). The incidence of ADT-related gynecomastia 
depends on the therapeutic approach with patients undergoing non-steroidal anti-
androgens alone (such as bicalutamide, flutamide, or nilutamide) suffering the most with 
incidence rates that range from 30 -79% (243). PCa patients treated with LHRHa 
produce gynecomastia in approximately 1 to 13%, while surgical castration is related to 
gyrtecomastia in 1 to 14% of patients (243). Complete androgen blockade, that is 
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castration plus anti-androgen, is associated with a gynecomastia incidence of 13 to 22% 
(243). Unfortunately, the assessment of ADT-related gynecomastia is complicated by the 
occurrence of idiopathic gynecomastia that is prevalent in many older males (245). 
Current treatment options for PCa treatment-related gynecomastia include radiation, 
surgery, anti-oestrogens, and aromatase inhibitors (242, 243). To our knowledge, 
exercise has never been examined for its effect on gynecomastia and the biological 
plausibility of a reversal of chronic gynecomastia is unlikely. However, diet and exercise 
have been recommended for the treatment of pseudogynecomastia (enlargement of breast 
due to excessive adipose tissue and not glandular tissue (241)) for their combined general 
effect on muscle and adipose tissue (246). Aesthetically, this may be sufficient to 
appease men with PCa that are concerned with the appearance of overall excessive fat 
mass in the breast area. A chest skinfold, taken midway between the axilla and nipple, is 
utilized to measure subcutaneous fat in the breast region representing a relatively easy 
approach to assess the effect of exercise on fat tissue in this problematic region. 
These changes in body composition, metabolism, and muscular strength may 
negatively affect HRQOL in several ways. First, body image dissatisfaction is commonly 
reported, which can negatively affect self-esteem, self-confidence, and potentially cause 
patients to refrain from social engagement (247, 248). Second, deterioration in physical 
capacity can reduce recreational physical activity participation and leisure activity that 
may have physical, mental, and social implications. Third, reductions in general physical 
activity that have been reported ( 49) and are particularly important given the positive 
relationship between obesity and sedentary behaviour and a number of chronic. diseases, 
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including cardiovascular disease, diabetes, hypertension, cerebral vascular accident, 
osteoarthritis (249, 250). These are notwithstanding the direct association between ADT 
and metabolic and cardiovascular disease as well as osteoporosis ( 44-46). The aggregate 
effect of multi-morbidity further diminishes HRQOL (251 ). Collectively, the physical 
adverse effects of ADT have profound, undesirable effects on a several aspects of overall 
wellbeing (13, 198, 200, 223, 252). Exercise, because of its unparalleled benefit for 
physical health, has been an obvious lifestyle intervention strategy to ameliorate and 
reverse many of the physical changes associated with ADT. 
2.5.1 The Effect of Exercise on Body Composition for Prostate Cancer Survivors 
Undergoing ADT 
All exercise studies with PCa patients undergoing ADT (including concurrent 
radiation therapy) have reported on body composition outcomes. This is expected in light 
of the anthropometric adverse effects of the treatment and the anticipated clinical benefit 
of exercise for body composition. Researchers have assessed muscle and adipose tissue 
using numerous techniques, including: dual energy x-ray absorptiometry (DEXA) for 
localized and total body lean and fat mass (21, 23, 121), DEXA for BMD and bone 
mineral content (121 ), quantitative ultrasound for BMD (26), magnetic resonance 
imaging for quadriceps thickness (27), body fat percentage via skinfold measurements 
(triceps, biceps, subscapular, and iliac crest sites) (120), and waist circumference (24, 30, 
120, 122). Despite the universal hypothesis that exercise would improve some facet of 
body composition, the effects on body composition have been relatively modest 
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irrespective of the modality of exercise prescription parameters. However, it is apparent 
that exercise in the facility-based context provided more benefits for body composition 
outcome. Among the four home-based exercise programs, no study demonstrated an 
improvement in a body composition outcome. Culos-Reed et al (24) observed a slight 
increase in weight (p = 0.08) and body mass index (BMI) (p = 0.02). In the second trial 
in ADT patients by Culos-Reed et al (122) using the same home-based intervention in an 
RCT, exercising participants did not show an improvement in any measurement of body 
composition; however, neck girth (mean~= 0.71cm; p = 0.046) and waist circumference 
(mean ~ = 2.06cm; p = 0.059) increased from baseline to 16-weeks in control 
participants. These differences contributed to a Group x Time interaction effect for both 
variables (p < 0.05). One study examined the effect of a 12-week intervention that 
incorporated six weeks of primarily facility-based exercise followed by six weeks of 
primarily home-based exercise, in conjunction with dietary guidance that also did not 
provide body composition benefits (28). 
Four out of seven facility-based exercise intervention studies that examined body 
composition outcomes among ADT patients found an improvement in at least one 
measure (21, 23, 26, 121). Of the four studies that demonstrated an improvement in body 
composition, one was a pure RET program (121) while the rest were combined-modality 
programs (21, 23, 26). In the one pure RET intervention, Galvao et al (121) found that 
quadriceps muscle thickness increased by nearly 16% (SD = 12.1; p = 0.05). 
Unfortunately none of the other 10 measures of body composition were altered, including 
total body fat mass, BMD, lean mass or upper arm thickness. In contrast to their original 
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trial, Galvao et al' s second study of combined AET and RET intervention versus usual 
care controls found between-group differences for all of their measures of lean mass 
(total body, upper limb, lower limb, and appendicular skeletal muscle; all p < 0.05) but 
no difference in fat measures. In the subgroup of PCa patients undergoing radiation and 
ADT, Segal et al found that RET, and not AET, reduced total body fat percentage 
compared to controls (RET: - 2.79%, 95% CI= -4.71 to -0.87, p = 0.005; AET: -0.4%, 
95% CI=-2.6 to 1.8, p = 0.726). Finally, we recently reported that personal training 
improved waist circumference by approximately 2 cm (p < 0.1) and body fat percentage 
by almost 8% (p < 0.05) after 8 weeks of mixed-modality training (26). We did not 
observe, however, any improvements in weight, BMI, or BMD in either group-based 
exercise or personal training participants. 
The absence of meaningful benefit to body composition in home-based or partial 
home-based exercise trials for PCa patients may be attributed to a lack of programmatic 
intensity that failed to stimulate adaptation. In only two of these trials were exercise 
prescription details reported, and interestingly, both of these trials also included dietary 
recommendations or education but neither produced a change in body composition (28, 
30). In both trials by Culos-Reed et al (24, 122), although home-based exercise 
equipment was provided (resistance bands and an exercise ball), no specific intensity or 
duration of the three to five recommended exercise sessions was described. Another 
possible reason for poor fat and muscle response to the exercise intervention may be low 
adherence to one or all dimensions of the exercise prescriptions (intensity, frequency, or 
duration). To facilitate adherence, three studies investigated theory-based group exercise 
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classes designed to enhance motivation and social support while addressing barriers to 
exercise (24, 30, 122). However, only one home-based program provided actual 
objective monitoring of physical activity volume, providing their participants with 
pedometers (30). Unfortunately, pedometers do not address the critical element of 
intensity in an exercise program. A heart rate monitor would likely provide better 
information regarding intensity because they often allow for the input of upper and lower 
limits of exercise intensity with audible cues that can alert participants to stay within their 
prescribed intensity range. 
Further distinctions in the evidence regarding the effect of exercise on body 
composition in this population are drawn between AET and RET. All three of the 
facility-based programs that did not improve body composition were pure RET programs 
(27, 120, 180). In the two other pure RET programs, one found significant improvements 
in body fat percentage by almost 3% compared to controls (21) and the other found an 
increase in quadriceps muscle thickness by ,..., 16% ( 121 ). Across both of these trials, these 
were the only two body composition outcomes that improved of the 13 that were 
measured. Conversely, it appears that mixed-modality exercise has been most effective 
at improving body composition, although the relative contribution of AET to 
anthropometric changes has not been studied thoroughly. Only Segal et al (21) used a 
pure AET intervention in ADT therapy patients undergoing concurrent radiotherapy and 
found no difference between exercisers and controls. In theory, the metabolic cost of 
AET should exceed that of RET given the prolonged continuous activity required. 
Alternatively, RET should stimulate the muscular development to a greater extent than 
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AET because of the adaptation to microtears of the muscle fibers that occurs. It appears 
that a combination of AET and RET is most appropriate; however, the relative 
contributions of each modality, particularly in the home-based setting are unclear. Thus, 
further examination of modality specific training among ADT-only patients is warranted 
to clarify the roles of these training approaches. This is especially important in the home-
based setting as chronic physical activity is required to maintain healthy body 
composition. 
2.5.2 The Effect of Exercise on Physical Performance for Prostate Cancer Survivors 
Undergoing ADT 
Compared to the effects of exercise on body composition, physical capacity has 
been considerably more responsive to training in men with PCa treated with ADT. As 
would be expected, all exercise studies in this population have assessed exercise or 
functional capacity in some way as a measure of intervention efficacy. The most 
common measure used to assess fitness has been the six-minute walk test, which was 
used in four trials (24, 27, 30, 122) and is generally considered a reliable measure 
functional capacity in older adults that correlates well with direct measures of maximal 
oxygen consumption (225, 253, 254). In addition to the six-minute walk test, functional 
capacity has been measured by the sit to stand test (23, 28, 121), six-meter walking test 
(forward and backward) (23, 121), hand grip dynamometry (24, 122) and the timed-up 
and go test (27). In addition to functional tests, more conventional performance-based 
fitness tests have been employed, such as directly measured V02 peak (21, 26), isokinetic 
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muscular strength (23, 26-28, 121), and upper and lower body muscular endurance by a 
standard load test (21, 23, 120, 121). 
Again, discordant effects have been observed in the home-based and facility-
based setting. Two of the four home-based studies assessing physical fitness have 
produced statistically significant improvements in findings, but have been relatively 
minor and the clinical utility of such changes may be questioned. In a sample of ADT-
only patients, · Culos-Reed et al (24) found an approximate seven meter increase in six-
minute walk test performance from baseline to 12 weeks, but this is far below even 
conservative estimates of clinically important improvements (54 to 80 meters) (255). 
Windsor et al (66), however, found that walking distance using the Modified Shuttle Test 
improved by approximately 70 meters over four weeks of home-based AET. It should be 
noted that more than 70% of participants in this trial were not undergoing ADT, but 
rather, were receiving radiation therapy only and no stratified analysis was provided for 
patients receiving concurrent therapy. 
Facility-based exercise, on the other hand, has produced fitness benefits in all 
studies with ADT patients, with many of the improvements having clinical relevance. 
Segal et al (120) observed an approximate 20-40% improvement in upper and lower 
extremity muscular endurance after 12 and 24 weeks of RET compared to controls in 
men receiving ADT with and without external beam radiation (21, 120). In a small 
sample of ADT patients (n = 10) undergoing 20 weeks of high-intensity RET, Galvao et 
al (121) demonstrated between 40 and 96% improvements in muscle strength (chest 
press, seated row, and leg press; p < 0.001) and between 115% and 167% in muscular 
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endurance (chest press and leg press; p < 0.001). In their second trial that combined AET 
and RET versus usual care controls over 12 weeks in a sample of n = 57, Galvao and 
colleagues (23) reported comparable effect sizes for the exercising group which were 
significantly greater than controls. Hansen et al (27) found an almost 20% improvement 
in right leg isokinetic strength after 12 weeks of eccentric resistance training in ADT 
patient . Finally, in terms of musculoskeletal fitness, we recently observed a 90% and 
40% improvement in maximal leg strength in personal training and group-based exercise, 
respectively. 
The findings regarding the effect of exercise on aerobic fitness have been less 
impressive across facility-based trials. In the two studies assessing cardiorespiratory 
fitness using directly measured V02 peak, the measure remained unchanged following 
mixed modality, AET, or RET interventions (21, 26). Functional measures of 
cardiorespiratory function appeared to be only slightly more responsive to exercise 
training. Galvao et al ( 121) observed modest improvements in timed walking 
performance or chair-rise tests compared to controls after 12 weeks of mixed modality 
training (400-meter walking time, mean between groups/),.= -7.0 seconds, 95% CI: -15.0 
to 0.88, p = 0.08; chair rise test: mean between groups /),. = -1.0 seconds, 95% CI: -0.1 to 
2.1, p = 0.074). Although, in Galvao's 20-week pure RET single arm trial, more 
substantial improvements in 400-meter walk test and chair rises were observed ( 400-
meter walking time, mean within groups /),. = -26.8%, SD: 7.1, p < 0.001; chair rise test: 
mean with groups/),.= -7.4%, SD: 5.9, p = 0.003) (121). 
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Across trials that have investigated the effect of exercise on physical fitness 
outcomes, the findings have been generally positive with more substantial benefits related 
to facility-based, RET programs. However, pure AET programs have received minimal 
investigation with one study in each of the facility-based and home-based settings using 
this type of training approach. Moreover, in both of these trials, AET was investigated 
among patients that were undergoing ADT and radiation therapy. Pure AET programs 
have yet to be examined in an ADT-only population. This is significant because radiation 
therapy is associated with significant fatigue and physical deconditioning independent of 
ADT, and ADT tends to be a chronic treatment with long-lasting adverse effects that 
would benefit from sustained exercise. Common AET prescriptions, such as walking, are 
likely more amenable to sustained participation because they are familiar and easily 
adaptable to training settings. In this respect, facility-based trials are not generalizable to 
many sectors of the population that cannot afford to continue supervised training in a fee-
for-service institution and tertiary care hospitals are, at present, not able to sustain clinical 
exercise programs. As such, a comparison of AET and RET, as well as an independent 
evaluation of their pre-post intervention effects, is necessary in the home-based context 
will provide important information about the clinical efficacy and long-term 
sustainability of the two primary modalities of exercise training. 
2.6 Fitness-related Biomarkers and their Role in Tumourigenesis in Prostate Cancer 
The overt, physical manifestations of androgen suppression, physical fitness, 
increased fat mass, and reduced muscle mass and bone density, result from a fundamental 
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alteration of endocrine balance ( 42, 48, 49, 52). While distressing, more insidious are the 
changes that contribute to a tumourigenic environment that may facilitate tumour 
progress10n. The paradox of ADT, and other cancer therapies is that their anti-
proliferative effects are often eventually counterbalanced by increased risks of cellular 
mutation of the original tumour, rendering it subsequently unresponsive to many 
therapies and possibly resulting in the growth of secondary cancers (256-258). It is well 
recognized that PCa in the presence of ADT eventually develops into a castrate-resistant 
state (also termed androgen independent or hormone refractory), meaning tumour 
proliferation resumes despite the low androgen environment (259). This advanced stage 
of PCa is associated with significantly higher mortality despite intensive chemotherapy 
(260). A hypothesis for hormone-refractory PCa is that the PCa phenotype is inherently 
aggressive and maintains stem-cell properties that do not require androgens for survival 
and growth (259). Therefore, alternative growth factors, or local adipokines, may figure 
in the development or progression of PCa. Creating an anti-tumourigenic environment 
through the limitation of alternative growth factors may have an important contribution to 
disease control. Lifestyle interventions, such as diet and exercise, have shown to 
favourably influence human biology and potentially reduce the risk of PCa 
progression/recurrence, although the mechanisms remain elusive and not well understood 
(261). 
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2.6.1 Effect of Leptin and Adiponectin on Prostate Cancer 
The effect of androgens on PCa development and progression is well documented. 
It is less clear, however, how obesity and excess weight affect androgen levels and 
subsequent PCa risk. Age-related declines in testosterone in addition to obesity-related 
hypoandrogenemia (262) are potential reasons why a higher proportion of advanced PCa 
is diagnosed in obese men. This is especially true when abdominal adiposity exceeds 
healthy recommendations (263, 264). In this scenario, obesity-related hypoandrogenemia 
provides an environment where aggressive and androgen-insensitive disease may flourish 
while coincidentally reducing the incidence of low-grade, non-aggressive disease (264). 
Beyond the effects of obesity on testosterone, there are direct mechanisms of cell-cycle 
control via adipokines (cell signalling proteins originating in fat/ adipose tissue) notably 
adiponectin and leptin. Adipokines have cell-cycle accelerating and arresting qualities 
through autocrine and paracrine effects2. With respect to PCa, adipokines may exert a 
paracrine effect on localized disease due to excess adipokine excretion from the 
retropubic, periprostatic fat pad (265). The adipokines adiponectin and leptin, in 
particular, work in mutually antagonistic ways, with leptin being pro-proliferative and 
adiponectin being anti-proliferative. Therefore, the ideal anti-proliferative effect would 
involve relative reductions in leptin and increases in adiponectin. 
Leptin, first identified in 1994, is an adipokine predominantly secreted by white 
adipose tissue (266). Leptin's role is to regulate satiety and energy expenditure by 
2 autocrine: a form of cell signalling where the cell secretes a chemical messenger, or hormone, that 
influences its own su9sequent activity; paracrine: a form of cell signalling where the cell secretes a 
chemical messenger that influences other proximal cells. 
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informing the brain of energy stores (i.e. fat) (267). The coding gene for leptin, known as 
the 'obesity gene' or Ob gene, has been termed such because of its association with 
human obesity (268). Given its relationship with obesity and its tumourigenic properties, 
several studies have assessed the association between leptin and several cancers, 
including PCa (269). In a review of thirteen epidemiological studies, Hsing et al (270) 
reported inconclusive evidence linking leptin with PCa incidence. Nonetheless, leptin's 
effects on PCa cells in vitro have been shown to stimulate growth of androgen-dependent 
and independent PCa cells (LNCaP versus DU145 and PC-3, respectively) (271-277). 
Recent findings suggest that leptin-mediated cell cycle regulation is also linked to 
alterations in p53 and BCl-2 expression (277), which may also have influences on cancer 
recurrence following treatment. 
Adiponectin has the highest serum concentration of all adipokines, accounting for 
up to 0.05% of all plasma protein (278) and is inversely correlated with obesity and 
several morbidities, including cardiovascular disease and diabetes (265, 278). 
Adiponectin deficiencies have been associated with leukemia, and cancer of the breast, 
liver, and prostate (279-286). Low adiponectin levels have also been correlated with 
histological grade and stage of PCa (286). Adiponectin has been termed the "anti-cancer 
adipokine" because of its demonstrated anti-proliferative effects on various cancer cells 
(287). These protective benefits occur through many potential pathways that impact 
carcinogenesis, proliferation, and angiogenesis (287, 288). 
Dysregulation of leptin and/or adiponectin is related to obesity in humans and has 
been implicated as a risk factor for PCa incidence and progression. ADT has consistently 
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shown to increase body fat percentage and waist circumference, as well as increase risks 
of diabetes mellitus ( 46). This is relevant because the core elements of metabolic 
syndrome (associated with Type 2 diabetes) have also been shown to increase cancer 
risks (289). Changes in total and regional adiposity may contribute to adverse 
leptin/adiponectin ratios. Conversely, maintenance of a healthy weight and/or weight 
loss may contribute to healthier levels of these hormones and subsequently improved PCa 
prognosis. Healthy body composition may be achieved through lifestyle interventions 
like exercise which has been shown to improve PCa survival ( 110), although with few 
direct investigations of the potential biological, tumour control mechanisms (115-118). 
2.6.1.1 Effect of Exercise on Adiponectin and Leptin with Reference to Cancer 
Control 
In the oncologic literature, there is a paucity of research on both the acute and 
long-term effects of exercise intervention on adiponectin and leptin levels, despite the 
aforementioned tumourigenic properties of various adipokines In a pre-post test study of 
16 older, obese adults (without cancer) participating in a 12-week AET and stretching 
program, 0 'Leary et al ( 69) demonstrated significant reductions in body weight and fat 
mass, as well as leptin, but no change in adiponectin. Fatouros et al (70) examined the 
impact of a 48-week RET program for elder men (N=50) that compared various 
intensities (low, moderate, and high-intensity) of training. At post-test, the researchers 
found that leptin was reduced in each intervention group (p<0.05) and adiponectin was 
increased in the high intensity intervention group only (p<0.05). They additionally 
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reported that changes in leptin were positively associated with changes in BMI and sum 
of skinfolds. They also found that leptin was negatively associated with changes in V02 
max; a relationship first reported by Pasman et al (71) in a study of 15 obese males that 
described exercise-related changes in leptin that were independent of changes in body fat. 
Despite these promising results, the effects of exercise on an elder population of PCa 
patients that is susceptible to deleterious changes in body composition that can affect 
adiponectin/leptin ratios, have not yet been examined. 
2.6.2 Effect of Insulin-Like Growth Factors on Prostate Cancer 
Insulin-like growth factors (IGF) were discovered in 1957 and share similar 
structural characteristics to insulin (290). Whereas insulin primarily acts on the liver, 
muscle and fat, IGFs are produced by the liver under regulatory control of the 
hypothalamus (via growth hormone-releasing hormone) and the pituitary gland (via 
growth hormone) (290, 291). IGFs can be produced by most tissues in the body and cell-
cycle regulation (and hence proliferation, differentiation, and apoptosis) through 
autocrine and paracrine mechanisms (292). IGFs are regulated by high-affinity binding 
proteins (IGFBPs) that are regulated by dietary factors, whereas IGFBP concentrations 
are lowest in the nutritionally satiated state versus highest in the fasting state (293, 294). 
Of the 6 IGFBPs, IGFBP-3 is the most abundant pairing with nearly all of the circulating 
IGFs (292, 295). 
IGF increases cellular proliferation by increasing DNA synthesis and by 
stimulating cyclin Dl (a key cell-cycle regulator that promotes transition from the G 1 to 
54 
S phase) (295). IGF also has anti-apoptotic qualities as it increases the expression of Bel 
and suppresses Bax (296) to mediate the activity of p53 (an apoptotic protein) (117). IGF 
has also been shown to stimulate vascular endothelial growth factor (VEGF) in the 
promotion of angiogenesis (297, 298). These 'pro-growth' qualities have implicated IGF 
in a number of cancers, including PCa (97, 299-305). The risk of PCa relative to IGF 
may be more than 4 times greater in those in the highest quartile compared to those in the 
lowest quartile (305). Increased risk is also associated with decreased IGFBP-3 
concentrations (306-309). Mechanistically, the IGF-axis may be linked to PCa through 
lifestyle risk factors. Abdominal adiposity and hyperinsulinemia reduce sex-hormone 
binding globulin (SHBG) which increases bioavailable testosterone and reduces IGFBPs 
(71, 114, 119, 303, 310, 311). Furthermore, a diet high in fat is known to increase PCa 
risk (104) and IGF-1 is positively associated with red meat and fat intake and negatively 
associated with carbohydrate and protein intake (312-314). 
As previously stated, ADT can negatively influence body composition in ways 
that increase adiposity and is related to insulin insensitivity. These deleterious changes in 
body composition and metabolism create an environment for the IGF-axis to favour 
malignant growth. Impeding the typical transition into a state of, or approaching, 
metabolic syndrome through life sty le approaches such as exercise would be 
advantageous in terms of reducing the bioavailability of these tumour promoting growth 
factors. 
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2.6.2.1 Effect of Exercise on the IGF Axis 
Chronic physical activity has been associated with reduced levels of circulating 
IGF-1(300,303, 315, 316). The effect of exercise on the IGF-axis is not well described 
but generally considered to be intimately related to insulin and metabolism. Exercise 
may reduce liver and muscle insulin-resistance and increase glucose uptake through 
postreceptor insulin signalling (including the Glut-4 pathway), increasing glycogen 
synthesis, increased metabolism of free fatty acids, elevated muscle glucose delivery 
through greater capillary density, and changes in muscle composition that favour 
increased glucose metabolism (317). As previously stated, insulin suppresses IGFBP 
concentration (318, 319), therefore means to reduce insulin are protective against the 
proliferative qualities of I GF-1. It is worth noting, however, that increases in I GF -1 
following acute bouts of exercise have been observed and may be due to an acute 
increase in pituitary activity and growth hormone secretion (320). 
At present there is no interventional research that has examined the effect of 
exercise on the IGF axis in men with PCa. A recent series of studies in older men 
demonstrated that chronic (> 14 years) and relatively acute (11 days) participation in an 
exercise program combined with maintenance of a low-fat diet resulted in serum changes 
in vivo that reduced the proliferation and increased the apoptosis of androgen dependent 
PCa cell lines (LNCaP and LAPC-4) in vitro (113-116). In a follow-up study to this 
series, Barnard et al (118) sought to determine the relative role of chronic exercise 
(without dietary intervention), by culturing LNCaP cells in serum from elderly men 
participating in a long-term fitness program only. They found that, in vitro, tumour cell 
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proliferation was reduced with concomitant increases in apoptosis when serum from the 
exercising men was compared to serum from obese, sedentary men. To determine the 
relative role of IGF in this experiment, they strategically blocked IGF using tryphostin in 
the serum from sedentary men and observed that the anti-proliferation and enhanced 
apoptosis effects were comparable to those seen in the exercise serum (indicating that 
IGF was likely driving the proliferative and anti-apoptotic characteristics of serum from 
less healthy men). This suggested that the chronic exercise effects on the IGF-axis might 
be similar to the administration of known I GF -1 inhibitors and likely due to changes in 
apoptotic and anti-apoptotic proteins (p53, p21, and Bcl-2). It is worth re-emphasizing 
that these studies have only been conducted with serum healthy men and measurement 
of I GF-1 concentrations in vivo have not been conducted in a PCa population undergoing 
exercise. 
Only one RCT within a cancer population has investigated the effects of an acute 
exercise intervention on the IGF axis. Fairey et al (321) demonstrated reduced IGF-1 (p 
= 0.045), increased IGFBP-3 (p = 0.021 ), and decreased molar ratio ofIGF-1 :IGFBP-3 (p 
= 0.017), all anti-proliferative changes, in a population of post-menopausal breast cancer 
patients undergoing 15 weeks of AET compared to controls. Other intervention-based 
studies in healthy, older adults have yielded inconsistent results regarding the impact of 
exercise on the IGF-axis (322-329). When juxtaposed to the rather convincing literature 
regarding chronic exercise and IGF, whether or not IGF axis is responsive to short 
duration interventions remains unknown. Furthermore, what exactly constitutes a 'short-
duration' is also difficult to discern from existing literature. Intervention-based research 
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that serially collects IGF-axis proteins over an extended period(> 15 weeks) is needed to 
assess when the IGF-axis is responsive to changes in physiology associated with exercise 
and whether or not exercise modalities that have distinct metabolic benefits have 
differing influence on these biomarker concentrations. Ultimately, the essential objective 
in this strategy is to reduce IGF-1 and increase IGFBP-3 as quickly as possible and to 
maintain these changes as long as possible. 
2. 7 Determinants of Exercise Adherence 
Research concerning the psychosocial determinants of physical activity in cancer 
survivors is essential because exercise benefits are rapidly lost when exercise is 
discontinued (24, 330). Thus, adherence is essential during the intervention to achieve 
benefit and after the intervention to maintain benefit. To effectively promote and support 
adherence throughout the continuum of exercise behaviour, a deeper understanding of the 
psychosocial factors that determine exercise adherence is needed. In healthy populations 
this is challenging as individual variability in motivation and attention must be 
considered. The task is even more daunting in clinical populations where individual 
variability in motivation and intention are compounded by additional disease-related 
psychosocial and physical barriers to health behaviours. This is apparent in the existing 
literature that generally describes a reduction in physical activity during cancer treatment, 
which often does not return to baseline, even several years after treatment completion 
(331-335). 
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Early research on the determinants of physical activity after a cancer diagnosis 
has lacked a consistent theoretical orientation. However, researchers have generally 
gravitated towards established cognitive-behavioural theories to understand health 
behaviours in the oncological context (340). Health-behaviour models commonly used to 
describe and predict physical activity in cancer survivors include Ajzen's Theory of 
Planned Behaviour (TPB) (341), Bandura's Social Cognitive Theory (SCT) (148, 149), 
and Prochaska and DiClemente's Transtheoretical Model (TTM; also known as the 
Stages of Change Model) (146, 147). More recently, measures of social support and 
exercise-induced feelings have been integrated as independent correlates or potential 
mediators of other theoretical frameworks (30, 342-346). As scientists continue to 
explore various determinants of exercise behaviour, multiple theoretical constructs can be 
tested across different cancers. 
2. 7.1 Theoretical Models of Exercise Behaviour in Cancer Survivors 
2.7.1.1 Theory of Planned Behaviour 
The TPB is the most frequently used theoretical model to describe exercise 
behaviour in cancer survivors during and after treatment. The TPB proposes that the 
intention to perform a behaviour is highly predictive of the actual performance of that 
behaviour because intention reflects motivation and the willingness to invest effort in 
actualizing behaviours (341 ). This model contends that attitude, subjective norm, and 
perceived behavioural control all influence intention and subsequently behaviour change 
(see Figure 2 for TPB model). The element of 'attitude' refers to one's positive or 
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negative evaluation of performing the behaviour (e.g. "I feel that exercising is ... "). 
Subjective norm reflects the perceived social pressure that one may feel to perform or not 
perform the behaviour (e.g. "I believe that exercise will be perceived favourably by 
important others"). Finally, perceived behavioural control can be defined in a similar 
fashion to self-efficacy, that is, the perceived ease or difficulty with which the behaviour 
may be performed, reflecting one's control over a behaviour (e.g. "I believe that I can 
routinely complete my exercise prescription"). Using the example of exercise, the TPB 
proposes that individuals will exercise if they intend to exercise because they 1) maintain 
a positive evaluation of exercise, 2) believe that important others think they should 
exercise, and 3) perceive that the successful performance of exercise is within their 
control. 
In describing physical activity behaviours, the TPB has been studied in breast 
cancer (340, 347-356), colorectal cancer (332, 357), bladder cancer (358), lymphoma 
(359-361), multiple myeloma (362), ovarian cancer (363), brain cancer (364), head and 
neck cancer (365), mixed-cancers (including child and adolescent cancer survivors) (366-
373), and specifically in PCa (339, 347, 374). Across studies, the TPB has explained 
between approximately 30% - 70% of the variance in intention to exercise, with specific 
TPB dimensions (i.e. social norm, perceived behavioural control, and attitude) 
independently contributing to the overall explained variance depending on cancer type 
(375). 
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2.7.1.2 Social Cognitive Theory (SCT) 
Self-efficacy is the central determinant of behaviour change according to 
Bandura's Social Cognitive Theory (SCT) and is arguably the strongest and most 
consistent predictor of exercise behaviour in current literature (148, 149, 376). Self-
efficacy refers to people's beliefs about their capacities to successfully perform specified 
behaviours (148). Relative to exercise behaviours, self-efficacy is often referred to as the 
confidence to overcome various barriers to physical activity participation (i.e. barrier 
efficacy) and the confidence to perform the constituent components of healthy exercise 
behaviour appropriately (i.e. task efficacy) (342). The inclusion of barrier efficacy, 
specifically, allows for the consideration of environmental factors that may influence 
exercise behaviours, like the availability of exercise facilities or equipment and 
transportation to exercise facilities. Also fundamental to the SCT are outcome 
expectancies, oriented towards positive or negative self-evaluations (e.g. an emotional 
response), physical outcomes (e.g. pain or pleasure), and/or social outcomes (e.g. 
approval or disapproval from peers). 
The SCT has been used to explain physical activity behaviours in breast cancer 
(342, 354, 377-385, 388, 389), colorectal cancer (384, 386), lung cancer (387), and PCa 
(30, 384). Some researchers have used the SCT as a guiding theoretical model in 
developing exercise interventions, by focusing on exercise instruction and strategies to 
overcome barriers to exercise (e.g. setting time aside for daily exercise, providing 
participants with home-based exercise equipment or training manuals, routine discussion 
with an exercise professional to address unique barriers, etc.). While these approaches 
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have been relatively effective at increasing physical activity volume in those that are not 
exercising, their effect compared to exercise programming that does not included an 
efficacy-boost strategy is unknown. Furthermore, their effects on measures on exercise-
specific self-efficacy have not been described. 
2.7.1.3 Transtheoretical Model 
The TTM is another well-established psychological framework that has been used 
to describe physical activity behaviours in cancer survivors, albeit to a lesser extent than 
the SCT and the TPB. According to the TTM, people move through six stages of 
readiness with respect to health behaviours (146): 1) pre-contemplation (unaware of or 
not acknowledging an unhealthy behaviour that requires change), 2) contemplation 
(aware/acknowledgment of an unhealthy behaviour, debating the pros and cons of 
behaviour change), 3) preparation (taking necessary steps towards a healthy behaviour 
change), 4) action (actual participation in the desired health behaviour), 5) maintenance 
(continuing to participate or act in a desired way, relative to the health behaviour), and 6) 
relapse (returning to the previous unhealthy behaviour) (146). While transitioning 
between stages of the TTM, individuals engage in various cognitive and behavioural 
processes of change (e.g. self and/or circumstantial evaluation, purchase of exercise 
equipment, contingency management) that play significant roles in the initiation and 
maintenance of health behaviours. This model of health behaviour change is useful for 
characterizing the motivational state that can be targeted with specific approaches to 
intervention delivery. For example, for the cancer patient in a pre-contemplation state, 
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education-based interventions may be most effective in raising awareness of the benefits 
of exercise. The TTM has been applied to explain exercise behaviours among breast 
(354, 379, 382, 385, 388-392), lung (387, 393), and mixed cancer patients(384). Two 
trials have also incorporated the TTM into exercise interventions for PCa patients (30, 
391). 
2.7.1.4 Self-Determination Theory 
An emerging theoretical approach to assessing and enhancing the psychosocial 
determinants of exercise in cancer is the Self-Determination Theory (SDT) which 
postulates that healthy behaviours are regulated by motives that are internally and 
externally oriented (394). These motives range across a continuum from completely 
extrinsic motivation (external influence on motives) to completely intrinsic motivation 
(internal desire to complete a behaviour) (see Figure 4). People may perform 
extrinsically motivated behaviours in response to a threat (including the threat of chronic 
disease) or, conversely, in response to an external reward system. Conversely, their 
intrinsically motivated behaviours may satisfy an inner pleasure or challenge orientation. 
A state of amotivation may also exist with respect to a particular behaviour when a 
person feels no intrinsic or extrinsic motivation to perform a behaviour. Deci and Ryan 
(394) suggest that intrinsically motivating factors are most predictive of health behaviour 
change owing to greater personal interest, confidence, and persistence for that behaviour. 
Only a few studies have used the SDT to predict physical activity in cancer patients (395-
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399), but some investigators believe its application has provided additional insights 
beyond the more established theoretical frameworks in this field (399). 
2. 7 .2 Theoretical Models of Exercise Adherence in Prostate Cancer 
Only 30% of men with PCa maintain an exercise program sufficient for health 
benefit (336-339). However, when PCa patients are offered an exercise intervention, 
they appear relatively receptive as participation rates in research-based exercise programs 
range from 64 % to 100%. Participation in the exercise program once enrolled, on the 
other hand, is more difficult to ascertain because of the considerable variance in 
interventions employed and exercise adherence assessment methods used. Nonetheless, 
it is important to gain whatever insights are possible into the 'quality' of adherence and 
the determinants of exercise behaviour to effectively design interventions that result in 
better adherence and benefits that extend beyond programmatic periods. The ultimate 
goal in this respect is to achieve a lifestyle change or enhancement that includes more 
routine exercise. 
Determinants of programmatic exercise adherence in PCa is not well understood 
as few studies have applied psychosocial theoretical framework investigations during the 
intervention periods (64, 337, 339, 347). In a RCT by Courneya and colleagues (64), the 
researchers examined TPB and TTM-based predictors of adherence to RET in ADT-
treated PCa survivors (as measured by number of supervised sessions attended) and 
found that intention, age (higher age predicted lower adherence) and exercise stage-of-
change were the strongest predictors of exercise adherence, accounting for 20.4% of the 
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variance. Blanchard and colleagues (339) found that intention (TPB) explained 36% of 
the variance in exercise behaviour among 46 PCa survivors participating in a mail-in 
survey of physical activity volume and behavioural determinants. The TPB constructs of 
subjective norm and perceived behavioural control have also been shown to be 
independent predictors of physical activity in PCa survivors (337, 347). 
In an attempt to improve physical activity in breast and prostate cancer survivors 
via print-based materials, researchers have combined SCT and the TTM to improve the 
fidelity of their interventions (384, 400-402). In the largest of these trials, Demark-
Wahnefried and colleagues examined the role of print-based health lifestyle materials in 
the FRESH START trial for breast and prostate cancer patients in a randomized, single 
blind trial ( 400-402). The intervention was designed to promote healthy changes in 
eating and exercise with the following specific goals: 150 minutes or more of moderate to 
vigorous exercise per week, consumption of more fruits and vegetables per day, and 
restriction of total and saturated fat to less than 30% and 10% of daily caloric intake, 
respectively ( 400). To achieve this substantial change in healthy behaviours, the 
researchers developed a comprehensive theory-driven, home-based program using the 
SCT and TTM. The SCT was implemented by focusing on improving self-efficacy, self-
monitoring, and goal setting to improve health behaviour intention, and subsequently, 
performance ( 400). The TTM was incorporated through tailored print messages mailed 
to participants which were constructed based on their current stage of change, providing 
stage-related motivation and/or education to facilitate behaviour change ( 400). To 
support the home-based program, patients were provided with a workbook, resistance 
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bands, a pedometer, and a senes of personalized mailed-out newsletters meant to 
encourage participants throughout the program ( 400). N = 543 breast (n = 306) and 
prostate cancer survivors (n = 237) were randomly assigned to the FRESH START 
intervention or to an attention-control group. Participants in both groups completed 
fitness assessments and questionnaires over the 12-month intervention period and at one-
year post-intervention (401, 402). At 12 months, both study groups improved their 
lifestyle behaviours (p < 0.05); however, FRESH START participants reported more 
frequent: practice of two or more goal behaviours (p < 0.0001), exercise minutes per 
week (p = 0.02), fruit and vegetable consumption per day (p = 0.01), and less dietary fat 
intake (total: p<0.0001; saturated fat: p=0.004) (401). Over 12-months, both groups 
decreased BMI although more participants in the intervention arm shifted from 
overweight (BMI = 25.0 to 29.9 kg/m2) to normal weight (BMI = 18.5 to 24.9 kg/m2). At 
one-year post-intervention, participants in both groups were engaging in similar physical 
activity volume, which was achieved by a reduction from post-intervention physical 
activity volume levels in the intervention group and a slight increase in physical activity 
volume from baseline in the control group. This suggests that, over time, home-based 
print materials can help improve chronic physical activity, but adherence eventually 
decays to levels comparable to non-intervention participants. This study once again 
emphasizes the importance of long-term adherence and current deficits in our 
understanding and influencing adequate chronic behaviour change in this population. 
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2.7.3 New Theoretical Approaches to Facilitating and Understanding Post-
Intervention Exercise Adherence in Men with Prostate Cancer Receiving ADT 
Exercise interventions for PCa survivors receiving ADT have been effective at 
improving a number of clinically relevant outcomes over the course of study. Given this 
demonstrated efficacy, greater attention must be shifted towards understanding the 
maintenance of post-intervention exercise adherence, especially because the determinants 
of exercise initiation and adherence are not always similar ( 403). Furthermore, 
preliminary investigations into the determinants of exercise in PCa have incorporated 
established behavioural theories, while the roles of exercise-specific social support and 
the experiential effects of exercise (e.g. exercise-induced feelings or sensations) as they 
relate to exercise motivation behaviours remain under-studied. Exercise-specific social 
support and exercise-induced feelings require more investigation to understand their roles 
as potential determinants of health behaviours as they appear logically connected with 
exercise motivations, adherence and the subsequent effects on overall HRQOL (344, 345, 
404). 
As demonstrated in the FRESH START trial, physical activity participation in 
those that are intervened with by correspondence can achieve equivalence with 
participants that are not intervened with one year following the physical activity program. 
In that study, the intervention was personalized but not personal (i.e. face-to-face), per se, 
as all intervention-related communication was done through mail. Conversely, Culos-
Reed and colleagues (24) did intervene for 12 weeks in a more face-to-face fashion with 
PCa survivors receiving ADT, yet also observed that four months following the 
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intervention, vigorous physical activity participation declined with corresponding 
declines in HRQOL. These findings indicate that intervention-related motivations, 
exercise behaviours, and resulting benefits subside over a relatively short period 
following the formal programmatic period and can remain there for the indefinite future. 
An approach that combines the theoretical strengths of the FRESH ST ART study and that 
of Culos-Reed and colleagues may be to provide a personalized, home-based exercise 
program that is initially delivered face-to-face (i.e. exercise prescription that is based on a 
fitness assessment to personalize the parameters of exercise and demonstrated by an 
instructor to ensure basic competence with the program), followed up with routinely in-
person and via the telephone encounters to address barriers and support physical activity, 
that also incorporates theory-based print materials for immediate reference and exercise 
monitoring. Within this intervention design, an expanded face-to-face intervention 
period of 24 weeks (rather than 12 weeks) may be warranted to ensure that exercise 
comfort and familiarity are satisfactorily achieved and that a post-intervention follow-up 
occur somewhere between the 4 and 12 month follow-ups incorporated thus far. 
Specifically, 6 months appears to be an ideal time-point to measure adherence given the 
likelihood of people to continue exercising if they reach this milestone (350). Finally, 
objective measures of fitness such, as exercise sustained capacity following an 
intervention, would provide more reliable information regarding the adherence post-
intervention that is not obtainable through self-report. This type of intervention and 
adherence measurement approach would add considerable insight into the determinants 
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of exercise behaviour usmg the strengths (and acknowledging the weaknesses) of 
previous research groups. 
Given that a diverse range of factors likely influence physical activity in PCa 
survivors and that most survival expectancies of PCa survivors extend beyond six 
months, interventions for participants must incorporate a long term plan for activity. 
Fundamental to this element of exercise interventions will be to establish which factors 
are related to long-term adherence and then develop ways to exploit them for optimal 
long-term behaviour change. 
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3.0 Summary of Identified Empirical Gaps in the Literature of 
Exercise for Men with Prostate Cancer Receiving ADT 
1) A growing body of literature demonstrates the efficacy of AET and RET to improve 
a variety of physical and psychosocial outcomes for PCa patients; however, their 
respective effects, especially in the home-based setting, are not well understood 
among those treated with ADT-only. Furthermore, important aspects of body 
composition, such as body fat percentage or chest skinfolds, have not yet been 
examined in home-based exercise. 
2) Given that a) the duration of ADT treatment is often 2 years or more, and b) the 
benefits of an exercise intervention diminish when exercise is discontinued, 
strategies to enhance long-term adherence are essential. However, the extent to 
which PCa patients adhere to a personalized exercise prescription after the 
intervention ends is poorly understood. Furthermore, we know little about the 
psychosocial determinants of exercise in this population, especially with respect to 
social support and the experiential effects of exercise. 
3) Little is known about the effects of exercise during ADT for PCa in terms of the 
biomarker outcomes related to the tumourigenic environment, in particular the IGF 
axis and adipokines. ADT patients represent an important group to examine given 
the effects of ADT on body composition that may contribute to tumourigenesis when 
malignant cells become hormone-refractory. To our knowledge, no studies have 
examined these biomarkers in relation to cancer progression, nor have any assessed 
modality-specific effects. 
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4.0 Rationale for Feasibility Assessment 
Important questions remain regarding what type of exercise is best for PCa 
patients receiving ADT and if home-based exercise interventions can elicit comparable 
results to facility-based interventions, while producing better long-term adherence. To 
appropriately address these questions through conventional hypothesis testing research 
approaches, large sample sizes with appropriate institutional infrastructure, support, and 
expertise are needed. Given the scale and cost of such a study, it is prudent to ensure that 
conducting such a trial is feasible by the investigative group. According to Arain et al 
( 405), a feasibility study is "research done before the main study ... used to estimate 
important parameters that are needed to design the main study". Arain et al continue to 
describe the role of the feasibility study as a study that does not necessarily intend to 
definitively evaluate the outcome of interest (which should be left to the main study), but 
to determine estimates of outcome variance for sample size calculations and evaluate 
characteristics and suitability of the proposed outcomes measures for a given population. 
Additional essential elements of a feasibility study are to assess the willingness of 
participants to be randomized, recruitment participation from affiliate staff, the available 
pool of potential participants, adherence to protocols and compliance with follow-up 
schedules. While hypothesis testing is not the primary aim of a feasibility study, analyses 
are required to formally establish effect size estimates for future sample size calculations. 
Because they are statistically underpowered to detect clinically important changes in 
outcomes, feasibility studies must be interpreted as inconclusive, but the results of 
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hypothesis testing within this context are worth discussion in the hypothetical narrative to 
guide intervention or protocol re-evaluation and/or re-design ( 406). 
The Princess Margaret Hospital is internationally recognized as leader in cancer 
care and research, but it has not attempted a research study to investigate the role of 
exercise in disease management of this magnitude. Fortunately, a group of clinician-
scientists with expertise in psychosocial oncology, exercise, and urology have 
demonstrated significant interest and willingness to collaborate on exercise-based 
research; but evidence of support and capacity to overcome logistic challenges was 
needed. Thus, before embarking on such substantial research endeavour, it was deemed 
prudent to conduct a formal feasibility assessment of the research design and protocols 
before proceeding with a large-scale study. The intent of the feasibility study was to be 
as comprehensive as possible in order to assess methodological approaches for 
participant recruitment, data collection and management, site-based exercise program 
delivery, home-based exercise program delivery, routine follow-ups, adverse event 
occurrence and management, serum sample collection, and estimates of overall success 
of the intervention. The significant breadth of this undertaking was considered to provide 
an appropriate understanding of delivery capacity for multi-purpose exercise studies in 
the future. 
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5.0 Objectives 
Primary Objective: Feasibility Assessment 
Logistic and conceptual feasibility for a large-scale, adequately powered trial was 
assessed in this feasibility study using the following indices: 
1) Recruitment rate (recruitment-success percentage) 
2) Reasons for non-participation 
3) Study retention rate (throughout the intervention period and follow-up) 
4) Attendance rates to the group-based booster sessions 
5) Prevalence and management of advers~ events 
6) Effect size of efficacy outcomes 
Secondary Objectives: Hypothesis Testing for Main Trial Sample Size Calculation 
and Conceptual Framework 
Aligned with the identified gaps in knowledge regarding exercise for men with 
PCa treated with ADT, our secondary objectives were: 
1) To compare the effect of 6 months of home-based RET with 6 months of home-based 
AET on psychosocial and physical fitness outcomes that are clinically relevant to men 
with PCa treated with ADT. The specific efficacy outcomes of interest were: 
Psychosocial Outcomes: 
• Fatigue 
• Disease-specific HRQOL 
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Physical Fitness Outcomes: 
• Body mass index (BMI) 
• Waist circumference 
• Body weight 
• Chest skinfold 
• Cardiorespiratory fitness (peak oxygen consumption or V02 peak) 
• Musculoskeletal fitness (grip strength) 
2) To a) compare the effect of home-based AET and RET on physical activity 
participation and efficacy outcomes at 6-months post-intervention as a measure of long-
term adherence and benefit, respectively; and b) assess program adherence using self-
report measures of physical activity volume (questionnaire) and program compliance 
(exercise logbook) as well as an objective measure of physical fitness (aerobic fitness via 
V02 peak). 
3) To compare the effect of home-based AET and RET on biological outcomes known to 
influence PCa cell proliferation. Specifically, these biomarkers are: 
• Insulin-like growth factor-1 (IGF-1) 
• IGF-binding protein-3 (IGFBP-3) 
• Leptin 
• Adiponectin 
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4) To elucidate potential psychosocial determinants of physical activity participation 
(quantified by self-report and objective measures). Specifically, we assessed: 
• Self-efficacy 
• Social support 
• Exercise-induced feelings 
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6.0 Hypotheses 
1) Recruitment and attrition rates will resemble previous observations in this 
population (20-40% and 10-20%, respectively) with few, if any, adverse events. 
2) RET will be superior to AET at improving grip strength; while AET will be 
superior to RET at improving aerobic fitness, body composition, and psychosocial 
wellbeing (HRQOL and fatigue) at the end of 6 months of exercise training. 
3) AET will be superior to RET at maintaining the benefits observed at post-
intervention to 6 months post-intervention and will be superior in post-
intervention physical activity volume. 
4) AET will be superior to RET with respect to effects on biomarker outcomes (IGF-
1, IGFBP-3, leptin and adiponectin) over 6 months of exercise training. 
5) Self-efficacy, exercise-induced feelings, and social support will contribute 
significantly to the explained variance in program adherence measured by 
physical activity participation and V02 peak (as an objective proxy of susta.ined 
exercise). 
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7.0 Methodology 
7.1 Design 
This was a randomized feasibility study that compared the effects of AET to RET 
in a 6-month, home-based intervention for PCa patients undergoing ADT. The site of the 
research study was the Prostate Centre at Princess Margaret Hospital (PMH) in Toronto, 
Ontario, Canada. The study was approved by the institutional ethics boards at the 
University Health Network and York University. 
7.2 Sample Size Determination 
Approximately 15 patients per month receive ADT depot injections from 
participating urologists. With a conservative participation rate of approximately 30% 
(comparable to similar trials (20, 21, 67) ), and a time line for patient recruitment and data 
collection of two years (includ.ing 6-month, post-intervention follow-up), it was deemed 
appropriate to set a sample size of n = 60 (n = 30 randomized to AET and n = 30 to 
RET). The 60 patients provided an adequate sample size to test procedural aspects of the 
study, to refine the exercise intervention program and assessment protocols, and to 
estimate effect sizes and drop-out rates, for a future main RCT. 
7 .3 Participant Eligibility Criteria 
Eligibility criteria were assessed using chart review, patient discussion, and 
screening questionnaires (Physical Activity Readiness Questionnaire; P AR-Q, and 
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Charlson Comorbidity Index, Appendix A and B, respectively) by an exercise 
physiologist with cancer specific training (DSM) and a physician (SA). 
Participant Inclusion Criteria: i) histologically confirmed PCa with an indication for 
ADT (high-risk/locally advanced disease, rising PSA after definitive therapy, or 
metastatic disease); ii) initiating or currently receiving ADT for a planned duration 
equalling study duration (12 months); iii) willing and able to provide informed consent; 
iv) if metastatic, asymptomatic disease; v) no contraindications to exercise; vi) between 
the ages of 45 to 95 years. 
Participant Exclusion Criteria: i) severe coronary artery disease (Canadian 
Cardiovascular Society class III or greater); ii) uncontrolled hypertension (BP>200/100) 
or significant congestive heart failure (New York Heart Association class III or greater); 
iii) uncontrolled pain; iv) neurological or musculoskeletal co-morbidity inhibiting 
participation in AET or RET; v) diagnosed psychotic, addictive, or cognitive disorders 
(using the Charlson Index and chart review). 
7.4 Recruitment of Participants 
Attending PCa specialists (urologists, medical oncologists, and radiation 
oncologists) identified eligible participants and notified the research assistant (someone 
other than DSM). The research assistant approached eligible patients and provided an 
information package, including study specifics. Patients that expressed interest were 
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contacted by the study coordinator/exercise physiologist (DSM) for further description of 
the study, to confirm eligibility (including review of medical records to determine cardiac 
morbidity via Canadian Cardiovascular Society and New York Heart Association rating 
scales), and to obtain informed consent (Appendix C). The refusal rate and reasons were 
documented using a standardized questionnaire (Appendix D). At the orientation 
meeting participants were also offered an opportunity to ask questions about the study 
and to set an appointment for baseline evaluation, randomization, and exercise 
prescription. 
7.5 Participant Allocation to Treatment Conditions 
Participants were randomly allocated to either six months of home-based RET or 
six months of home-based AET. Prior to study initiation, opaque envelopes were stuffed 
with a folded piece of paper that indicated "AET" or "RET", the envelopes were sealed 
and shuffled. After shuffling, the contents of any given envelope could not be 
determined. These envelopes were then sequentially numbered and assigned to each 
participant as they entered the study. The envelope was opened following the 
participant's baseline assessment which then made apparent the group allocation. The 
research team could not know group allocation until after the baseline assessment in 
accordance with a blinded randomization process. Subsequent outcome assessments 
were not conducted by blinded outcome assessors. 
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7.6 Intervention Provision 
Patients allocated to the RET and AET groups were introduced to their designated 
exercise program after the baseline evaluation. Although there are inherent differences in 
the exercise modalities (AET versus RET) that cannot be completely reconciled, the RET 
and AET prescriptions were designed to approximate equivalent intensity and duration. 
Participants in each intervention arm received a detailed manual produced by the research 
coordinator (DSM) using principles of exercise adherence based on previous home-based 
interventions with PCa patients receiving ADT (24, 25). The manuals described the 
exercise prescription using narrative and visual descriptions, information about intensity 
monitoring, safety precautions, appropriate progression, and adaptation of the program, 
and an exercise log to record exercise participation. In addition to the manual, the 
research coordinator/certified exercise physiologist (DSM) demonstrated all of the 
required exercises to the point where patients could verbalize competence and confidence 
with their exercise program. Participants were also instructed on how to complete the 
exercise logs. To facilitate ongoing participation and exercise prescription compliance, 
the exercise physiologist contacted each participant every other week to ensure adherence 
to the program, completion of the exercise log, and to address any limitations/barriers to 
participation. 
7.6.1 Resistance Exercise Training Prescription 
Participants in the RET program were asked to perform their assigned exercises 3 
to 5 times per week, for approximately 30-60 minutes each session at a moderate to 
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vigorous intensity, for 6 months. RET guidelines indicate that a minimum of 48 hours 
between resistance exercises of the same muscle group be provided to ensure adequate 
recovery of muscle tissue. The present exercise prescription encouraged participants to 
complete the entire set of 10 exercises two to three times weekly. For participants that 
were new to exercise, it was recommended that they complete half of the exercises on 
alternate days to ensure that enough recovery time was available. No participant was 
asked to complete all exercises five times weekly. To complete the exercises at home, 
each RET subject was provided with a set of 3 resistance bands (light, moderate, and 
heavy resistance), an exercise mat, and a 55 cm or 65 cm exercise ball (dependent upon 
the participant's height). Each resistance exercise was performed for 1 to 3 sets of 8 to 12 
repetitions at an intensity of 12-15 out of 20 on the Rating of Perceived Exertion (RPE) 
scale (approximately 60-80% of lRM) (155). Initial intensity was based on the 
performance of the exercises during the exercise prescription session. The ten RET 
exercises that were prescribed were: ball squats, hamstring curl, push-ups, upright row, 
triceps extension, bicep curl, seated row, lateral raise, abdominal crunches, and hip 
extension. All exercises were designed to have three levels of intensity (beginner, 
intermediate, and advanced) to accommodate varying degrees physical fitness and 
exercise experience. Additionally, movement-specific accommodations or adaptations for 
patients with functional limitations were made. 
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7.6.2 Aerobic Exercise Training Prescription 
Participants in the AET program were asked to participate in aerobic exercise of 
their preference 3 to 5 times per week, for 15-60 minutes at a moderate to vigorous 
intensity (RPE of 12-15 out of 20 or 60-80% of heart rate reserve), for 6 months. 
Although participants were able to choose their preferred modality, walking was the 
primary/default modality for the exercise prescription. To ensure appropriate intensity 
was maintained during the course of the exercise sessions, patients were provided with 
heart rate monitors (Polar® Heart Rate Monitor FS2, Kempele, Finland) that provided 
audible cues when they were outside of their prescribed training zone (pre-set by the 
research coordinator based on findings from the cardiorespiratory fitness test). 
7 .6.3 Booster Sessions 
To promote adherence to the exercise interventions and address barriers to 
exercise, participants were invited to attend booster sessions every two weeks in a group-
based format for the 6-month intervention. Each 1.5-hour session included a one hour 
exercising training session and a 30-minute education/discussion component. The 
training sessions consisted of equivalent AET and RET durations (20 minutes each) with 
a 10-minute warm-up and cool-down. The education component was developed by Dr. 
Culos-Reed and addressed various topics related to exercise participation and long-term 
adherence, such as goal setting, barriers to exercise, and social support (see Appendix E 
for a description and the sequence of booster session topics). Booster sessions have been 
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useful and well attended in previous studies with PCa patients receiving ADT (24, 25). 
Attendance was taken at each booster session. 
7. 7 Outcome Assessment 
Participants were required to attend the study site (Princess Margaret Hospital) on 
four occasions to complete outcome assessments. Outcomes were measured at baseline 
(after randomization), mid-intervention (3 months), intervention completion (6 months), 
and a post-intervention follow-up (6 months after the completion of the intervention. 
Each assessment took approximately 60 minutes. All assessments were conducted by the 
research coordinator and CEP (DSM), who were not blinded to the treatment 
assignments. 
7 .8 Outcome Measures 
7.8.1 Psychosocial Outcome Measures 
7.8.1.1 Functional Assessment of Cancer Therapy-Fatigue (FACT-F) 
The FACT-Fis a 13-item measure that assesses cancer-specific fatigue (194, 201, 
407-413). The FACT-Fuses a 5-point Likert scale ranging from 0 (not at all) to 4 (very 
much so) to describe how true various fatigue-related statements are for participants over 
the last seven days (Appendix F). The total sum score ranges from 0 (worst fatigue) to 52 
(no fatigue). The F ACT-F has high test-retest reliability (r = 0.87), excellent internal 
consistency (Cronbach's a=0.93-0.95), and good convergent/discriminant validity ( 412, 
83 
413). The FACT-F has been used extensively in PCa research (61, 197, 199), including 
trials assessing the effect of exercise in PCa patient receiving ADT (20, 21 ). 
7.8.1.2 Functional Assessment of Cancer Treatment-Prostate (FACT-P) 
The FACT-P is a widely used instrument that uses 35 items from the generic 
FACT (FACT-G; a cancer-specific HRQOL measure) scale plus 12 items that are 
specific to PCa to produce a 47-item questionnaire (Appendix G). The FACT-G is an 
extensively validated cancer-specific measure with high reliability and internal 
consistency estimates and has been translated into several languages (176, 414-418). The 
F ACT-P has discriminated between PCa patients differentiated by disease stage, 
performance status and PSA score and is sensitive to performance status and meaningful 
clinical change over 2 month intervals (176). The F ACT-P has been validated in older 
cancer patients ( 417) and has shown significant differences in PCa patients related to 
exercise intervention in 3 previous studies (20, 21, 65). 
7.8.1.3 Patient-Oriented Prostate Utility Scale (PORPUS) 
To further assess PCa specific HRQOL changes associated with exercise, we also 
employed the PORPUS (177). The PORPUS is a psychometric and utility HRQOL scale 
that has been found to be reliable in discriminating between groups of PCa patients with 
metastatic versus nonmetastatic disease, men being administered ADT versus no-ADT, 
and men whose Charlson Comorbidity score was .:S 2 versus > 2, as well as change over 
time in these known groups ( 419). The PORPUS is a 10-item questionnaire that asks 
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patients to selecting 1 of 5 possible conditions in the following domains: pain and 
disturbing body sensations, energy, support from family and friends, communication with 
doctor, emotional wellbeing, urinary frequency, bladder control, sexual function, sexual 
drive, and bowel problems (Appendix H). The PORPUS has been used in several studies 
to assess treatment-related changes in HRQOL ( 420-424). A clinically important 
difference in the PORPUS (psychometric) is 5 points ( 425). 
7 .8.2 Physical Fitness Outcomes 
7.8.2.1 Body Composition 
Three measures of body composition associated with health-related fitness were 
employed: body mass index (BMI), waist circumference (WC), and body fat percentage 
using sum of three skinfolds (3SKF). BMI was calculated using the participant's weight 
and height (BMI =weight (kg)/height (m)2). WC was measured using anthropometric 
tape according to protocols defined by the World Health Organization (tape placed 
horizontally mid-way between the bottom of the rib cage and the iliac crest) (426). 
Measurements were taken to the nearest 0.5 cm. To assess body fat percentage, 3 SKFs 
were measured using Harpenden Calipers (FitSystems Ing, Calgary, Alberta) at the chest, 
abdominal, and thigh sites ( 426). All measurements were taken on the right side of the 
body. Body density and body fat percentage were calculated using population-specific 
standardized equations for men ( 426, 427): 
• Body Density (dB) in g/cm3 =1.109380-(0.0008267*(L3SKF))+(0.0000016*( L3SKF)2)-(0.0002574* age) 
• Body Fat%= (4.95)/dB-4.50 
85 
(At present, cancer-specific skinfold-based body fat percentage equations are not 
available and the equation for white adult males, aged 18-61 years was used as the most 
accurate approximation of the study sample). Body composition changes are highly 
prevalent in PCa patients receiving ADT (11, 49), are associated with poor prognosis and 
PCa mortality (264, 270), and have been shown to be beneficially augmented with 
exercise (22-25). 
7.8.2.2 Cardiorespiratory Fitness 
Cardiorespiratory fitness refers to the ability of one's heart and lungs to deliver 
oxygen to working tissues and is important for most functional tasks. Cardiorespiratory 
fitness is often expressed in maximum or peak volume of oxygen consumption (V02 max 
or V02 peak) and is typically described relative to one's body weight (millilitres of 
oxygen consumed per kilogram of body mass per minute; ml 0 2/kg/min). To assess V02 
peak in AET and RET participants, the modified Bruce treadmill protocol ( 426, 428) was 
selected because it uses a prolonged warm-up and walking (rather than running) 
combined with increases in grade (incline) to bring participants to maximum intensity 
( 429, 430). The modified Bruce Treadmill protocol requires participants walk at 1. 7 to 
3.7 mph (5.95 km/h) at elevations from 0-18% grade, with speed/grade increased every 3 
minutes to a point of subjectively described 'maximal' effort using the 10-point Borg 
Rating of Perceived Exertion Scale (155). V02 peak is estimated using standard 
American College of Sports Medicine (ACSM) metabolic equations ( 429). 
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A certified exercise physiologist (CEP) accredited to conduct testing in 
symptomatic/asymptomatic populations, and certified in Basic and Advanced Cardiac 
Life Support (ACLS), with ACLS equipment and supplies on-hand, conducted all tests. 
Standard termination criteria for clinical graded exercise testing was applied: chest 
discomfort, nervous system symptoms (ataxia, dizziness, near syncope), cyanosis/pallor, 
or participant's desire to stop (426). In a clinical population, the risk of complications 
associated with exercise testing is typically extremely small when the testing protocol and 
guidelines for exercising tolerance testing are carefully followed, as well as continuous 
monitoring the client's physiological response ( 426). The risk of a fatality during an 
exercise test is approximately 0.00005% (1/20,000), and for a myocardial infarction is 
approximately 0.0004% (1/2,500) ( 426). Maximal cardiorespiratory fitness testing has 
been safely assessed in previous exercise intervention studies with PCa patients (21, 65). 
7.8.2.3 Musculoskeletal Fitness 
To assess musculoskeletal function grip strength was measured using a Jamar 
Dynamometer (Sammons Preston, Bolingbrook Illinois, U.S.A.) according to the 
Canadian Society for Exercise Physiology protocol ( 431 ). Grip strength is an independent 
predictor of mortality in older adults and may identify patients, including those with a 
high level of function, who are at risk of deteriorating health (225, 432). Grip strength has 
been used frequently as a measure of physical function in PCa patients undergoing ADT 
(24, 25, 197, 433). 
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7 .8.3 Biological Outcomes 
To assess the effect of exercise on biomarkers associated with cancer progression, 
DSM collected serum samples at the hospital and transported to York University under 
the care of Dr. Michael Connor, who supervised the analysis by the research coordinator 
(DSM). Each participant provided a whole blood sample, but due to budgetary 
constraints, only 26 participants had their samples analyzed at baseline, mid-intervention, 
and intervention-completion time points. These participants were the first 26 to complete 
the first three time points. Given that assays were only available on a small proportion of 
participants, we consider these analyses only exploratory in nature. 
7.8.3.1 Blood Collection 
Twelve mL of whole-blood was drawn by the research coordinator (DSM) who is 
a certified research phlebotomist at the University Health Network. Whole-blood was 
labeled and centrifuged at a lab at Princess Margaret Hospital to separate red blood cells 
from serum. Red blood cells were discarded and serum ( "'5 ml) was stored in duplicate, 
labeled aliquots at -30 degrees Celsius before batch transfer to York University. 
7 .8.3.2 Serum Analysis 
A 'sandwich' Enzyme-Linked Immunosorbent Assay (ELISA) was used to 
quantify the amount of the proteins of interest (insulin-like growth factor-1 (IGF-1), IGF-
binding protein (IGF-BP3), leptin and adiponectin). Aliquots of co-culture serum were 
incubated in a 96-well plate with protein antibodies for each protein (IGF-1, IGF-BP, 
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leptin or adiponectin). The desired proteins adhere to their antibodies and remain on the 
plate after washing. Following the wash, protein biotinylated primary antibodies (biotin) 
were added to the wells and bind to the specific protein present during a 2-hour 
incubation period at room temperature. Following this incubation, excess primary 
antibody was washed away and streptavidin-linked horseradish peroxidase (HRP) is 
added to the wells. The streptavidin on the HRP binds to the biotin on the primary 
antibodies and after incubation (1 hour) any excess HRP is washed from the wells, the 
HRP substrate is added, and the luminescence in each well is measured/recorded using an 
ELISA analyzer. The amount of luminescence is indicative of the amount of protein 
present in the wells. These values are compared to a standard curve to determine the 
specific amount of each protein present in each well. 
7 .8.4 Program Adherence Outcomes 
7.8.4.1 Godin-Shephard Leisure Time Exercise Questio.nnaire (GLTEQ) 
As a proxy of adherence to the exercise prescription, past-week physical activity 
and exercise was assessed using the GL TEQ ( 434). The GLTEQ is a 3-item measure that 
assesses the frequency of mild, moderate and strenuous bouts of leisure physical activity 
or exercise performed for at least 15 minutes over the past week (Appendix I). To provide 
data in MET-hrs/wk that could yield insight into the activity volume relative to the 
ACSM (American College of Sports Medicine) guidelines for physical activity in cancer 
survivors ( 435), the questionnaire was modified by adding the specific duration for each 
intensity as per the previous work by previous groups (e.g. (350, 436)). An independent 
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evaluation confirmed its reliability and validity compared to mne other self-report 
measures of exercise participation ( 43 7). Specifically, The GL TEQ demonstrated 
reasonable 1-month test-retest reliability of 0.62 and concurrent validity coefficients of 
0.32 with accelerometer-assessed physical activity, 0.56 directly measured V02 peak, and 
-0.43 with body fat percentage. A change of 15 MET-hrs/wk was considered clinically 
significant given its correspondence with health benefits (110, 435). The GL TEQ has 
been widely used with cancer patients and survivors participating in exercise 
interventions (331, 340, 357, 436, 438-444), including PCa patients receiving ADT (24, 
25). 
7 .8.4.2 Physical Activity Logbook 
Although the GL TEQ provides crude estimates of weekly physical activity 
volume, in order to gain a more detailed understanding of exercise behaviours, a physical 
activity log was included in the RET and AET manuals for analysis. These logbooks 
were created for patients to easily record the frequency and intensity of their respective 
programs. These logbooks also served as reminders to patients of what they have 
completed and what they needed to complete over the course of each week, and provided 
feedback regarding progress of physical fitness. Exercise logbooks were collected at the 
end of 6 months for examination and quantification of total physical activity volume in 
MET-hours per week (MET = metabolic equivalent, a measure of activity intensity 
relative to resting state). 
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7.8.4.3 Objective Proxy of Program Adherence: Cardiorespiratory Fitness 
Home-based exercise research has been challenged to find an accurate, reliable, 
and feasible method of determining program compliance. At present time, the only 
method of objectively quantifying exercise behaviours is direct observation but it is often 
not feasible to implement, and the potential benefits are offset by the bias introduced by 
the routine presence of a researcher to examine active behaviours. With these limitations, 
indirect assessments of program adherence are commonly employed, such as the doubly-
labeled water technique, accelerometry, self-report, and objective measures of physical 
fitness. 
The doubly-labeled water technique measures changes in concentration levels of 
ingested 'heavy' isotopes of hydrogen and oxygen, which degrade and exit the body in a 
fashion that allows for the estimation of metabolic activity. The doubly-labeled water 
technique is the gold standard of measuring energy expenditure, but is expensive 
( ~$250,000 USD for the analyzers), time-consuming, and the analysis does not provide 
specific information on adherence parameters, such as type, frequency, intensity, or 
duration of exercise sessions (445, 446). Accelerometry via pedometers and three-
dimensional accelerometers are increasingly popular in exercise interventional research. 
Pedometers measure step count by monitoring vertical movement mechanically or 
electronically. Pedometers are small, easy to use, relatively inexpensive, and have 
demonstrated a moderate-strong correlation with activity heart rate (r = 0.54), doubly 
labeled water (r = 0.55), and direct observation (r = 0.69) (446). Unfortunately, they are 
not effective for assessing non-ambulatory exercises, such as cycling, swimming, or 
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resistance training ( 445). Modern accelerometers are now widely available and are able 
to measure activity in three dimensions, but they are more costly compared to pedometers 
and are still ineffective at measuring resistance training exercises. 
Self-reporting of physical activity is the most commonly employed method of 
exercise adherence measurement and is quantified using data from logbooks and/or 
exercise questionnaires (both used in the present study) ( 445). These methods generally 
require participants to recall and/or describe their physical activity over a period of time 
which can be translated into a total physical activity volume given the frequency, 
intensity, time, and type of exercise performed. There are several advantages to self-
report measures of physical activity, such as ease of completion/administration, 
convenience (they can be completed via telephone, mail, or in person), require few 
resources, and can provide relatively detailed information about exercise behaviours. 
Exercise logbooks provide a detailed account of exercise behaviour and can reinforce the 
actual prescription (by providing specific program parameters for each exercise session 
for the participant to complete and record). Unfortunately, they are often inconvenient 
for the participant and thus poorly maintained ( 446, 44 7). Recall surveys, such as the 
GL TEQ, may be quickly and easily administered and require respondents to recall 
aspects the activities in which they participated over the specified time period. Physical 
activity questionnaires used as a measure of adherence assume that an increase in 
physical activity volume from baseline is attributable to the adoption of the exercise 
prescription. Unfortunately, the specific details of the activities are often not available 
and specific exercise activities can be inferred only by changes in total physical activity 
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volume. Moreover, both exercise logs and activity volume questionnaires are subject to 
response bias and recall bias, which impair their validity and reliability ( 446-448). 
A third method of indirectly assessing program compliance is through 
physiological/performance changes. Given the strong and direct correlation between 
physical activity and fitness performance measures, it is reasonable to assume that 
changes in performance over the duration of an intervention are likely due to some 
increase in physical activity, and hopefully, activity that corresponds with the provided 
exercise prescription. Physical fitness measures, such as musculoskeletal strength tests or 
cardiorespiratory fitness assessments, are modality-specific; however, a graded exercise 
treadmill test may be most generalizable to overall improvements in physical fitness 
given the muscular and cardiorespiratory demands of general physical activity. For 
example, Jones et al ( 131) found that for lung cancer patients who were 80% adherent to 
the facility-based/supervised exercise program (as indicated by direct observation), V02 
peak increased by 3.3 ml02/kg/min; whereas no change in V02 peak was observed 
participants that were non-adherent ( < 80% adherence). Furthermore, changes in 
cardiorespiratory fitness are indicative of extended periods of inactivity, which would 
correspond with program non-compliance ( 449, 450). Exercise and physical activity 
studies that employ fitness measures often show a stronger association between the 
behaviours and health outcomes because there is less error and they are not vulnerable to 
social desirability or recall bias ( 445). 
In the present study, we used observed changes in cardiorespiratory fitness to 
provide an objective assessment of physical activity participation to supplement/validate 
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the exercise log and GLTEQ. The operational definition of adherence in this context, the 
threshold for determining an adherent participant, was an improvement in V02 peak of 
3.3 ml02/kg/min. This cut-off closely resembles the generally accepted minimal 
clinically important difference of 3.5 ml02/kg/min (the equivalent of one metabolic 
equivalent or MET) and it has previously been correlated with exercise adherence in lung 
cancer patients (131). The protocol for V02 peak measurement is provided in Section 
1.4.8.8.2. 
7 .8.5 Correlates of Exercise Adherence 
The following measures were employed to examine various psychosocial 
correlates of exercise behaviour in our intervention. 
7.8.5.1 Exercise-Induced Feeling Inventory-Chronic Training (EFI-C) 
The Exercise-Induced Feeling Inventory for Chronic Training (EFI-C) contains 
two subscales that measure physical exhaustion and pleasant mood states associated with 
physical activity during the past week (451). The EFI-C was founded on the EFI-Acute, 
which measured acute changes in feelings to exercise using 4 subscales (452). The EFI-C 
is a 12-item measure that requires participants to rate how often they experience the 
stated feelings during physical activity, such as "refreshed", "worn-out", and "happy" 
(Appendix J). Both subscales (physical exhaustion and pleasant moods) of the EFI-C 
demonstrated strong internal consistency and reliability coefficients (---0.90) ( 451 ). The 
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EFI-A and the EFI-C have been used widely to describe predictors of physical activity 
participation and adherence in a diverse range of populations, including elders ( 453-456). 
7.8.5.2 Self-Efficacy for Physical Activity Survey (SEPAS) 
The SEP AS is a 12-item scale that assesses self-efficacy for exercise behaviours 
( 457). The SEP AS uses two subscales to assess whether respondents are confident in 
allocating time and energy to exercise and resisting exercise relapse (return to sedentary) 
by 'sticking to' an exercise program under conditions of stress, added demands, 
depression, fatigue and peer disruption ( 457). In the SEP AS, respondents are asked to 
rate their confidence from "I know I cannot" to "I know I can" in various circumstances 
including "Get up early, even on weekends to exercise" and "Stick to your exercise 
program when you have household chores to do" (Appendix K). Self-efficacy is an 
important concept in improving adherence to novel behaviours, including exercise, and 
has been studied frequently in cancer populations (343, 380, 458-462). The SEPAS 
demonstrated acceptable test-retest reliability (r=0.68), internal consistency (Cronbach's 
alpha= 0.83-0.85), and construct validity ( 457). The SEP AS has previously been used to 
gauge self-efficacy in sedentary women who participate in novel strategies to improve 
physical activity ( 463) as well as in older patients with a cardiac diagnosis( 464). 
7.8.5.3 Social Support for Physical Activity Questionnaire (SSPAQ) 
Social Support for Physical Activity (SSPAQ) Questionnaire ( 465) was used to 
measure the social support of family and friends in two separate subscales. Both 
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subscales (20 items in total) rate the frequency with which family members or friends 
have done or said something to support physical activity (Appendix L). For example, 
respondents are asked to rate how often their family or friends "exercised with me", 
"gave me encouragement to stick with my exercise program", or "changed their schedule 
so we could exercise together." The SSPAQ (complete questionnaire and selected items) 
has been used previously with a variety of populations, including cancer survivors (342, 
346, 466). 
7 .8.5.4 Demographic, Disease, and Treatment Information 
Demographics (e.g., age, education, marital status, etc.) and other information 
believed to have a possible influence on outcome (tumour stage and Gleason grade, 
previous treatments, etc.) were collected (Appendix M). 
7.8.5.5 Comorbidity 
Comorbidity was quantified by the research coordinator (DSM) usmg the 
Charlson Comorbidity Index ( 467) based on self-report information from the participant 
during each assessment. The Charlson Comorbidity Index rates 22 morbidities using 
scores of 1 (low morbidity), 2, 3, and 6 (high morbidity) to yield a total score that 
predicts one year mortality (467) (Appendix B). The Charlson Comorbidity Index has 
been used widely in exercise research for cancer patients ( 131, 468-4 71 ). Comorbidity 
index scores were used as a means of adjusting for individual medical conditions ( 4 72-
474). 
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7 .9 Data Management and Statistical Analysis 
Data were entered and analyzed using Statistical Package for Social Sciences 
(SPSS) version 19.0 (IBM, Armonk, New York). All data were reviewed for 
completeness and accuracy by the research coordinator (DSM) and a research assistant. 
Obvious errors in data entry were compared against hard copies of the assessment 
documentation and corrected to ensure completeness and accuracy. For all hypotheses 
testing analyses, the alpha level was set to 0.05 to identify statistically significant 
differences and associations with minimal risk of making a Type 1 error. 
7.9.1 Sample Characteristics, Baseline Equivalency, Normal Distribution, and 
Outliers 
Descriptive statistics (e.g. mean, standard error, frequency) for all outcomes were 
assessed at baseline to describe the general sample. Prior to analyzing data relevant to the 
a priori objectives, independent samples t-test for continuous variables and chi square 
tests for categorical variables were conducted to assess group equivalency at baseline 
(AET versus RET and dropouts versus non-dropouts). Histograms of continuous 
variables were used to visually assess the distribution of data. Data distribution was also 
assessed using skewness and kurtosis statistics to screen for outcomes with potentially 
skewed or non-normal distributions. Screening for potentially skewed outcome measures 
was conducted by dividing the skewness and kurtosis factors by their standard errors, 
respectively (475). Values that exceeded the threshold of± 1.96 were compared to 
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graphical (histogram) interpretation (475). Outcomes that were confirmed to be skewed 
were log-transformed for analysis. Outliers were maintained throughout all analyses. 
Data for HRQOL outcomes and adherence variables were re-coded when necessary such 
that increases in scores represent improvements in symptoms and higher levels of the 
adherence-supporting characteristic, respectively. 
7.9.2 Efficacy Estimates 
To assess and compare the efficacy of each intervention over time, a two-way 
(two factor) repeated-measures analysis of variance (RM-ANOV A) was used. This test 
produced main effects for Group and Time as well as the Group x Time interaction. 
When an interaction effect was significant, simple effects were calculated to determine 
the time points where the interaction occurred. In cases where violations of sphericity 
were observed (Mauchly's Test: p > 0.01), the Greenhouse-Geisser correction for F-
statistic and statistical significance was used. 
We also conducted paired-samples t-tests to derive effect size estimates from 
baseline to 3, 6 and 12 months and from 6 months (post-intervention) to 12 months 
(follow-up) within each intervention arm. This strategy was implemented to provide 
estimates of effect size for within group analyses in future trials that investigate the effect 
of varying durations of AET or RET. 
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7.9.2.1 Intention-to-Treat (ITT) 
Given the large volume of data to be collected over two years in elderly PCa 
patients that likely have one or more co-morbidities, missing data and attrition were 
inevitable. To most stringently assess the effect of an exercise intervention (AET or RET) 
in this population, an intention-to-treat (ITT) approach was employed. While some 
debate exists regarding the most appropriate method of handling missing data (476, 477), 
imputation, using the last value carried forward (LVCF) is widely employed to provide 
conservative estimates of effects while maintaining sample sizes and statistical power 
which facilitate sample size calculation in future trials. 
The exception to this approach was during the group and time analysis of the 
psychosocial correlates of physical activity behaviour (i.e. self-efficacy, exercise-induced 
feelings, and social support). In this case, only a per protocol approach was used to 
assess changes in outcomes as they reflect determinants of behaviour rather than efficacy 
(clinically relevant) outcomes. Because determinants of behaviour are sensitive to 
exposure and experience within an exercise program, use of the last value carried forward 
(LVCF) technique might 'wash out' potential changes in participants' experiences, 
without offering additional insight into behavioural mediators. In other words, if the 
'participants' are not actually participating in the program (as per L VCF approach), their 
behaviour cannot be reliably determined. Thus, only participants that completed these 
questionnaires at each time point were used. 
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7.9.2.2 Per Protocol Analysis 
A per-protocol analysis was conducted usmg only those participants that 
completed the assessments at the study time points. This was conducted to provide 
estimates of program efficacy for those participants who remained connected to the 
intervention, in contrast to the ITT analysis that provided conservative estimates of 
program delivery efficacy across the population. 
7.9.2.3 Sub-Group Analysis of Biomarker Outcomes 
As previously mentioned, only 26 participants (n = 13 from each of the groups) 
had their serum samples assayed for biomarker concentrations. These 26 participants 
were the first to complete all three intervention assessment time points in their respective 
intervention arms (i.e. baseline, 3 months, and 6 months). Their data were analyzed 
using RM-ANOVA with main effects and interaction effects described. Paired-samples 
t-tests were employed to assess within group changes for effect size, and subsequent 
sample size, calculations. 
7.9.3 Correlational Analyses and Multivariate Models 
7.9.3.1 Correlations and Explanation of Variance between Changes in Physical 
Outcomes and Biomarkers 
Bivariate correlations were tested using Pearson's r to assess the relationship 
between physical outcomes and various biomarkers (e.g. body fat percentage and 
adipokines). These correlations were conducted on grouped data (AET + RET) to 
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determine the relationship between the outcomes irrespective of training modality. 
Pearson correlations were also conducted to examine whether changes in various 
physical outcomes were correlated with changes in biomarker concentration. 
7.9.3.2 Bivariate Analysis of Adherence Measurements and Determinants of 
Exercise 
To assess the relationship between self-report (GLTEQ and exercise logbook) and 
objective (V02 peak) measures of adherence, a Pearson's correlation coefficient, r, was 
conducted with combined group data. Pearson's r correlations were also conducted to 
assess the relationship between determinants of exercise variables (self-efficacy, 
exercise-induced feelings, social support), control variables (age and comorbidity status), 
and the self-report and objective measures of adherence (GLTEQ/exercise logbook and 
aerobic fitness, respectively) to confirm inclusion into subsequent multivariate regression 
models. 
7.9.3.3 Multivariate Models of Psychosocial Correlates of Exercise Behaviour and 
Self-Report Physical Activity Volume and V02 peak 
To determine the extent to which self-efficacy, social support, and exercise-
induced feelings predicted adherence to the exercise interventions, we conducted a 
hierarchical multiple linear regression (similar variables are entered in blocks) to examine 
the relative contributions of each independent variable on the variance in physical activity 
volume (GLTEQ), logbook-determined physical activity volume, and V02 peak (as an 
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objective proxy of program adherence). A priori, we hypothesized that comorbidity 
status and age would contribute to the explained variance in adherence. As described 
previously, we conducted bivariate correlations of control variables with the outcome 
measures at each time-point to ascertain whether age and comorbidity were related 
inorder to decide whether one or both control variables should be included into the 
model. This was deemed necessary to ensure a comprehensive model while maximizing 
statistical power. Although most statistical textbooks indicate that a minimum of 10-20 
participants per independent variable is required for adequate power in multiple linear 
regression ( 4 78), it was deemed appropriate to reduce the statistical power in light of the 
exploratory nature of this investigation and consequently interpret the findings 
cautiously. 
Each regression model assessed the effect of self-efficacy, social support, and 
exercise-induced feelings (independent variables) on physical activity volume or V02 
peak while controlling for exercise modality (AET versus RET) and comorbidity status 
(Charlson Index). These models were conducted for each time point (baseline, three 
months, six months, and six months post-intervention). To assess whether baseline 
psychosocial variables were predictive of changes in physical activity volume or V02 
from baseline to post-intervention, a multiple linear regression was conducted using 
baseline values for social support and exercise-induced feelings, controlling for age and 
exercise group, on the change scores in physical activity volume and V02 over this 
period of time. Self-efficacy was excluded from this analysis given the smaller number 
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of participants completing the baseline self-efficacy measure with baseline and six-month 
data for all model covariates (n = 20). 
7.9.4 Post-hoc Power Analysis and Sample Size Estimation of Efficacy Outcomes 
For all analyses, observed effect sizes (partial 112) and power were reported for 
between-factors analyses from the SPSS output (i.e. AET versus RET). Sample size 
calculations for the observed between-factor effect size were calculated using G*Power 
Statistical Analysis Software (261). For 'Sample Size Calculation for Observed Effect' 
the Observed Effect Size (f) was calculated in G*Power as f=-Vpartial 112/ (1- partial 112). 
Sample size calculations were also conducted for hypothesized effect size using 
established minimal clinically important difference (MCID) and standard deviations (SD) 
from previous exercise-related research to calculate Cohen's d (d =MCID/SD) which was 
converted to Cohen's f ( 515). In circumstances where MC IDs were not established, a 
medium effect size (f = 0.25) was used as a conservative default. Correlation among 
repeated measures (required for sample size calculation) was conducted using the mean 
of the Pearson r values across all time points. For sample size calculations, alpha level 
and power were set to 0.05 and 0.80, respectively. 
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8.0 Results 
8.1 Results of Feasibility Assessment 
8.1.1 Recruitment 
The CONSORT (Consolidated Standards of Reporting Trials) (479) diagram is 
presented in Figure 1. Sixty-six (n = 66) participants were recruited from among the 205 
eligible participants we approached between June 2009 and July 2010 (recruitment rate= 
32% ). Reasons for refusal were: no time (n = 33), lack of transportation/too far to travel 
(n = 8), traveling during the intervention period (n = 12), not interested/no reason (n = 
27), self-determined inability to participate (n = 35), or already exercising (n = 24). 
8.1.1.1 Sample Characteristics 
Participant demographics are presented Table 2. At baseline the AET and RET 
differed in IGFBP-3 concentrations (AET = 5582.7, SEM = 1514.3 versus RET = 4360.5, 
SEM = 1370.9, p = 0.05) and the emotional wellbeing subscale of the FACT-P (AET = 
20.8, SEM = 0.52 versus RET = 18.5, SEM = 0.84, p = 0.02; data not shown). 
8.1.2 Study Retention 
From baseline to 6 months, attrition was 26% and 44% for the AET and RET 
groups, respectively. This difference between groups did not reach conventional levels of 
statistical significance (dropout versus non-dropout in AET versus RET; x2 = 1.941, 
p=0.164). In the AET group, reasons for dropout were: disease progression inhibiting 
continued participation (n = 1 ), loss of interest/motivation (n = 1 ), too far to travel for 
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assessments (n = 1 ), symptoms/comorbidities interfered with exercise participation (n = 
2), no time (n = 4). In addition, four patients were lost to follow-up without explanation 
(i.e. they could not be reached after multiple attempts). For the RET group, reasons for 
dropping out were: advanced disease inhibiting continued participation (including 
deceased) (n = 3), loss of interest/motivation (n = 3), too far to travel for assessments (n = 
3), symptoms or comorbidities interfered with exercise participation (n = 4), no time (n = 
2). In addition, seven patients were considered lost to follow-up when they could not be 
reached after several attempts. From post-intervention to the 6 month follow-up, n = 5 
and n = 8 participants were lost in the AET and RET groups, respectively. There were no 
statistically significant differences in the baseline characteristics between those who 
dropped out before the 6-month follow-up versus the non-dropouts (p > 0.05); however, 
there was a trend for the dropouts to be older (p = 0.067), heavier (p = 0.077), and to have 
lower aerobic fitness (p = 0.052) (Table 3). 
8.1.3 Booster Session Attendance 
The AET and RET groups attended a mean of 16.4% and 5.5% of the booster 
sessions, respectively (p = 0.045). 
8.1.4 Adverse Events 
There were no serious adverse events related to the exercise intervention in either 
group. 
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8.4.5 Exercise Logbook Completion 
Only 43% and 30% or participants completed the exercise logbook at 3 and 6 
months, respectively. Further, the quality of log completion was inadequate for an 
accurate quantification of adherence to the exercise prescription. Therefore, it was 
decided by the research team to exclude the exercise logbook from any analysis given the 
poor completion rate. 
8.2 Distribution of Data 
After statistical and graphical consideration, data were judged to be normally 
distributed across all outcomes and at all time points. Accordingly, data were analyzed 
using parametric tests. The only exception to this was physical activity volume at each 
time point, which was highly positively skewed because most participants at baseline and 
throughout the trial increased their physical activity volume from 0 MET-hrs/wk. In this 
scenario, central tendency was near 0 MET-hrs/wk with an apparent normal distribution 
above zero, but no values below zero (as zero is the absolute minimum), thus producing 
graphical skewness (as well as statistical skewness). The measure of physical activity 
volume, the GL TEQ, has been used in numerous exercise studies in cancer (including 
PCa) and despite similar issues with skewed distributions, most studies have not tried to 
normalize the distributions before conducting parametric statistical tests (e.g. (24, 122, 
331, 374)). This has likely been done to maintain interpretability of findings. To 
circumvent this issue, numerous studies have elected to convert physical activity volume 
into categorical variables of sedentary (no physical activity), insufficiently active for 
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health benefit (1-149 minutes of physical activity) and meeting exercise guidelines (> 150 
minutes of physical activity) (e.g. (370, 480, 481)). In the present trial, we decided to 
maintain the fidelity of the measure and keep physical activity volume in a continuous 
variable format. Moreover, adherence may be considered most appropriately in the 
context of degree or extent, rather than kind or type (374). 
8.3 Results of Intention-To-Treat Analysis 
8.3.1 Fatigue and HRQOL Outcomes 
Fatigue and HRQOL outcomes, using an ITT analysis, are presented in Table 4. 
There was a significant main effect of Group for the FACT-P emotional wellbeing 
subscale (F(l,58) = 7.3, p = 0.009). Simple effects analysis indicated there were 
significant between-group differences at each time point (p ~ 0.02, See Figure 5). This 
was consistent with a discrepancy in baseline equivalency described earlier. There was a 
trend towards a significant main effect of Group for fatigue (F(l,60) = 2.86, p = 0.096) 
with simple effect analysis showing trends towards significance for between-groups 
differences favouring AET at 6 months (mean ~ = 4.5, SEM = 2.63, p = 0.092) and 12 
mo~ths (mean ~ = 4.7, SEM = 2.69, p = 0.084; See Figure 6). The FACT-P social 
wellbeing subscale also demonstrated a trend towards group main effects (F(l,58) = 3.65, 
p = 0.06), with between-group differences favouring AET observed at 6 months (mean~ 
= 2.9, SEM = 1.26, p = 0.027). There were no additional significant main effects of 
Group or Time. There were no significant interaction effects. Within-group comparisons 
between time points by paired-samples t-tests did not reveal significant differences. 
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8.3.2 Physical Fitness Outcomes . 
Physical fitness and body composition outcomes, using an ITT analysis, are 
presented in Table 5. There was a significant main effect of Time for chest skinfolds 
(F(l.99, 123.08) = 4.813, p = 0.01), body fat percentage (F(2.07, 126.36) = 5.554, p = 
0.004), and physical activity volume (F(2.51, 152.89) = 5.491, p = 0.003). There were 
trends towards significant main effects of Time for waist circumference (F(3, 186) = 
2.565, p = 0.056) and V02 peak (F(2.32, 127.65) = 2.655, p = 0.066). There were no 
significant main effects of Group. There was a significant Group x Time interaction 
effects for physical activity volume (F(2.51, 152.89) = 3.122, p = 0.003; Figure 7). 
Simple effects analysis of this interaction indicated that only AET improved in GL TEQ 
scores from baseline to 3 months (mean /1 = 13.34 MET-hrs/week, SEM = 4.35, p = 
0.003), baseline to 6 months (mean /1 = 17.20, SEM = 4.64, p < 0.001), and from baseline 
to 12 months (mean 11=14.18 MET-hrs/week, SEM = 3.80, p < 0.001). 
Paired-samples t-tests showed that, from baseline to 3 months, the AET group 
improved weight (mean /1 = -1.5 kg, SEM = 0.6, p = 0.013), waist circumference (mean 
11 = -1.4 cm, SEM = 0.5, p = 0.012), BMI (mean /1 = -0.5 kg/m2, SEM = 0.2, p=0.014), 
chest skinfold thickness (mean ;). = -3.0 mm, SEM = 1.2, p = 0.020), body fat percentage 
(mean ;). = -1.6%, SEM = 0.8, p = 0.054), and physical activity volume (mean ;). = 13 .3 
MET-hrs/week, SEM = 5.2, p = 0.016). Significant improvements in physical activity 
volume for the AET group from baseline to 3 months were maintained at 6 months (mean 
11 = 16.7 MET-hrs/week, SEM = 5.5, p=0.005) and 12 months (mean /1 = 13.8 MET-
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hrs/week, SEM = 4.3, p = 0.003). At 12 months, the AET group showed significantly 
improved body fat percentage (mean /J,. = -1.9%, SEM = 0.09, p = 0.029) and waist 
circumference (mean /J,. = -1.4 cm, SEM = 0.6, p = 0.03) compared to baseline. From 
baseline to 6 months, the RET group displayed a significant increase in V 0 2 peak (mean 
/J,. = 2.2 mL02/kg/min, SEM = 0.8, p=0.011). The RET group also demonstrated reduced 
body fat percentage from 6 months to 12 months (mean ~ = - 1.4%, SEM = 0.5, p = 
0.014). 
8.4 Results of Per Protocol Analysis 
8.4.1 Fatigue and HRQOL Outcomes 
Fatigue and HRQOL outcomes, using a per protocol analysis, are presented in 
Table 6. There was a significant main effect of Time for HRQOL via the PORPUS 
(F(3,69) = 4.184, p = 0.009). There were no significant main effects of Group. There 
was a significant Group x Time interaction effect for HRQOL via the PORPUS (F(3, 69) 
= 3.431, p = 0.022; Figure 8). Simple effects analysis of this interaction indicated that 
only RET improved in PORPUS scores from baseline to 12 months (mean ~ = 8.90, 
SEM = 2.54, p = 0.002), from 3 months to 12 months (mean /J,. = 6.92, SEM = 2.59, p = 
0.014), and from 6 months to 12 months (/J,. = 6.658, SEM = 2.50, p = 0.014). 
In within-group comparisons via paired-samples t-tests, RET improved m 
PORPUS scores from baseline to 12 months (mean /J,. = 8.09, SEM = 2.45, p = 0.008) 
with a trend towards a statistically significant difference from 6 months to 12 months 
(mean /J,. = 4.92, SEM = 2.70, p = 0.093). From baseline to 12 months, the RET group 
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demonstrated a near clinically important difference from baseline for fatigue (MCID = 
3.0 points, (120, 413)); however, this was not statistically significant (mean Ii = 2.83, 
SEM = 1.83, p = 0.145). There were no other significant within-group differences. 
8.4.2 Physical Fitness Outcomes 
Physical fitness outcomes, using a per protocol analysis, are presented in Table 7. 
There was a significant main effect of Time for waist circumference (F(3,93) = 2.461, p = 
0.087), body fat percentage (F(3, 90) = 5.483, p = 0.001), and V02peak (F(3, 78) = 2.876, 
p = 0.041), with a trend towards a Time main effect for chest skinfold thickness (F(3,93) 
= 2.461, p = 0.087). There were no significant main effects of Group. There were no 
significant Group X Time interactions. 
In within-group comparisons via paired-samples t-tests from baseline to 3 months, 
AET improved weight (mean Ii= -1.8 kg, SEM = 0.65, p ~ 0.012), waist circumference 
(mean Ii= -1.7 cm, SEM = 0.61, p = 0.011), BMI (mean Ii= -0.6 kg/m2, SEM = 0.22, p 
= 0.014), chest skinfold thickness (mean Ii = -3.6 mm, SEM = 1.4, p = 0.02), body fat 
percentage (mean Ii= -1.9%, SEM = 0.9, p = 0.054), and physical activity volume (mean 
Ii= 16.0 MET-hrs/week, SEM = 6.1, p = 0.016). At 6 months, compared to baseline, 
AET participants had significantly greater V02peak (mean Ii = 3.0 ml02/kg/min, SEM = 
1.3, p = 0.03) and physical activity volume (mean Ii =21.5 MET-hrs/week, SEM = 7.6, p 
= 0.01). At 12 months, compared to baseline, AET participants had lowered waist 
circumference (mean Ii= -1.8cm, SEM = 0.8, p = 0.037) and body fat percentage (mean 
Ii = -3.3%, SEM = 1.2, p = 0.013), while demonstrating increased physical activity 
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volume (mean ~ = 13.7 MET-hrs/week, SEM = 6.1, p = 0.038). RET participants 
improved chest skinfold thickness (mean ~ = -3.9 mm, SEM = 1.5, p = 0.018) and 
V02peak (mean~= 3.8 ml02/kg/min, SEM = 1.3, p = 0.011) from baseline to 6 months 
as well as body fat percentage from 6 months to 12 months (mean ~ = -3.0 MET-
hrs/week, SEM = 1.0, p = 0.012). There were no other significant within-group 
differences. 
8.5 Results of Exploratory Biomarker Assay Analysis 
The subgroup analyses of those that underwent biomarker assays at baseline, 3 
months, and 6 months are presented in Table 8. A main effect of Time was observed for 
IGFBP-3 (F(2, 44) = 3.338, p = 0.045). There were no main effects of Group. There were 
no interaction effects. 
Within-group comparisons by paired-samples t-test demonstrated that the RET 
group demonstrated a significant reduction in IGF-1 (mean~= 20.9 ng, SEM = 7.7, p = 
0.019). At 6 months compared to baseline, the AET group demonstrated a significant 
decrease in IGFBP-3 (mean ~ = -1332.9 ng, SEM = 591.2, p=0.049, a non-preferable 
trend), whereas the RET group showed a significant increase in IGFBP-3 (mean ~ = 
527.4 ng, SEM = 234.0, p=0.044, a preferable change). These changes at 6 months 
corresponded with significant changes in IGF-1 :IGFBP-3 ratios, with the AET group 
increasing the ratio by 0.01 (SEM = 0.01; p < 0.05) and the RET group decreasing the 
ratio by 0.01 (SEM = 0.003; p < 0.05). 
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8.6 Exploratory Analysis of Correlations between Outcomes 
8.6.1 Correlations between Physical Fitness Outcomes and Biomarkers at Baseline 
Correlations between physical outcomes and biomarkers at baseline are presented 
in Table 9. As would be predicted, weight, BMI, waist circumference, and body fat 
percentage were all significantly negatively correlated with adiponectin and positively 
correlated with leptin and leptin:adiponectin ratio (p < 0.05). Grip strength was inversely 
correlated with leptin (r = -0.415, p = 0.039) and trended towards a significant inverse 
relationship with IGFBP-3 (r = -0.394, p = 0.057) and leptin:adiponectin ratio (r = -
0.381, p = 0.066). 
8.6.2 Correlations between Changes in Physical Fitness Outcomes and Biomarkers 
at 3 months 
Changes in physical outcomes and their association with changes in biomarker 
concentration at 3 months are presented in Table 10. At 3 months, changes in weight, 
BMI, and waist circumference were positively correlated with changes in leptin (r = 0.41 
to 0.61, p<0.05), while an increase in V02 peak was associated with a decrease in leptin 
concentration levels (r = 0.41, p < 0.05). Changes in IGF-1 :IGFBP-3 ratios were 
inversely associated with changes in weight, BMI, and waist circumference (r = -0.44 to 
-0.46, p < 0.05), with a trend towards a positive relationship with V02 peak (r = 0.38, p = 
0.068). 
112 
8.6.3 Correlations between Changes in Physical Fitness Outcomes and Biomarkers 
at 6 Months 
Changes in physical outcomes and their association with changes in biomarker 
concentration at 6 months are presented in Table 11. At 6 months, changes in leptin were 
positively correlated with changes in weight and BMI (r = 0.52 to 0.53, p < 0.01) and 
negatively correlated with increases in V02 peak (r = -0.471, p = 0.020). 
Leptin:adiponectin ratio changes were positively correlated with changes in weight and 
BMI (r = 0.52 to 0.53, p < 0.01) and negatively correlated with body fat percentage (r = 
-0.53, p = 0.008). A positive relationship between waist circumference and IGFI:IGFBP-
3 was also observed (r = 0.432, p = 0.035) which is discordant with findings observed at 
3 months (r = -0.456, p = 0.025). 
8.6.4 Change in Determinants of Exercise Over Time 
Se If-Efficacy 
Change in mean self-efficacy scores for both groups is presented in Figure 9. 
There was no significant main effect for Time or Group. There was no Group x Time 
interaction. Using paired-samples t-tests, a significant within-group difference was 
observed between baseline and 12 months for the AET group (mean 11=-1.06,p=0.014; 
95% CI: 0.250 to 1.868). There were no other within-group differences for the AET or 
RET group. 
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Family Social Support for Exercise 
Change in mean scores of social support from family for both groups is presented 
in Figure 10. There was no significant main effect for Time and no significant Group x 
Time interaction. There was a trend towards a main effect for exercise Group (F(l, 58) = 
3.443, p = 0.069). Simple effects analysis of this interaction demonstrated that there was 
a between-groups difference at 12 months, with the AET group having significantly 
higher family social support than the RET ·group (mean /1 = 6.2, p = 0.037, 95% CI: 
0.398 to 12.002). 
Friend Social Support for Exercise 
Change in mean scores of social support from friends for both groups is presented 
in Figure 11. There was no significant main effect for Time or Group, and no significant 
Group x Time interaction. A significant within-group difference for aerobic exercisers 
was observed between baseline and 6 months (mean /1 = -0.443, p = 0.043; 95% CI: 
-0.015 to -0.871). There were no other significant differences within-group differences 
for AET and RET participants. 
Social Support (Total) 
Change in mean scores of total social support for both groups is presented in 
Figure 12. There was no significant main effect for Time or Group, and no significant 
Group x Time interaction. Significant within-group differences for the AET group were 
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observed from 3 to 12 months (mean /1 = 0.258, p = 0.027; 95% CI: 0.033 to 0.483) and 
from 6 to 12 months (mean /1 = 0.265, p = 0.030; 95% CI: 0.028 to 0.502). There were 
no other within-group differences for AET and RET participants. 
Exercise-Induced Feelings 
Change in mean scores of exercise-induced feelings for both groups is presented 
in Figure 13. There was no significant main effect for Time or Group, and no significant 
Group x Time interaction. A significant within-group difference for the RET group was 
observed between 3 and 12 months (mean /1 = 0.439, p=0.018; 95% CI: 0.082 to 0.797) 
There were no other within-group differences for AET and RET participants. 
8.6.5 Relationship Between Determinants of Exercise, Self-Reported Physical 
Activity Volume and V02 peak 
Bivariate correlations between determinants of exercise measures, control 
variables, and measures of program adherence (as assessed by the GLTEQ and V02 
peak) at each time point are presented in Tables 12-15. Notably, age had a strong 
negative correlation with V02 peak at each time point (r = -0.61 to -0.70) and therefore 
was incorporated into the multivariate models. The Charlson comorbidity index was not 
significantly correlated with physical activity (GLTEQ) or V02 peak and therefore was 
excluded from the multivariate models. In terms of correlations between the candidate 
exercise-determinant variables, exercise-induced feelings had a moderate positive 
correlation with self-efficacy at every time point (r = 0.31 to 0.53). Social support for 
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exercise (total score) also had a low to moderate positive correlation with self-efficacy at 
every time point except at 6 months (r = 0.29 to 0.34). In terms of outcome 
measurements, physical activity volume and V02 peak had a low to moderate positive 
correlation at every time point (r = 0.29 to 0.53). 
Model fit for multiple regression analyses of psychosocial determinants of 
exercise behaviour with physical activity volume and V02 peak at each time point are 
presented in Table 16 (individual predictor variable coefficients for physical activity 
volume and V02 peak are presented in Tables 17-20 and Tables 21-24, respectively). 
The models were not predictive of self-reported physical activity volume at any time 
point. While the models were significantly predictive of V02 peak, this relationship was 
driven largely by age. Model fit for multiple regression analyses of social support, 
exercise-induced feelings and control variables with change in physical activity volume 
and V02 peak from baseline to 6 months are presented in Table 25 (individual predictor 
variable coefficients are presented in Tables 26 and 27). Neither model explained a 
significant amount of the variance in the change-scores of the adherence outcomes (self-
report or objective). 
8. 7 Post-hoc Power and Sample Size Calculations 
8. 7.1 Fatigue and HRQOL Outcomes 
Post-hoc power and sample size calculations for fatigue and HRQOL outcomes 
are presented in Table 28. The effect size (converted from partial 112 to Cohen's./) for a 
main effect of Group (between-factors analysis) in a RM-ANOVA for FACT-F, FACT-P, 
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and PORPUS was 0.22, 0.139, and 0.173, respectively if of 0.1 is considered to be a 
'small' effect size,/ of 0.25 is considered to be a 'medium' effect size). For the observed 
effect sizes, sample sizes of between n = 172, n = 348, and n = 226 are required for the 
FACT-F, FACT-P, and PORPUS, respectively. However, a priori sample size 
calculations should be based on clinically important differences, which yield sample size 
requirements of n = 78 (FACT-F), n = 92 (FACT-P), and n = 134 (PORPUS) to provide 
80% power at alpha= 0.05. 
8. 7 .2 Physical Fitness Outcomes 
Post-hoc power and sample size calculations for select, clinically important 
physical fitness outcomes are presented in Table 29. The effect size (converted from 
partial 112 to Cohen's j) for a main effect of Group (between-factors analysis) in a RM-
ANOVA was very low and thus sample sizes to reliably detect such small differences 
were quite substantive (n = 252 ton= 6668). N=l 10 (n = 55 per group) is required to 
provide 80% power at alpha = 0.05 using a medium effect size if= 0.25) based on 
clinically important difference and previous research, for the other physical fitness 
outcomes. 
8. 7 .3 Biomarker Outcomes 
Post-hoc power and sample size calculations for the biomarker assay outcomes 
are presented in Table 30. The effect size (converted from partial 112 to Cohen's}) for a 
main effect of Group (between-factors analysis) in a RM-ANOVA ranged from small to 
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medium (referent values for effect sizes using Cohen's f 0.1 = small, 0.25 =medium, 
0.4 = large). In the absence of any established MCID information regarding these 
outcomes, medium effect sizes (Cohen's f = 0.25) were used to calculate sample sizes 
yielding a sample ofN=l 10 (n = 55 per group) per biomarker analysis with 80% power at 
alpha of 0.05. 
8. 7.4 Determinants of Exercise Outcomes 
Typical recommendations for sample sizes in multiple linear regression models 
refer to Cohen's estimate of n = 10 per predictor variable with some texts recommending 
up to n = 20 per predictor variable ( 475, 478, 482). Some have criticized this approach 
for being over-simplistic and for not relying on the hypothesized effect size (475). The 
effect size in a multiple linear regression can be determined by the fit of the overall 
model (i.e. how much variance is explained by the model, denoted by R2) or by the 
influence of the predictor variables (denoted by unstandardized (B) and standardized 
(beta) coefficients). Green (483) proposed an algorithm for effect size calculation based 
upon the type of information being pursued. Green suggests that 50+8k is necessary to 
test for model fit (where k = number of predictors). To test for individual predictor 
influence, Green suggests 104 + k ( 483). In circumstances where both the fit and strength 
of the predictors is desired, both sample sizes should be calculated with the larger of the 
two used in the design of the trial (483). Green's calculations generally fall within the 
'rule of thumb' recommendations n = 10-20 per predictor variable with added 
consideration for the effect size of interest. In the present trial, sample sizes ranged from 
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n = 29 to n = 48 for models that examined the explained variance of determinants of 
exercise outcomes at specified time points (depending on the amount of participants with 
complete data for the model at the analyzed time point). In these models, there were 5 
predictor variables. According to Green's recommendations, the necessary sample size 
to test for model fit would be n = 90 and for the individual predictors it we would need n 
= 109. 
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9.0 Discussion 
The underlying premise of hormonal therapy for PCa is to minimize the exposure 
of PCa cells to testosterone, which is its primary growth factor. Unfortunately, this 
disruption of normal endocrinology has downstream effects that significantly undermine 
HRQOL by negatively interfering with normal physiological and psychosocial activity. 
Exercise has been shown to improve physical and mental wellbeing in healthy 
populations, with effects opposite to those of ADT. As ADT has demonstrated strong 
cancer-control efficacy, strategies that can reduce the negative burden of treatment and 
possibly enhance disease management are highly desirable. Accordingly, research over 
the last two decades has explored the actual benefit of exercise in PCa patients treated 
with ADT. Positive findings regarding the efficacy for exercise among ADT patients 
have led researchers to combine exercise with intervention design features aimed at 
enhancing long-term exercise (21, 24, 30, 121). Our study assessed the feasibility of 
conducting a randomized trial of distinct exercise programs (AET and RET) for PCa 
patients receiving ADT and provided exploratory hypothesis testing of several outcomes 
pertinent to participants' physical, physiological, and psychosocial wellbeing. Given the 
relatively immature state of exercise intervention literature for PCa patients, it is 
appropriate to begin the discussion of our results with both the position and relevance of 
this study in the context of the overall PCa-exercise body of research. 
At the time of this study's conception, only five studies assessing exercise 
interventions for PCa patients were published, four of which were in men treated with 
ADT (24, 65, 66, 120, 121). These studies were highly heterogeneous in intervention 
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design, methodological quality, and results, even though exercise was generally 
associated with physical and/or psychosocial benefit. In the time since this study was 
initiated, seven additional exercise interventions for PCa patients have been published 
(21, 23, 26-28, 122, 180) and at least four additional studies are underway with published 
methodology ( 126-128, 484 ). Our study treated 66 PCa patients with an exercise 
intervention, which represents approximately 8% of all PCa patients (n = 868) 
participating in research-based exercise program among published trials. This is also 
comparable to the average sample size of PCa-exercise studies that have a mean of n = 62 
participants. Given the growing interest and publication in this field, the effect of 
exercise on PCa management is arguably the most rapidly advancing area of exercise 
study in oncology with our study contributing a significant proportion to the overall data. 
Our study adds numerous novel elements to the literature while re-examining 
important aspects that still require clarification and additional insight. The unique 
aspects of this study include: 1) a comparison of home-based AET to RET, 2) utilization 
of the PORPUS as a secondary disease-specific HRQOL measure, 3) independent 
analysis of chest skinfold thickness (apart from a sum of skinfolds calculation for body 
fat percentage), 4) use of an objective fitness measurement to validate self-report 
measures of program adherence, 5) assessment of the hormones adiponectin and leptin 
which may react to exercise and be altered in ways that prevent cancer progress, 6) 
inclusion of exercise-induced feelings as a potential determinant of exercise behaviour, 
and 7) a 6 month post-intervention follow-up (previous research followed participants for 
4 months after the intervention). This was also the first exercise intervention for PCa 
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survivors at the Princess Margaret Hospital (PMH) that, prior to this study, did not 
contribute to the exercise oncology literature despite its international prominence as a 
centre for excellence in cancer care and research. This study also builds on the ground-
breaking results of earlier research by supporting previous findings and raising questions 
about the generalizability of past results. The commonalities our research shares with 
earlier exercise intervention research in PCa are: I) examining the efficacy of generalized 
home-based exercise programs, 2) group booster sessions that are theory-based to 
improve exercise adherence, 3) usage of validated measures of HRQOL, fatigue, and 
physical activity volume, 4) assessment oflGF-1 and IGFBP-3, 5) examination of social 
support and self-efficacy for exercise, and 6) reporting of recruitment, safety, and 
attrition findings. The present study's novelty juxtaposed to the commonality it shares 
with the greater body of exercise intervention research in PCa provides a strong 
foundation for generalizability of our findings as well as advancement in the research 
field. 
Likely the key feature that this research contributes to the overall literature of 
exercise-related effects in ADI-treated PCa survivors is a better understanding of 
modality-specific effects in the home-based setting. It was important to assess the 
difference between AET and RET in this population for various reasons. For exercise 
professionals, there is significant utility in the ability to identify the modality-specific 
benefits in order to tailor exercise prescriptions based on patient symptoms and goals. It 
also provides information that assists patients and clinicians to make priority-based 
decisions on the relative investment of time that they focus on competing modalities. 
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Possibly most importantly, it is important to know which modality is most likely to yield 
chronic behaviour change in this population as ADT may be indicated for many years, 
and possibly for the remaining years of the patient's life. This importance is dramatically 
underscored by recent epidemiological evidence showing that men who exercise for 2:_ 9 
MET-hrs/wk after a diagnosis of PCa have a 33% and 35% reduction in all-cause and 
PCa-specific mortality, respectively (110). This includes men who were sedentary prior 
to a PCa diagnosis, highlighting the importance of exercise behaviour initiation during 
and/or after treatment. Men in the current trial assigned to AET increased their physical 
activity volume by 15-20 MET-hrs/wk which may provide survival benefit if the 
behaviour is maintained over time (110). Physical activity volumes of approximately 35-
40 MET-hrs/wk as observed in the AET group of this trial are consistent with cancer-
specific recommendations of moderate-vigorous activities on most days and have also 
been shown to reduce disease-specific mortality (110, 435). 
Ultimately, a combination of AET and RET is most likely to produce the most 
comprehensive health benefits. A recent study completed by Galvao and colleagues (23) 
examined the effect of a 12-week combined AET +RET intervention in a RCT of 57 
patients receiving ADT. Treatment group participants completed 8 RET exercises at 6-
12 RM (moderate to strenuous RET) for 2-4 sets per exercise. The AET component 
consisted of 15-20 minutes of cycling, walking, or jogging at 65-80% of maximum heart 
rate or 11-13 out of 20 on the Rating of Perceived Exertion Scale. Participants completed 
exercises in a facility-based, supervised setting in small groups of 1 to 5 participants. 
Primary outcomes were whole body and regional lean mass measured by dual energy x-
123 
ray absorptiometry (DEXA). At the end of 12 weeks, the exerc1smg participants 
demonstrated greater lean mass, muscle strength, and functional capacity than controls (p 
:S 0.05). Over the course of the trial, exercising participants also improved HRQOL, 
reduced fatigue, and reduced C-reactive protein (p < 0.025). Their study was the first to 
demonstrate a reversal in muscle loss in androgen-suppressed PCa patients and 
demonstrated significant HRQOL, fatigue, and muscle strength outcomes with a mixed-
modality exercise intervention. These important findings highlight the importance of a 
comprehensive and relatively intense exercise intervention for men with PCa receiving 
ADT. 
9.1 Discussion of Feasibility Findings 
The primary objective of this study was to assess the safety and feasibility of 
conducting an adequately powered, single modality, home-based exercise intervention 
with PCa patients undergoing ADT. This was the first exercise intervention study to be 
conducted at the Prostate Centre, and the PMH in general, and there were a number of a 
priori concerns that we had regarding trial implementation which required resolution 
before attempting a large-scale research project that could appropriately assess efficacy 
outcomes. From inception to data analysis it has taken approximately 36-40 months to 
complete this feasibility-study which provided experiences and insights for future 
exercise trials and exercise program management at the Prostate Centre at PMH. 
A total of 66 patients were recruited over 13 months (n ~ 5/month), which is 
comparable to other major cancer centres recruiting for exercise trials in PCa (21, 120). 
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As it was the first exercise intervention trial to be conducted at the Prostate Centre, it was 
questionable whether patients would be interested in participating in this type of study. 
Unfortunately, our recruitment rate of 32% of eligible participants was lower than 
anticipated and below the median recruitment rate of PCa-exercise intervention studies 
(median: 4 7.9%, range: 22- 86% ). However, the most comparable trials (i.e. home-based 
exercise in ADT patients) have either not reported participation rates (24, 122) or rates 
have been comparable (22% participation rate in Carmack-Taylor et al's home-based 
lifestyle intervention; (30)). Thus, an appropriate comparison is lacking and reasons for 
refusal were similar to other exercise studies in ADT patients. One postulation regarding 
the relatively poor participation rate is that a majority of the other exercise interventions 
in PCa patients have been facility-based which may stimulate greater participation due to 
the appeal of a more intensive intervention, greater trainer-related motivation, or the 
feeling of safety/security of exercising in supervised setting. On the other hand, a recent 
facility-based trial among PCa patients undergoing ADT completed by our group 
(initiated following the completion of the present study) found similar recruitment rate to 
the home-based intervention utilized in the present trial (recruitment rate: 24%) (26) 
indicating that there may be regional reasons for lack of participation, such as traffic, cost 
of parking, or challenging public transit system. The challenge of recruiting participants 
to participate in an urban exercise program due to transportation barriers (distance, time, 
and cost) has been previously described in general exercise preference literature in 
populations with cancer (142, 400, 485-487). 
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An equally important concern was whether there would be institutional and 
physician support for an exercise intervention. It was apparent early in our trial initiation 
that our mandate and objectives were supported. We were able to proceed with capital 
equipment and consumable purchases through internal funding committed by the Prostate 
Centre. Furthermore, the physicians from the department of urology and radiation 
oncology with PCa patients undergoing ADT were amenable to trial participation and 
patient referral to our study. This was facilitated through departmental emails and 
research meeting presentations. Ultimately, the present study initiated the development 
of the Prostate Centre's Survivorship Exercise Program that is now an on-going clinical-
research program founded on the home-based model described in this trial. A thorough 
description of the Survivorship Exercise Program has been recently published (26). 
Attendance to the group-based exercise classes in PCa patients undergoing ADT 
was poor, in stark contrast with previous trials of home-based exercise programs (24, 26, 
122). In two trials of home-based, mixed-modality exercise for PCa patients receiving 
ADT, Culos-Reed et al observed that approximately 80% participants in both trials 
attended at least 5 of the 6 offered booster sessions (24, 122). Our recently completed 
pilot study of mixed-modality group-based exercise versus personal training for ADT-
patients found that group-based exercise participants attended 88% of their facility based 
sessions which were offered three days per week for eight weeks (26). However, the 
attendance differences may be due to the fact that these trials were fundamentally 
different in terms of the delivery strategy: the former being a home-based program and 
the latter being a facility-based program. Thus, participants may have identified the 
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expectation to attend group-based classes in the facility-based trial more than those in the 
home-based trial, explaining the difference in attendance rates (i.e. they were likely to be 
more committed to, and less bothered with, attending the frequent facility-based exercise 
sessions). In the present study, the most commonly cited reasons for non-attendance to 
the booster sessions were distance and travel time. Furthermore, due to resource 
constraints, it was not feasible to provide booster sessions specific to AET and RET 
which may have deterred participants from attending knowing that a portion of the 
session was not consistent with their home-based program. 
We observed an overall attrition rate of 33% from baseline to 6 months. This was 
particularly problematic in the RET group that lost nearly half of the participants that 
started the intervention (although there was no statistically significant difference in 
attrition when compared to the AET group). Attrition in home-based exercise studies is 
not uncommon in the published literature in this population. From baseline to 6 months, 
Carmack-Taylor et al (30) lost 16% of their population; and from baseline to 4 months, 
Culos-Reed et al (24) lost 34% of their sample to dropout. Moreover, significant dropout 
is not limited to home-based research as facility-based exercise interventions in ADT 
patients have also reported significant attrition. Hansen et al (27) observed a 38% 
attrition rate over 3 months and our group recently found a 23% attrition rate over 2 
months; but it should be noted that both of these studies employed very small sample 
sizes (26) (n = 10 and n = 13, respectively). 
To facilitate sample size calculations for subsequent studies that examme 
comparable outcomes in this population, our efficacy results of all time points and change 
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scores between time points are presented with means and standard deviations. Using the 
established minimal clinically important difference (MCID) for fatigue via the FACT-F 
(3 .5 points) to calculate sample size requirements for a three-arm RCT of AET versus 
RET versus usual care, Segal et al (21) reported requiring n = 3 7 per group (total: N = 
111) for a 3-group ANOV A to compare change scores over-time. They recruited N = 
121 to account for an anticipated 10% attrition. In the present two-armed randomized 
trial, appropriate estimates of effect size would similarly be based on the established 
MCID and the standard deviation (SD) from Segal et al's earlier work (120) describing 
change from baseline in a ADT-only group (SD = 5.8). The effect size, calculated in 
Cohen's d (d = MCID/SD) and converted to Cohen's f (using a reference table (515)) 
produced d = 0.6 (from 3.5/5.8) and/= 0.3. (Of note, these were the same parameters of 
effect size and variance that Segal used to calculate N=l 11 described above). The 
resultant sample size for the two-way RM-ANOV A (with 2 groups and 4 time points, as 
per the current analysis) at 80% power and alpha of 0.05 is N=78. Given this sample size 
requirement and accounting for the observed attrition in this trial of 33%, a total of 103 
participants would need to be recruited. With an accrual rate of n,._,5 per month, the 
estimated duration of a full-scale trial incorporating the present study' s design will be 
approximately 3 3 months (21 months of recruitment plus 12 months for intervention and 
follow-up). Furthermore, for n = 103, it would cost approximately $7,416 to provide 
each participant with home-based equipment (average cost per participant for the AET 
and RET equipment= $72). 
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The reasons for dropout do not appear to be related specifically to intervention 
design, as a majority of patients dropped out due to individual circumstances such as 
disease/symptom exacerbation, lack of time to exercise, or loss of interest/motivation to 
exercise. In light of these reasons, development and evaluation of participation-
maintenance strategies is imperative to ensure continued participation in research and 
long-term exercise behaviour, in general. In the instances of 'lack of time' and/or 'loss of 
motivation', modifications to the exercise prescription and program design are warranted 
to maintain interest and address pragmatic barriers to participation. Given the lack of 
attendance to our booster sessions, one strategy might be to have participants switch to a 
facility-based program to enhance the connection between the training staff as attrition 
rates appear generally lower in facility-based, supervised trials. Another approach might 
be to arrange for home-based supervision of exercise to maintain motivation. Finally, for 
those that lose general interest, a completely different exercise approach might be 
necessary to appeal to the individual activity interests, by altering the activity prescription 
to be more aligned with their activity preferences (e.g. dance, dog-walking, hiking, etc). 
Unfortunately, these approaches will generally undermine the empirical process due to 
lack of standardization of programmatic approach within a specific study; however, they 
should be considered as options in the 'tool-box' for clinicians to enhance adherence and 
overall exercise participation. 
Historically, exercise trials in PCa have been conducted safely with only one 
study reporting a severe adverse health event (21 ). Our study had no adverse events 
beyond typical post-exercise muscle soreness that normally occurs with the initiation or 
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re-initiation of exercise. These observations confirm the safety of exercise, and especially 
home-based exercise, for PCa patients. Noteworthy is that recent trials have examined 
considerably higher intensity training without incident and have yielded important 
improvements in physiological and functional outcomes (23, 27, 121, 222). A high-
intensity home-based program would be an important study to consider given the 
convenience of home-based exercise and benefit of high-intensity training. 
Finally, there was a significant amount of positive feedback from the participants 
to their attending physicians regarding satisfaction with the exercise program. Numerous 
participants anecdotally expressed appreciation, satisfaction, and enjoyment with the 
program; and they have maintained communication with the research group since trial 
completion. This has generated additional program interest from physicians in other 
departments and spawned the initiation of additional exercise trials at PMH. 
9.2 Discussion of Fatigue and HRQOL Hypothesis Testing Findings 
This is the first study to compare the effects of AET to RET delivered in a home-
based setting in any cancer patient population. Furthermore, we are the first group to use 
common, disease-specific metrics of HRQOL and fatigue in a home-based exercise 
program that provides direct comparison to facility-based trials. In an ITT analysis, we 
did observe a significant between-group main effect for emotional wellbeing; however, 
after visual interpretation and in the absence of any main effect of time, it appears this 
reflects baseline group differences rather than true between group differences. Our ITT 
analysis also showed trends towards improved social wellbeing and fatigue in the AET 
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group compared to the RET group. These novel findings are in some contrast with Segal 
et al' s previous work (21) that found RET to be better than AET when both were 
compared to controls for fatigue and HRQOL outcomes (however they did not do a direct 
intervention arm comparison). These findings were only very modest trends towards 
significance and be in part due to the inherent differences in facility-based training versus 
home-based training where RET is likely better supported in the presence of training staff 
compounded with AET (via walking or cycling, for example) likely being easier to do 
independent from a trainer and possibly with a friend or family member. In general, our 
ITT analysis found that HRQOL and fatigue were relatively unchanged over-time with 
AET and/or RET which is consistent with findings from previous home-based and hybrid 
physical activity/lifestyle interventions in this population (28, 30, 122). 
In a per protocol analysis of participants that completed each assessment, we 
observed that RET was associated with a clinically and statistically significant increase in 
disease-specific HRQOL as measured by the PORPUS which was not apparent in the 
AET group. Our study is the first to use the PORPUS in an intervention-based exercise 
study in PCa patients and, interestingly, we did not observe similar differences in 
HRQOL measured by the FACT-P (including most subscales). These findings must be 
interpreted with caution given the limited sample size and because the sample is 
comprised of the most adherent and motivated participants. Further, the discordance 
between PORPUS and F ACT-P results necessitates further investigation in larger 
samples for cross validation in exercising participants. Our finding that RET may be 
more effective than AET at improving HRQOL is novel and, in part, contrasts with Segal 
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et al's (21) findings in m~n undergoing radiation therapy and adjuvant ADT since neither 
AET nor RET improved HRQOL following 24 weeks of facility-based training in that 
trial. However, it is consistent with other studies in PCa populations that demonstrate an 
improvement in disease-specific HRQOL with RET (120, 180) but not with AET (66) or 
mixed-modality training (24, 28, 30, 122). 
Reasons for the greater RET efficacy at improving general and disease-specific 
HRQOL may the novelty of the training modality for most participants. Although RET is 
the quintessential complement to AET, AET in the form that is utilized in most clinical 
exercise intervention trials (i.e. walking and/or cycling) is likely more familiar to most 
participants than various RET exercises. This novelty may have been amplified in the 
present trial (and comparable with others) that incorporated resistance bands, which 
require familiarization and confidence to be utilized correctly and effectively. The 
heightened level of concentration required for RET completion may serve as a distraction 
from distressing aspects of disease and/or treatment. Conversely, since AET can be 
rather monotonous, it may create a psychological environment susceptible to rumination 
about distressing aspects of PCa management compromising HRQOL (albeit, potentially 
benefiting ratings of fatigue, as indicated in our ITT analysis). The acute effects of 
exercise (RET and/or AET) on psychological wellbeing have not yet been assessed. One 
approach may be to examine measures of distress, HRQOL, or neurophysiological 
correlates of psychological wellbeing immediately before and after bouts of exercise. 
Our group is currently undertaking such a study, which we hope will add insight to the 
acute and enduring effects of exercise in this population. 
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Fatigue is arguably the most profound and distressing adverse effect of ADT and 
is specifically treated through lifestyle and cognitive-behavioural interventions (189, 193, 
199, 201, 209, 410). Exercise is hypothesized to improve ADT-related fatigue via 
physical and psychological benefits by improving functional capacity and cognitive 
resilience, respectively. The physical and psychosocial effects of exercise have been 
lauded for their early benefits in PCa patients undergoing ADT (120). Unfortunately, the 
magnitude of benefit observed in the initial assessment of exercise for ADT by Segal et al 
(120) has not been replicated. In fact, of the 9 exercise trials in ADT patients that have 
employed a fatigue-specific outcome measure, only 3 have produced statistically 
significant improvements (21, 24, 120). Two of these trials used RET (21, 120), and only 
in one trial was the benefit observed to be clinically significant (120). Despite our 
observed trend towards between-groups differences in fatigue which maintained a small 
to medium effect size, our findings are generally consistent with most of the existing 
exercise literature with respect to null effects of exercise on fatigue over-time. Cancer-
related fatigue is a multifaceted construct with a diverse and likely dynamic etiology with 
physical and psychological components. Within the context of an exercise intervention, 
improvements in physical capacity may be a more representative and appropriate 
measure of physical fatigue than self-report measures that ask respondents to reflect on 
the experience of fatigue. Compared to fatigue measures, physical fitness measures 
appear to be more sensitive exercise training for men on ADT. Although these 
physical/functional changes have not consistently translated into perceptual benefits 
regarding fatigue, they may be more reliable in describing physical fatigue components 
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but less accurate at describing the psychological components. Additional research into 
the etiology of ADT-related fatigue from a cognitive, emotional, and psychological 
perspective is necessary. 
9.3 Discussion of Physical Fitness Hypothesis Testing Findings 
This is the first study to compare training modalities in a home-based setting in a 
population of cancer survivors. Our findings contrast to those of Segal et al's facility 
based comparison of AET and RET to usual care controls (21 ). In that study, the authors 
found that RET was more consistently associated with benefit in physical fitness whereas 
we found that AET demonstrated greater benefit (versus RET) particularly at 3 months. 
In addition to being facility-based, the training provided to participants in the Segal et al 
trial was more closely supervised and participants could receive instruction and support 
during each of their training sessions. This likely reduces the learning curve for the RET 
program and accelerates musculoskeletal adaptation through earlier and more targeted 
intervention progression. Furthermore, the facility-based nature of RET allows for 
confidence and comfort with training intensity that is crucial for fitness improvement. 
AET, on the other hand, can be conducted at comparable intensities in the home-based, 
unsupervised setting via walking, jogging, and/or cycling programs. Moreover, the 
familiarity of AET as a functional and transportation-related training modality may allow 
for more confidence in meeting the upper limits of target intensity. Collectively, this may 
lead to better outcomes for AET participants in the home-based setting and RET in the 
facility-based setting. 
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Changes in physical activity volume were greater with AET at 3, 6, and 12 
months compared to RET indicating a greater adoption and adherence of the prescribed 
intervention. This is likely why significant improvements in several body composition 
measures were observed in the AET group rather than the RET group. Greater physical 
activity volume for AET participants in both the ITT and per protocol analysis suggest 
that AET may be a more effective exercise prescription for stimulating and maintaining 
clinically relevant increases in physical activity. One reason for this may be that 
common modes of AET (e.g. walking) are more familiar to patients than RET and are 
more easily reproducible in the absence of the routine instruction or demonstration that 
may be required for RET. Furthermore, the home-based AET prescription provided in 
this study (primarily walking) is more amenable to partner or peer participation, thus 
facilitating a social element that may support ongoing behaviour change. Social support 
for exercise has been studied in only one trial among PCa patients (30) and several other 
studies in various clinical populations have noted the importance of a supportive social 
network in achieving and maintaining exercise behaviour (342-346). This may also be a 
reason for why walking is commonly described as a preferred modality for exercise 
among cancer survivors ( 468, 488). 
Although consistent differences were seen between AET and RET in terms of 
physical activity volume, it should be noted that self-report measures of physical activity 
are vulnerable to social desirability and should be considered cautiously. Logbooks were 
also used to assess overall compliance with the exercise prescription but could not be 
reliably analyzed because too few participants completed them effectively. Objective 
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assessments of physical activity such as doubly-labeled water techniques and 
accelerometry would produce more definitive evidence regarding physical activity status. 
Unfortunately, they were cost-prohibitive within the context of this study. It is worth 
highlighting, however, that at 3 and 12 months the changes in physical activity volume 
were accompanied by beneficial changes in body composition that are suggestive of 
actual improvements in physical activity rather than simple response bias. As described 
previously, objective measures of fitness may represent the most important clinical 
outcome of an exercise intervention that may provide credence to self-report measures of 
activity. 
Similar to the findings of previous researchers examining exercise in men with 
PCa, (21, 27, 121, 180) we observed an increase in aerobic fitness with RET. We did 
not observe an improvement in aerobic fitness with AET, which is also consistent with 
previous intervention studies in PCa patients (21, 65). The improved aerobic capacity in 
RET rather than AET may be due to a combination of factors. First, the aerobic benefits 
of AET can be achieved by simply increasing walking frequency and intensity as a matter 
of general physical activity or incorporation into commuting patterns. This is a possible 
source of contamination in our study, as participants assigned to RET may have engaged 
in this ancillary activity with subsequent benefits. In the absence of information 
regarding contamination in the RET group, we cannot conclusively determine whether 
this occurred in the present trial. However, in Segal et al's study, they reported that n = 8 
RET participants engaged in AET 2:. 3 time per week versus n = 5 AET participants 
engaged in RET :::_ 2 times per week demonstrating that AET may be more frequently 
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integrated into an RET program, in contrast to the reverse integration. This could 
possibly account for the greater improvement observed in the RET group compared to the 
AET group. 
An alternative hypothesis for greater aerobic benefit in RET participants is that, 
while AET is likely to improve overall oxygen consumption by facilitating 
cardiorespiratory adaptation, the observed change in aerobic capacity in the RET group is 
a function of improved lower extremity strength and subsequent increased capacity to 
complete the graded exercise test on a treadmill. Graded exercise testing for aerobic 
capacity using a treadmill relies on systematic increases in speed and incline. 
Participants engaged in home-based AET (without a treadmill) may not have routine 
access to walking routes that consist of significant elevations in grade and thus fail to 
stimulate neuromuscular adaptation for walking at incline. However, RET participants 
are trained to specifically improve lower extremity strength, thus facilitating 
neuromuscular adaptation that would support deeper walking strides (i.e. greater knee 
flexion) common to inclined walking at > 10% incline during a graded exercise test on a 
treadmill. Future studies would optimally compare AET to RET on aerobic fitness using 
graded walking programs and measured via treadmill-based graded exercise testing 
protocols. 
Finally, we are the first to report on exercise-related changes in chest skinfold 
thickness in men undergoing ADT for PCa. We observed a main effect of time on chest 
skinfold thickness in the ITT (p = 0.01) and per protocol (p = 0.087) analyses. Although 
ADT-induced gynecomastia is primarily due to changes in the glandular ducts, breast 
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epithelial tissue, and periductal edema ( 489), the size of the breast may be measured, in 
part, through a skinfold. Additionally, the subcutaneous fat accumulation that arises 
systemically with ADT may contribute to the undesirable changes in breast shape and 
size. Given the psychological distress associated with gynecomastia in ADT patients 
(243), therapies such as exercise, that may reduce the extent to which the breast is 
enlarged would be welcomed, as would investigations into the relationship between 
exercise and adaptions of body image. Conventionally, skinfolds are utilized in 
combination (i.e. a sum of skinfolds from multiple sites) to calculate body density (dB) 
and subsequently body fat percentage. Despite the absence of formal validation, we 
elected to examine chest skinfold thickness as an independent outcome because of its 
clinical relevance and potential meaningfulness to the participant. To our knowledge this 
is the first time chest skinfold thickness has been used and it will require further 
investigation to ensure its validity and reliability as an independent indicator of 
programmatic success. 
9.4 Discussion of Exploratory Analysis of Biomarker Assays 
A large body of literature suggests that IGFs play a role in the incidence of PCa 
(97, 299-303) but only one other study reported on the effects of exercise on these factors 
in men already diagnosed with PCa (28). To our knowledge, no studies have assessed the 
effect to which leptin and adiponectin concentrations can be modified with exercise 
programs for PCa patients receiving ADT and vulnerable to deleterious changes in body 
composition potentially negatively influencing these biomarkers. Hypothetically, IGFs 
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and adipokines can be beneficially altered, via healthy lifestyle changes, in ways 
contributing to improved cancer control and survival rate in PCa. The present trial is the 
first to report on the effect of an individually prescribed exercise program on leptin, 
adiponectin, and IGF-1 for men with PCa receiving ADT. This is particularly novel 
because it adds insight to the relationship between exercise, specific exercise modalities, 
and ADT-related changes in body composition that influence tumourigenic biomarker 
concentration. Although we did not observe a significant interaction effect, we did 
observe within group differences via paired samples t-tests that may guide further 
hypothesis testing. Specifically, we found that after 6 months of RET, IGFBP-3 was 
significantly increased compared to baseline (a preferable change) while AET 
demonstrated a decrease in IGFBP-3 (a non-preferable change). After 3 months of RET, 
we observed a significant reduction in IGF-1, this was not maintained at 6 months. As 
hypothesized, baseline indicators of adiposity were negatively associated with 
adiponectin and positively associated with leptin and leptin:adiponectin ratio. Our 
findings altogether suggest that a home-based exercise intervention, particularly 
involving RET, may have beneficial effects on adipokines and the IGF-axis possibly due 
to improved body composition. 
Previous interventional studies with PCa patients have found that exercise does 
not exacerbate disease progression as indicated by levels of testosterone and prostate-
specific antigen (PSA) levels not being increased (20-23, 28). PSA and testosterone 
levels in men with PCA were also observed to be unchanged after acute bouts of heavy 
resistance training (29). However, acute and high intensity RET was associated with 
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significant increases in serum growth hormone (GH), dehydroepiandrosterone (DHEA), 
interleukin-6, tumour necrosis factor-a (TNFa) and differential blood leukocyte levels. 
These positive changes in immune system markers and non-androgenic growth factors 
may have implications for chronic tumour control and physical wellbeing. Previous 
research has shown that acute increases in DHEA and GH may be related to observed 
improvements in functional capacity and muscle maintenance/development in the 
absence of testosterone (29). 
To further support potential exercise-related effects on cancer control biomarkers, 
Galvao and colleagues (23) found that C-reactive protein (a systemic inflammatory 
marker) was decreased in exercisers and increased in controls after 12 weeks of mixed-
modality exercise, although glucose, insulin, lipids, and homocysteine levels remained 
unchanged. These changes in C-reactive protein require further investigation as previous 
research has found no change in older adults, including those with breast or prostate 
cancer participating in exercise interventions (401, 490). 
Beneficial changes in IGF-axis proteins have been observed in vivo with a low fat 
diet and/or routine exercise in older men at risk for PCa. These changes have been 
associated with in vitro reduction in PCa cell growth (114, 116, 117). To assess the 
effect of chronic exercise specifically, Leung et al (117) compiled serum from sedentary 
men and men with a minimum of 10 years of routine exercise, all of whom were not 
diagnosed with PCa. Compared to the serum from sedentary participants, LNCaP cell 
growth was reduced by 27% in the chronically active participants, with a concomitant 
100% increase in p53 content and 371 % increase in apoptotic activity (117). For men 
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undergoing ADT for PCa, Bourke et al recently found no difference between usual care 
participants and participants assigned to 3 months of mixed-modality exercise and dietary 
advice for insulin, IGFBP-3 IGFBP-1, or IGF-1. In the present trial, we report a 
significant reduction in IGFBP-3 and IGF-1 :IGFBP-3 ratio with RET but an increase in 
these biomarkers with AET after 6 months of training. Our results differ from those of 
Fairey et al (321) that found beneficial changes in IGF-1, IGFBP-3, and IGF-1 :IGFBP-3 
in postmenopausal women with breast cancer after 15 weeks of AET compared to usual 
care. Our findings require further examination in larger trials given the study is 
underpowered for definitive statements regarding these effects. However, the current 
array of data appears to favour RET in terms of generating anti-tumourigenic changes 
Research into the acute and short-term effects of exercise on adiponectin and 
leptin is lacking, particularly in interventional cancer research. This is likely due to the 
modest body of literature describing the tumourigenic properties of various adipokines. 
In a pre-post test study of 16 older, obese adults (without cancer) participating in a 12-
week AET and stretching program, O'Leary et al (491) demonstrated significant 
reductions in body weight and fat mass, as well as leptin, but no change in adiponectin. 
No correlations between changes in adiposity and leptin or adiponectin levels were 
presented. In the current trial, changes in leptin were positively correlated with changes 
in weight, BMI, and waist circumference, although these anthropometric changes were 
not statistically significant over the course of the intervention. While these small changes 
may not necessarily be associated with exercise, these findings do reflect the sensitivity 
of leptin to changes in measures of adiposity. Furthermore, we found that V02 peak, 
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adjusted for body mass, was negatively correlated with leptin, corroborating earlier 
studies which demonstrate that aerobic exercise training can improve leptin levels 
independent of changes in body fat percentage ( 492). 
9.5 Discussion of Correlational Analysis Findings of Determinants of Exercise 
With research describing a relatively rapid withdrawal of benefits when cancer 
patients discontinue exercise (24, 332), there is a strong need to determine the predictors 
of chronic exercise adherence. Long-term exercise adherence for cancer patients has 
been defined as engaging in regular physical activity for at least six months post-
intervention ( 403). For men with PCa undergoing ADT, the benefits of exercise with 
respect to multiple aspects of wellbeing are impressive, suggesting that exercise be 
included as part of a comprehensive disease management strategy over the long term. 
Chronic exercise for ADT patients is particularly essential, because ADT is typically 
administered over many years (often indefinitely) and the adverse effects persist long 
after ADT is discontinued. 
Our study explored the relationship of established and novel determinants of 
health behaviour on physical activity participation, as well as an objective measure of 
fitness hypothesized to be an indicator of ongoing exercise participation. In bivariate 
and multivariate analyses, we found that age was the strongest predictor of V02 peak at 
any time point. This is consistent with the literature that describes a strong negative 
correlation between age and aerobic capacity, with sedentary adults typically losing 3.5 
ml02/kg/min (1 metabolic equivalent) every 7 years after the age of 25 (i.e. 0.5 
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ml02/kg/min per year) ( 493). It also underscores the necessity of continued aerobic 
activity in older men with PCa receiving ADT who are vulnerable to treatment-related 
exacerbations and/or functional decline. 
Our bivariate analyses showed a low to moderate correlation between self-report 
physical activity volume and V02 peak, which provides some support for our hypothesis 
regarding using an objective measure (V02 peak) to validate a self-report assessment of 
program adherence. However, because the correlation is only moderate, additional 
measures of adherence are required for further validation. Given that logbook 
completion rates in our study were inadequate for analysis, future studies should consider 
emphasizing the importance of the logbook completion, possibly utilizing reminders 
and/or incentives. Ultimately, it would be ideal to utilize more than one objective 
measure of physical activity adherence to validate program participation and chronic 
physical activity. Pedometers and accelerometers have become less expensive and more 
commercially available, providing an objective source of physical activity volume that 
can be compared to self-report program compliance and objective measures of fitness. 
Dracup et al ( 494) conducted a RCT of home-based exercise in 173 heart failure patients 
over 12 months. The researchers in this study measured program compliance in three 
ways: sealed pedometers (sealed so that participants could not see how many steps were 
recorded in an effort to prevent tampering with data quality/integrity), self-report physical 
activity (walking) volume using a log sheet, and a weekly summary of total physical 
activity questionnaire. Nonetheless, Dracup et al also encountered difficulties in 
obtaining quality adherence data, with only 44% of the intervention group providing 
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complete pedometer and logbook data. However, they did observe that patients who 
demonstrated a ::::_ 10% increase in pedometer scores had improved aerobic capacity 
scores at 6 months (measured by the six-minute walk test), with a strong, positive 
correlation between the two measures (r = 0.6, p=0.001). Collectively, our findings 
suggest that objective measures of physical fitness are reasonable proxies for program 
participation and are especially useful in light of poor data completion and quality from 
self-report measures. 
We also sought to describe temporal patterns in behavioural determinants that 
could provide insight into why participants engage in routine exercise and possibly assist 
in the development of interventions to prevent, and recover from, relapse to sedentary 
behaviour. There was no main effect of time on any of the psychosocial determinants of 
exercise behaviour suggesting that participation in a general physical activity program 
may not significantly alter these variables. In exploratory analyses of within-group 
effects, however, we did observe the following novel findings. The AET group 
significantly decreased in self-efficacy from baseline to 12 months. This is inconsistent 
with previous findings from Demark-Wahnefried et al that showed an increase in self-
efficacy for exercise 6 months after an exercise workbook and counselling intervention 
for older breast and prostate cancer patients ( 495). One reason for this discrepancy in 
findings is that our intervention was not principally predicated on education and 
information on exercise, but rather based on a provided individualized exercise 
prescription based on a fitness assessment. Demark-Wahnefried and colleagues, on the 
other hand, tailored their intervention delivery to reflect the constructs of SCT by 
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providing telephone counselling sessions that were "dedicated to increasing feelings of 
self-efficacy by setting achievable goals, monitoring progress and providing positive 
reinforcement" (it is worth noting, however, that their intervention did not produce 
statistically significant changes in physical activity volume in N = 182) (3 91 ). Our 
follow-up telephone calls and booster sessions attempted to support self-efficacy by 
facilitating similar patient-oriented positive attitudes towards exercise, but we did not 
explicitly strive for the incorporation of key aspects of SCT during each interaction. Our 
negative findings for the AET group may be explained with an inability to increase 
aerobic intensity sufficiently without the on-going support of the training staff (which 
ceased at 6 months), thus leading to a significant decrease in exercise self-efficacy 
between the intervention and follow-up phase. Conversely, the RET group had specific, 
fundamental instructions to increase resistance on the resistance bands and advance their 
training when 12-15 repetitions was no longer challenging. Therefore, their critical path 
to exercise efficacy may have included an initial phase of exercise technique acquisition 
followed by a reasonable understanding of exercise prescription progression. In our 
home-based exercise program, it was deemed unsafe for many of participants to engage 
in running or vigorous cycling, which may have undermined the AET group's ability to 
feel comfortable, competent, and confident with making appropriate exercise prescription 
progression. Additional research is required to assess longitudinal patterns in self-
efficacy for exercise in people with cancer, specifically focusing on the post-
programmatic period that appears vulnerable to a loss m exercise self-efficacy, 
particularly for those participating in AET. 
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Paired samples t-tests of social support for exercise from friends and family 
indicated social support was significantly greater at 12 months when compared to 
baseline and 6 months among AET participants. These findings may be indicative of 
AET being more suitable for partner exercise compared to RET. The primary mode of 
AET in this intervention was walking which can be a very social mode of activity given 
the ease with which one can converse with a 'training' partner. Walking has been 
repeatedly cited as a highly preferred form of exercise among cancer patients (e.g. ( 488, 
496, 497)) and the American College of Sports Medicine suggests that exercise programs 
incorporate traditional exercise modalities, like walking, due to the numerous health 
benefits and ease with which it can be performed ( 429). This aligns with research 
among breast cancer patients that reveals that patients that preferred low intensity 
exercise also desire high social support, which is congruent with the idea that high 
intensity exercise presents difficulty for ongoing conversation (346). The added value of 
social engagement that accompanies aerobic activity and the fact that it can be 
incorporated into daily activities makes it an ideal form of general physical activity, 
although it cannot address many needs of upper extremity musculoskeletal fitness and 
will likely not be high intensity. 
Only Carmack-Taylor et al (30) have assessed social support as a correlate of 
exercise behaviour in PCa survivors prior to this study. They found that social support 
did not change over 12 months in either the home-based healthy lifestyle or educational 
support programs. To facilitate family social support for exercise with the intent on 
improving exercise program adherence, Winters-Stone and colleagues (127) are currently 
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conducting a RCT called 'The Exercising Together Project' designed to increase 
adherence to home-based RET by incorporating the PCa survivors' marital partners into 
the exercise program. This novel approach to exercise programming for cancer survivors 
reflects a scenario that favours partner-based approach to exercise: 1) many men with 
PCa are married, 2) PCa can put a significant strain on marital relationships given the 
detrimental effects to aspects of intimacy, and 3) PCa affects men that are commonly 
retired with partners who are also likely to be retired and therefore have free time to 
commit to partner-based activity. In light of these circumstances, exercise can be a 
uniting activity where couples can conjointly confront and overcome the physical and 
psychosocial challenges of PCa and associated treatment. The results of this study are 
eagerly awaited as outcomes address several unexamined areas in PCa-exercise literature, 
such as marital quality and partner physical activity/health status, as well as conventional 
ADT-relevant outcomes that pertain to physical fitness and psychological wellbeing. 
While our study and the studies by Carmack-Taylor et al and Winters-Stone et al remain 
the first to explore social support for PCa patients engaged in an exercise intervention, 
the balance of research in this field has been only among those with breast cancer. In 
these studies, social support has been shown to be related with several facets of exercise 
behaviour, such as intensity, desire to exercise with friends or family (and negatively 
correlated with preference to exercise alone), overall mood, vigour, and physical 
functioning, (342-346). Clearly, more research on social support and exercise for PCa 
patients is warranted as approaches that integrate training partners may be revealed to be 
an important strategy to enhance long-term exercise. 
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To our knowledge, this is the first study to examine the role of exercise-induced 
feelings in a population with cancer. Exercise-induced feelings, if positive, may play a 
role in enhancing exercise participation. Naturally, if participants do not enjoy exercise, 
they will likely discontinue exercise. Our findings suggest that (positive) exercise-
induced feelings remain relatively stable for AET participants but may increase after 3 
months for RET participants. This may be due a learning effect associated with 
familiarization with the exercises and subsequent integration into a routine that they are 
confident in and comfortable with. This hypothesis is supported by our findings in 
bivariate analyses showing that exercise-induced feelings are associated with self-
efficacy, suggesting that participants that enjoy their exercises also feel confident in their 
exercises. Our findings are also consistent with previous literature that indicates 
modality differences in exercise-induced moods. Szabo, Mesko, Caputo and Gill ( 498) 
observed that persons participating in t' ai chi or yoga had higher tranquility scores (using 
an itemized analysis of exercise-induced feelings) and less physical exhaustion than 
persons engaging m martial arts, while RET participant demonstrated higher 
revitalization than the martial arts group. As a possible behavioural determinant, 
exercise-induced feelings represent a manifestation of some psychological, social, or 
physiological response to exercise. Our upcoming study in PCa patients (on and off 
ADT) that examines the role of an acute bout of exercise on exercise-induced feelings 
with concomitant transcranial electromagnetic stimulation aimed at assessing the duration 
of cortical silent period will shed new insight on the neurophysiology of acute exercise 
and its relationship to exercise-stimulated changes in mood. This is relevant to men with 
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PCa who are often depressed and anxious (499-501) as early findings suggest exercise 
can reduce anxiety and depression in this population (30, 65, 122). A greater 
understanding of the acute benefits of exercise on cancer patients may provide insight 
into the mechanisms of chronic positive shifts in mental wellbeing and factors that affect 
exercise program compliance (i.e. immediate experiences of psychological benefit may 
translate into routine physical activity). The usage of objective measures of 
psychological wellbeing circumvents the typical response biases (placebo effect, social 
desirability, recall bias) that confound self-report measures. 
As the most extensively researched theoretical frameworks may provide the 
foundation on which many exercise interventions are based, current theoretical 
approaches to behavioural maintenance have been criticized for failing to make a 
distinction between determinants influencing the initiation of a health behaviour and 
those influencing its maintenance over time (502). To encourage long-term adherence, 
the literature supports use of cognitive-behavioural approaches predicated on the belief 
that an individual responds to his or her perceptions about the environment or situation 
rather than the actual environment (503). According to cognitive therapy, maladaptive 
behaviour is the product of faulty, or irrational thinking and cognitive approaches to 
behaviour change are designed to modify how an individual thinks about or perceives a 
situation (503). Behavioural therapies are based on the idea that new and constructive 
behaviours can be learned through various types of reinforcement and reward. Using 
such models, specific techniques can be used to educate patients on how to identify, 
monitor, and achieve valued long-term outcomes associated with exercise (504). 
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Moreover, attempts can be made at improving self-efficacy and social support for 
exercise as well as exercise-induced positive moods by focusing on process-oriented 
goals and outcomes. Culos-Reed and colleagues (122) used cognitive-behavioural 
therapy techniques (e.g., goal setting, monitoring behaviour, overcoming barriers, 
positive attitudes and social support) in their 16-week RCT in ADT-treated PCa survivors 
but provided no quantitative or qualitative evidence of effectiveness. An appropriate trial 
design may be to randomize participants to routine exercise with and without a theory-
based adherence-boosting intervention. Given the established clinical efficacy of 
exercise in populations with cancer, this type of trial would fit with a movement towards 
improving sustained exercise adherence. 
9.6 Study Limitations 
The results of this study should be interpreted in light of various limitations. Our 
study' s a priori mandate was to assess feasibility for a future randomized trial at the 
PMH for PCa patients and was not intended to be true hypothesis testing project. The 
study was underpowered to conclusively demonstrate between-group differences in RET 
and AET. Despite the underpowered nature of the efficacy analyses, this study provides 
an important initial assessment of distinctly different home-based exercise intervention 
arms. 
Some may consider that a significant limitation to our study is the omission of a 
control group that prevents a full understanding of how these exercise modalities 
compare to standard care. However, the evidence for the beneficial effects of exercise for 
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cancer survivors, and PCa survivors particularly, suggests that both groups were likely to 
demonstrate significant improvements compared to non-exercising controls. At this 
juncture in the literature, it may be argued that exercise is unequivocally beneficial and 
that research should be targeted at identifying the most effective exercise prescriptions 
and adherence boosting strategies rather than re-examining common efficacy outcomes. 
The clinical benefit has been so widely described that several researchers, including our 
team, have published clinical calls-to-action and program descriptions to elicit a 
paradigm shift in disease management in oncology that integrates exercise with standard 
care ( 435, 505-508). Moreover, it could be perceived as unethical to knowingly withhold 
an effective therapy in the interest of research fidelity and thus all participants should, in 
some way, receive exercise support. One simple strategy to overcome this is to randomly 
assign patients to an intervention arm or a wait-list control where the control participants 
are asked to refrain from exercise until the intervention period is over. Unfortunately, 
this approach is susceptible to contamination in members of the control group who are 
aware of the benefits and likely motivated to start exercise in some fashion. Although 
contamination is under-reported in RCTs of exercise in patients with cancer, 
contamination rates of 15-50% have been cited (21, 140, 440). In Segal et al's 
comparison of AET and RET to controls, they found that 5 AET participants participated 
in RET, and AET was performed by 8 RET participants and 6 controls (21). Like others 
previously, we overlooked the necessity to collect data on possible sources of 
contamination. Nonetheless, we acknowledge the shortcomings of not having a control 
group but offer that, at this stage of empirical evidence, maintaining a usual care control 
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that is devoid of exercise advice/programming only does a disservice to patients and 
jeopardizes true exercise effect because of frequent contamination. In modality-
comparative research, contamination across groups remains an essential component of 
trial design. 
The significant attrition from baseline to 6 months, particularly in the RET group 
(although not statistically significant in comparison with the AET group) should be 
considered and represents a potential explanation for general lack of RET effect on many 
study outcomes. Across exercise intervention studies for PCa patients, attrition rates 
have ranged from 0 to 3 8% with a mean of approximately 16%. In PCa and exercise 
research, our attrition rate of 33% to 6 months with an additional loss of 30% (n = 13/44) 
from post-intervention to 6 month follow-up is higher than most; however, three exercise 
studies in this population have had at least 30% dropout (27, 28, 65). In comparison to 
the two studies that assessed 4-6 month post-intervention follow-up periods, our study 
compares rather favourably with Culos-Reed et al (24) and Bourke et al (28) reporting 
42% and 64% attrition over this phase of study, respectively. To address attrition due to 
non-medical issues, we would recommend greater interaction between trainer and 
participants in order to forge a stronger bond and instil a greater level of responsibility to 
program participation and data collection. This may be achieved with more routine 
follow-ups in person or via phone/email/text-message, home visits to support exercise, or 
inducements to participate. That said, it should be considered that there may also be a 
proportion of the population that is simply not interested in continued participation in 
exercise, which is evidenced by studies showing that approximately 75% of men with 
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PCa do not meet physical activity guidelines (336, 338). Future studies should attempt to 
distinguish two types of attrition 1) loss of research participation that is tied to intent to 
discontinue exercise, and 2) loss of research participation is tied to discontinuation of 
research interest. This requires an examination of dropouts that is generally not ethical 
practice when participants are explicitly stating that they do not want to participate 
anymore. However, this may be circumvented with 'exit interviews' that could provide 
useful for collecting insight on why participants withdrew from the study. 
We were unable to use the physical activity logbooks due to poor completion by a 
majority of the participants. This prevented us from verifying physical activity volume 
provided by the GL TEQ, making it impossible to specifically assess compliance with the 
individualized exercise prescription or contamination between the two groups. Although 
logbooks can be useful tools in monitoring behaviour and progress, they are an extra (and 
possibly onerous) task that burdens the participant. Previous studies have also had to 
limit or omit the analysis of logbooks due to lack of completion or unusable data (494). 
One approach to quantifying physical activity that could be more palatable for certain 
participants is through the use of electronic communication via 'health-coaching' or 
'electronic activity logs' that are contained within a mobile device, like a cell-phone, 
personal digital assistant, or tablet. An electronic recording device conceivably allows 
for easy, on-the-spot, data entry, that when paired with physiological monitoring devices 
(such as a heart rate monitor), can provide accurate and immediate information. This 
information could then be used to provide immediate feedback to participants regarding 
their exercise program. Our group is currently investigating whether or not electronic 
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health coaching software can improve exercise participation in heart failure and diabetic 
patients. Given the ubiquity of 'smart-phones', this approach may represent both a tool 
to enhance exercise participation/adherence and data collection/extraction. 
Our predictive models for physical activity adherence were not empirically 
grounded. Each of the model variables (i.e. social support, exercise-induced feelings, and 
self-efficacy) that previously examined as independent determinants of exercise 
behaviour, however they have never been tested in combination. We were particularly 
interested in how these specific determinants might interact to influence exercise 
participation given their fairly stark distinction between each other but in summation do 
not necessarily represent an established theoretical framework. Our conceptual approach 
was that the aggregate effect of social influence, perceived-behavioural control/self-
efficacy, and enjoyment of the activity would significantly contribute to the engagement 
of physical activity. Our exploratory analyses indicated that these had no influence on 
exercise participation, while age was likely the biggest factor. Future trials are required 
to further assess whether these individual components to exercise participation can 
collectively contribute to explained variance. 
Due to limitations in financial resources, we were unable to conduct an analysis of 
the biomarkers for all participants at all time points. In the absence of sufficient funding 
for a complete sample analysis, we conducted assayed the first 13 subjects to complete 
assessments at baseline, 3 months, and 6 months from the AET and RET groups (n=26 
total). This strategy was implemented to expedite the analysis with ambitions of securing 
additional funding for the balance of the assays. However, as funding was not secured 
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for the remaining samples our analysis of only the first 26 AET and RET participants is 
subject to selection bias via a training effect on behalf of the researcher. In this respect, 
our research may be criticized from the standpoint that the assessor's and researcher's 
skills or attitudes were not consistent over the course of the trial leading to participants in 
the early phases of the research project treated somewhat differently from participants in 
the . later phases of the research. In retrospect, a better approach would have been to 
collect serum samples from all participants and then randomly select 13 from each group 
to comprise the samples for actual assay. This method will be utilized in future studies 
under similar circumstances. 
In our study, neither the participants nor assessors were blinded to group 
allocation. In exercise research, blinding participants is virtually impossible without 
implementing some type of deception. In the present trial, it was unable to blind 
participants to which type of exercise they were completing because they needed to be 
aware of their specific exercise prescription. However, exemplary exercise intervention 
studies do maintain blinded outcome assessors to limit the risk of assessor bias. Blinding 
the outcome assessor (DSM) in the present trial was not feasible due to a lack of 
personnel resources. At the time of the study, there was no financial funding to support a 
blinded assessor and there was not graduate lab member with credentials and experience 
to conduct the fitness tests. Consequently, all assessments were completed by DSM who 
was also acting as the researcher and exercise physiologist. Given DSM' s broad role in 
this research, the present trial may be criticized by having significant experimenter's bias. 
However, it may be argued that consistency in assessments (i.e. the same assessor 
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conducting all assessments) is a positive methodological characteristic. Given that the 
qualifications and credentials of our research team have become more aligned with 
clinical exercise physiology, blinding and maintaining consistency in assessors has been 
used in subsequent trials. 
Finally, the booster sessions were poorly attended in contrast to previous home-
based exercise programs in this population (24, 122). Participants cited various reasons 
for not attending, notably distance and travel time to the urban-based group exercise 
classes. Furthermore, due to resource constraints, it was not feasible to provide booster 
sessions specific to AET and RET, thereby introducing potential contamination during 
these sessions (although 2 sessions per month would not likely produce relevant changes 
in outcome measurement given the limited attendance). Whether or not booster sessions 
have a significant effect on program effect or adherence remains uncertain. Their intent, 
as implemented in this study and those by Culos-Reed et al (24, 122), were to support 
home-based exercise through group exercise that could assist in forming stronger 
exercise technique and competence as well as addressing barriers to ongoing 
participation. As previously mentioned, studies that specifically examine strategies to 
boost program adherence are needed, that would include an empirical assessment of the 
efficacy of booster sessions. 
9. 7 Study Strengths 
The study' s strengths should also be highlighted. First, the novel aspect of home-
based AET versus RET provides important information regarding the acceptability, 
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safety, and efficacy of complementary exercise modalities as discussed earlier. To 
specifically reflect on the home-based nature of the exercise interventions, the value of 
assessmg interventions with low institutional cost burdens that may contribute to 
sustained exercise participation cannot be understated. This is also consistent with 
preference for home-based, unsupervised exercise programs among many cancer 
survivors ( 468, 488). While our study cannot definitively determine whether AET is 
better or worse than RET in achieving a number of clinical outcomes, several within-
group improvements suggest that either exercise modality is better than no exercise at all. 
Second, outcomes were carefully selected for both direct comparison and as a 
strategic complement to earlier work in the field. This aspect of trial design has ensured 
that this research will contribute meaningful information to clinicians and researchers 
working to improve the overall wellbeing of men with ADT. 
Third, to enhance participants' adherence to the exercise program, we provided 
exercise equipment and manuals to each group that would support exercise throughout 
the intervention period and afterwards. The cost of providing the exercise mat ( '""'$25), 
stability ball ( '""'$25), set of three resistance bands ( '""'$10) and exercise manual ( '""'$10) was 
approximately $70 per individual. The relatively low cost of materials that can provide a 
total-body workout and is dynamic to adjust intensity to the exerciser's ability have made 
the provision of this 'training' package a core component of the Survivorship Exercise 
Program. At present, the Survivorship Exercise Program employs a cost-recovery model 
that suggests a donation for participation in the program that goes towards covering the 
costs of the home-based exercise materials as well as general overhead costs. The 
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suggested donation amount is $100 and participants are free to donate as much or as little 
as they are comfortable with. No participant is obligated to donate and each participant 
receives the exercise program materials irrespective of donations. The donations allow 
the Survivorship Exercise Program to provide clinical care with home-based equipment 
for all participants with larger donations off-setting the costs of equipment for those that 
are not able to contribute. 
Fourth, the 6-month post-intervention follow-up period represents the longest 
follow-up period from a structured exercise intervention for PCa patients to date. At the 
time of trial design, only Culos-Reed et al (24) conducted a post-intervention follow-up 
that was conducted 4 months after the end of the intervention. A recent study conducted 
by Bourke et al has also examined 6-month post-intervention physical activity and fitness 
effects while a telephone-based lifestyle intervention by Demark-Wahnefried et al ( 401, 
402) assessed physical activity volume at 12-months post-intervention. Chronic exercise 
adherence in cancer populations is of critical significance and scientists in the field 
suggest that 6-months is an appropriate milestone to assess whether or not healthy 
lifestyle behaviours have been maintained (350). Although it may be resource intensive 
to extend a clinical trial to assess participation over the long-term, post-intervention 
follow-ups are a necessary aspect of research in this field to monitors, describe, and 
influence a permanent behaviour change. 
Finally, we conducted both an intention-to-treat and per protocol analysis for most 
outcomes to respectively assess the effect of the exercise intervention as provided to all 
patients of the Prostate Centre at the PMH, and for those who complete the program as 
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per the parameters of the exercise prescription. These analyses provide efficacy for 
program implementation as well as modality-specific effects. Our recruitment rate of 
32% is comparable to previous studies in this population but with approximately 70% of 
participants not willing to participate, greater effort must be directed towards improving 
motivation for exercise behaviour in this population. 
9.8 Future Directions 
The body of research investigating exercise for men with PCa is growing but 
additional studies are needed, to confirm ours and others' findings as well as explore new 
frontiers of research in clinical benefit, exercise maintenance, and program participation. 
Across PCa treatment populations, participants undergoing brachytherapy (many of 
whom are also undergoing ADT), chemotherapy, active surveillance, and radical 
prostatectomy) have received virtually no exercise-related information to base exercise 
recommendations or parameters. With minor treatment-specific adjustments, we have an 
opportunity (and likely an obligation) to extend our understanding of exercise-related 
benefit for all men with PCa that can be grounded in the evidence provided from ADT 
patients. 
In addition to reaching PCa survivors undergoing a greater variety of treatments, 
it is also essential that we expand our investigation of exercise-related benefits to other 
clinical outcomes in PCa such as bone health, fracture incidence, disease 
recurrence/progression, and survival. Our findings and those from previous studies 
indicate that large sample sizes are needed to control for various for various confounding 
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factors (e.g. socioeconomic status, race/ethnicity, medical comorbidity, exercise 
motivations, past exercise behaviours) (55, 57). Contamination effects must also be 
closely monitored as participants may adopt exercise regimens that are not a part of their 
prescribed intervention. This will remain a challenge given the impossibility of blinding 
participants to their intervention arm. 
It is also necessary to better understand the relevant factors contributing to 
physical activity initiation and chronic participation. Investigating the determinants of 
physical activity and more clearly defining the facilitators/barriers to participation may 
contribute to the development of more appealing interventions with better adherence 
rates. Embedding the intervention within a theoretical paradigm possibly offers a more 
cohesive perspective on the underlying determinants of health-related behaviour; 
however, the specific effect of adherence boosting strategies cannot yet be determined. 
The current body of literature contains numerous theory-based attempts at stimulating 
and enhancing exercise behaviours (77, 79)(72), but a new generation of research that 
tests interventions for exercise maintenance rather than exercise versus control or 
alternative modality is warranted. Optimizing long-term adherence will require 
innovative intervention strategies that are not only acutely beneficial, but convenient, 
attractive, and applicable across socioeconomic strata, geographic location, etc. 
Suggested strategies include: the incorporation of social supports, the provision of 
appropriate exercise equipment and instruction, motivation enhancement tools, satellite 
exercise facilities proximal to the patient's home, and home-based, self-directed exercise 
programs. Moreover, with research revealing that exercise is rarely discussed and 
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infrequently incorporated into standard PCa treatment (509-511) paired with findings that 
physicians maintain a strong influence on exercise behaviours of oncology patients (512), 
interventions aimed at improving physician discussion of exercise and/or referral to 
exercise programs is needed. 
To date, assessment of home-based exercise adherence in PCa literature has only 
been assessed using logbooks, physical activity questionnaires, and attendance to 
biweekly group exercise booster sessions. The former two methods of assessment are 
subject to response and recall bias, and attendance at exercise classes does not necessarily 
reflect adherence to the home-based component of the exercise prescription. 
Furthermore, these assessments of exercise adherence cannot examine experiential 
aspects of program adherence from the patient's perspective that may be available from 
more open-ended approaches to data collection. Qualitative examination of the 
experience, motivation, and satisfaction of PCa patients participating in an exercise 
intervention has not previously been conducted. In response to this gap in the literature, 
we incorporated a qualitative analysis of the experiential aspects of program participation 
via semi-structured interviewing as a sub-study of the current trial (see Appendix N for 
the Semi-Structured Interview questions). Interviews were conducted following the 
formal intervention period ( 6 months) and before the post-intervention follow-up time 
point (12 months). The results of this sub-study have recently been reported in the 
Master's thesis of A. Kornblum (513). A detailed description of the qualitative interview 
procedures and adherence-related results are presented in Section 6. This post hoc 
element to the present trial represents the first qualitative assessment of the participation 
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experience for PCa in an exercise intervention which should be replicated and expanded 
on to derive nuances of participation not captured in standard paper-and-pencil and 
fitness tests. 
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10.0 Conclusion 
Exercise has gained considerable attention as a behavioural approach to reducing 
many of the physical and psychosocial adverse effects associated with ADT for PCa. 
Our feasibility study demonstrates institutional and collegial capacity to conduct a large-
scale research study with participation and adherence rates that are comparable to those 
in more established cancer-exercise research programs. Our data indicate that a full-scale 
two-arm RCT could be conducted safely and within approximately 3 years. However, 
given our observations regarding booster session attendance and attrition, modifications 
to this study' s protocol for future studies should be considered. We provide a broad 
range of effect size and variance estimates for comprehensive statistical analyses (i.e. 
RM-ANOV A, multiple-linear regression) for a large-scale trial as well as more 
rudimentary analyses conducive to smaller research projects examining within group 
changes over varying intervention durations (i.e. paired-samples t-test). A direct result of 
this research project which will support, not only a main trial to examine this effect, but 
many trials in all facets of PCa and exercise research, is the conception and development 
of the Survivorship Exercise Program. The Survivorship Exercise Program is an ongoing, 
clinical-research initiative supported by the Prostate Centre and Princess Margaret 
Foundation to ensure that all men with PCa can be supported with lifestyle assistance 
while contributing to a greater understanding of the relationship between exercise and 
PCa management. Finally, while not the primary intent of this dissertation, hypothesis 
testing within the context of feasibility assessment yielded several interesting findings 
that must be considered with caution given the inadequate sample size. Of particular 
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note, it appears that the AET intervention was more effective at producing long-term, 
clinically significant increases in physical activity volume. Assessment of biomarkers, 
however, suggests that RET may be exclusively associated with anti-proliferative effects, 
while HRQOL and fatigue may be largely unresponsive to either AET or RET 
interventions in the home-based setting. Physical activity participation may be assessed 
indirectly in terms of observations of physical fitness changes in this population. 
Finally, although psychological determinants of physical activity were not associated 
with physical activity volume or fitness changes, exercise-induced feelings were 
routinely positively correlated with self-efficacy, which marks an area for further study 
because improving the enjoyment of the activity may elicit enhanced exercise adherence. 
Future exercise intervention trials must focus on strategies to improve participation and 
chronic adherence. 
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Table 1. Summary of Exercise Intervention Trials in Prostate Cancer 
Authors Sample Design Exercise Intervention Participation and Measures Results 
Adherence 
Interventions for PCa Patients Treated with Radical Therapy + ADT 
Windsor et N=66 PCa patients RCT: home- Minimum of 3 sessions weekly Participation Rate = 86% BFI, modified Control group: increased fatigue 
al, 2004 ( 66) treated with EBR; based exercise for 4 weeks, unsupervised, (n=l l refused); shuttle walking scores from baseline to treatment 
n=S l had early stage (n=33) vs. home-based walking at 60-70% Adherence Rate = 100% test, RHR, completion (p=0.013), stable fatigue 
tumors (Tl-T2); standard care of estimated MHR for 30 (all patients in the exercise exercise HR symptoms in the exercise group (p= 
n=l 9 were treated control (n=33) minutes. group recorded at least 90 0.203); greater walking distance for 
with adjuvant ADT); minutes per week of AET the exercise group compared to the 
mean age= 68.8 at the recommended HR); controls (p=0.0025) 
years. Attrition Rate = 3% 
Adverse events were not reported. 
Mongaet al, N=21; localized PCa RCT:AET 3 sessions weekly for 8 weeks, Participation Rate = 60%; Bruce treadmill Compared to controls, the intervention 
2007 (65) treated with EBR; (n=ll)vs. supervised, facility based, Adherence Rate not test; MSR; stand groups experienced significant 
mean age of AET control (n=l 0) walking at 65% ofHRR for 30 reported; Attrition Rate = and sit test; PFS; improvements in cardiovascular 
group= 68.0; mean minutes plus 5-10 minutes of 30% FACT-P; BDI fitness (p=0.006), lower extremity 
age of controls = warm-up and cool-down. strength (p<0.001 ), flexibility 
70.6 (p<0.01), fatigue (p<0.001), physical 
wellbeing (p<0.001), social wellbeing 
(p<0.002), functional wellbeing 
(p=0.04), and overall HRQOL 
(p=0.006). 
Adverse events were not reported. 
Segal et al, N= 121 PCa patients RCT:RET 3 sessions weekly for 24 Participation Rate: 37%; FACT-F; FACT- RET improved fatigue (p = 0.007), 
2009 (21) treated with EBR; (n=40) vs. AET weeks, supervised, facility Adherence Rate: RET = P; F ACT-G; PSA; aerobic fitness (p = 0.034), upper (p < 
n= 74 treated with (n=40) vs. wait- based AET or RET for 15-45 88% (63of72 sessions); testosterone; 0.001) and lower (p < 0.001) body 
adjuvant ADT; list controls minutes. AET = 83% (60of72 haemoglobin; fitness, and body fat percentage (p = 
(n=96 participants (n=41) AET group: exercises sessions) (p=0.845). serum lipids (total 0.029). Compared to controls, AET 
had stage I or II performed on elliptical, cycle Attrition Rate= 9.9% cholesterol, LDL, improved aerobic fitness (p = 0.047) 
disease; n=22 had ergometer, or treadmill at 50- HDL, and body fat percentage (p = 0.033); 
stage III or IV 75%ofMHR triglycerides); trend towards improved fatigue (p = 
disease; n= 3 had RET group: 9 upper and lower upper and lower 0.060); trend of RET superior to AET 
unassigned disease body exercises (leg extension, body muscular in aerobic fitness. 
staging) mean age leg curl, seated press, lat pull- strength test; 
66.3 down, overhead press triceps V02max (ramp Three adverse events related to 
extension, bicep curls and protocol) exercise, one serious (no fatalities) 
modified curl-ups), I set of 
each exercise at 60% of 1 RM, 
increased to 2 sets of 8 - 12 
repetitions. 
Serda et al, N=33 PCa patients Uncontrolled 2 sessions weekly for 24- Participation Rate: 78%; GL TEQ, aerobic From baseline to post-test, 
2010 (180) treated with RP trial; Pre/Post- weeks; 16 weeks under direct Adherence Rate: 93% (30 fitness (mCAFT), improvements were observed for: 
(n=l5), RP+ADT test supervision + 8 weeks of of 32 sessions); Attrition pain (VAS), BMI (p=0.007), WHR (p=0.003), WC 
(n=2), EBR+ADT autonomous exercise, all Rate= 8.3% urinary (p:S0.001), BF% (:S0.001), HRR 
(n=l), or ADT-alone exercises were facility-based incontinence (p=0.02), SBP (p=0.001), V02 peak 
(n=15) RET. RET consisted of 1-2 sets (VAS), arterial (p<0.001), cardiovascular response to 
of 8-12 reps (50-70% of 8RM) pressure, 1 RM of submaximal strength testing (p:S0.04), 
of exercises targeting the trunk and lower F ACT-P (p=0.003), urinary 
quadriceps, pectorals, limbs, FACT-P, incontinence (p<0.001), and pain 
ischiotibials, deltoids, FACT-F, (p<0.001). 
abdominals, biceps, triceps, muscular 
back, and pelvic floor. Intensity endurance 
was progressed incrementally. (standard load 
test), visceral 
adiposity (CT 
scan) 
Interventions for PCa Patients Treated on Androeen Deprivation Therapy 
Segal et al, N= 155 PCa RCT: RET 3 sessions weekly for 12 Participation Rate = FACT-F; FACT- RET participants reported less fatigue 
2003 (120) patients treated with program (n=82) weeks, supervised, facility- 30.6%; Adherence Rate= P; standard load (p=0.002), higher HRQOL levels 
ADT; n=75 with vs. a waiting list based RET at 60-70% of lRM 79%; Attrition Rate= 12.9 upper and lower (p=0.001), better upper (p=0.009) & 
stage I or II disease; control group for 2 sets of 10-12 repetitions. body strength test; lower (p<0.001) body muscular 
n= 51 with stage III (n=73) RET program consisted of9 body weight, fitness 
or IV disease; n=29 upper and lower body exercises BMI, WC, 
had unassigned (leg extension, leg curl, seated subcutaneous Adverse events were not reported. 
disease staging; press, lat pull-down, overhead skinfolds 
mean age 67.9 years press triceps extension, bicep 
curls and modified curl-ups) 
Galvao et al, N = 11; PCa patients Uncontrolled 2 sessions weekly for 20 weeks Participation Rate= (91 lRM; muscle Pre-post improvements in: upper body 
2006,2007 treated with ADT trial; Pre/Post- of supervised, facility based participants approached, endurance test strength and endurance (p<0.001); 
(29, 121) (n= 5 on acute ADT test RET (6-12RM for 2-4 sets) for n= 10 refused, n= 13 (maximum functional performance (p<0.05); 
:S 12 months; n= 6 60 minutes/session. eligible, n=67 ineligible); number of quadriceps muscle thickness (p<0.05) 
on ADT > 12 RT program consisted of 12 Adherence Rate = not repetitions at 70% 
months; mean upper and lower body exercise reported; Attrition Rate = of lRM); chair No adverse events related to exercise. 
duration= 1135.6 (chest press; lat pull-down, 9% rise to standing; 6-
days) seated row; shoulder press; m walk; 6-m 
biceps curl; triceps extension; backwards walk, 
leg extension; leg curl; squat; stair climb; 400-
leg press; abdominal crunch; meter walk; 
and back extension). sensory 
organization test; 
DEXA, 
ultrasound, Hb, 
PSA, testosterone, 
GH, and cortisol. 
Carmack- N=134; PCa patients RCT: lifestyle Monthly group-based sessions Participation Rate = 22%; SF-36, CES-D, No significant effects were found in 
Taylor et al, treated with ADT program (n=46) for 6 months to increase Adherence Rate = 64%; STAI, BPI, any of the outcome measures 
2006 (30) (mean duration of vs. educational unsupervised PA to 30 minutes Attrition Rate = I 5. 7% 6MWT,BMI, 
ADT=32.7 support group of moderate intensity exercise WC,HC, WHR, No adverse events related to exercise. 
months); mean age (n=51) vs. for most days per week. To ISEL, 7-DPARQ, 
69.2 years standard care facilitate PA adherence, The Stage 
(n=37) participants were taught Motivational 
cognitive-behavioural and Readiness for 
exercise monitoring strategies. Physical Activity, 
Processes of 
Change for 
Physical Activity 
Questionnaire, 
Decisional 
Balance for 
Physical Activity; 
Self-Efficacy 
Questionnaire 
Culos-Reed N = 31; PCa patients Uncontrolled 3-5 sessions per week for 12 Participation Rate: not GLTEQ;RHR; Pre-post intervention improvements in 
et al, 2007 treated with ADT trial; Pre/Post- weeks, unsupervised, home- reported; Adherence Rate: 6MWT; hand-grip strenuous/total PA (p<0.01) and 
(24) for a minimum of 6 test based mixed modality exercise. 81 % of participants dynamometer test; functional capacity (p<0.01), resting 
months; mean age = 90 minute "Booster Sessions" attended 5 or 6 of 6 offered MSR; EORTC- HR (p=0.03), BMI (p<0.01) and 
64.8 years held at 2-week intervals for booster sessions; Attrition QLQ C30; FSS; fatigue (p=0.05) 
Sub-sample (n=l 8) group exercise, and to discuss Rate: 0% at post- BMI 
were followed up 4 progress, concerns, and intervention; 41. 9% at 4- At 4 mos. post-intervention (n=18): 
months post- foster/monitor adherence. month follow-up) decreased strenuous PA (p=0.01) and 
intervention; mean HRQOL (p=0.04) 
age= 65. 7 years 
Adverse events were not reported. 
Hansen et al, N= 10; PCa Non- 3 sessions per week for 12 Participation Rate= not Quadriceps ADT Group: improved 6MWT 
2009(27) patients; n=5 randomized, weeks, supervised, facility- reported; Adherence Rate volume (via (p=0.01), isometric quadriceps 
currently non-controlled based exercise. Progressively = 100%; Attrition Rate = MRI); isometric strength (right leg: p=0.03, bilateral: 
undergoing ADT vs. trial (pre/post- longer and intense high force 38% (n=4 from the ADT quadriceps p=0.05). 
n=5 not undergoing test and eccentric cycle ergometry group) strength via 
ADT; mean age = between groups dynamometry, Non-ADT Group: improved physical 
66.5 years analysis for men Timed up and go subscale ofFACT-P (p=0.03), left 
on ADT vs. not- test, 6MWT, quadriceps volume (p=0.04). 
onADT) FACT-P, FACT-F 
No between group differences. 
No adverse events related to exercise. 
Culos-Reed N= 100 PCa RCT: Mixed- 3-5 sessions weekly for 16 Participation Rate = not EORTC-QLQ Intervention improved PA levels 
etal,2010 patients receiving modality weeks of unsupervised, home- reported; Adherence Rate C30; EPIC; FSS; (p<0.004), waist girth (p<0.044), and 
(122) ADT for a minimum exercise (n=53) based mixed-modality exercise, = 77.8%; Attrition Rate= CES-D; GL TEQ- neck girth (p<0.019), and hormone 
of6 months, vs. waitlist home-based intervention. 34% LSI; RHR, BP, symptoms (<0.074). 
intervention group control group 90 minute "Booster Sessions" 6MWT, hand grip 
mean age= 67.2, (n=47) held each week during dynamometer test, Adverse events were not reported. 
control group mean intervention, and then monthly modified sit and 
age = 68 years to the end of follow-up. Each reach, weight, 
session was designed to BMI, WC,HC, 
foster/monitor adherence, and WHR 
consisted of group exercise, 
and discussion regarding 
progress and concerns. 
Galvao et al, N = 57 PCa patients RCT: mixed 2 sessions weekly for 12 Participation Rate = DEXA (total body At 12 weeks the exercise group 
2010(23) undergoing ADT modality weeks; facility-based, 58.8%; Adherence Rate= and regional lean improved lean mass of the total body 
(for minimum of2 exercise (n=29) supervised exercise in small 94%; Attrition Rate= 5.3% mass, fat mass, (p=0.047), upper limb (p<0.001), 
months); vs. control groups; AET = 15-20 minutes body fat lower limb (p=0.019) and 
intervention group (n=28) of cycling, walking, or jogging percentage), 1 RM appendicular skeleton (p=0.003); 
mean age = 69.5 at 65-80% of HRM; RET = 2-4 for chest press, chest press (p=O.O 18), seated row 
years; control group sets of 6- l 2RM for chest press, seated row, leg (p<0.001), leg press (p<0.001), leg 
mean age = 70.1 seated row, shoulder press, extension, and leg extension (p<0.001), chest press 
years triceps extension, leg press, leg press, muscular muscle endurance (p=0.041), 6MWT 
extension, leg curl, and endurance for (p=0.024), 6-m backward walk 
abdominal crunches. chest press and (p=0.039), c-reactive protein 
leg press, chair ((p=0.008), and subscales of the SF-
sit-to-stand test, 6- 36 (general health: p=0.022; vitality: 
m walking test, p=0.019; physical health composite: 
400-m walking p=0.02) 
test, balance, falls 
self-efficacy, SF- No adverse events related to exercise. 
36, EORTC-QLQ 
C30, testosterone, 
PSA, insulin, 
glucose, c-reactive 
protein, blood 
lipid profile 
Bourke et al, N = 50 PCa patients RCT: Lifestyle 12 week lifestyle intervention Participation Rate= GL TEQ, FACT -F, At 12 weeks, the lifestyle intervention 
2011(28) receiving ADT for a intervention divided into two phases. 64. l %; Adherence Rate: FACT-G, FACT- group had improved PA volume 
minimum of6 (exercise+ Phase l (week 1-6): 2 sessions 95% of supervised sessions P, submaximal (GLTEQ; p<0.001), total caloric 
months, intervention dietary advice; per week of supervised exercise attended and 87% of aerobic fitness intake (p<0.005) total, saturated, and 
group mean age = n=25) vs. including 30 minutes of AET unsupervised sessions test, isokinetic and monounsaturated fat intake (p=0.005, 
71.3 years, control standard care (55-85% of HRM) plus 2 to 4 completed; Attrition Rate: isometric p<0.001, p<0.001), fatigue (p=0.002), 
group mean age = (n=25) sets of RET exercises of upper 14% at 12 weeks (post- dynamometry of aerobic fitness (p<0.001), chair sit to 
72.2 years and lower body plus one 30- intervention) and 64% at 6 the quadriceps, stand test (p=0.001) and isokinetic 
minute session of unsupervised, month post-intervention chair sit-to-stand muscle strength (p=0.033) compared 
home-based exercise. follow-up test, BMI, IGF-1, to usual care. 
IGFBPl, IGFBP-
Phase 2 (week 7-12): 1 session 3, insulin, PSA, At 6 month follow-up, the lifestyle 
per week of supervised training testosterone, free intervention group maintained 
outlined in Phase 1 plus two androgen index, significant improvements compared to 
30-minute sessions of SHBG usual care for PA volume (p<0.001), 
unsupervised, home-based fatigue (p=0.006), aerobic 
exercise fitness(p<0.001), chair sit-to-stand test 
(p=0.001), isokinetic muscle strength 
Dietary advice was provided in (p=0.035). 
group seminars for 15-20 
minutes every two weeks and Adverse events were not reported. 
emphasized reduction in 
saturated fat and refined 
carbohydrate intake, increased 
fiber intake, and moderate 
consumption of alcohol. 
Santa Mina N = 13 PCa patients Randomized, 3 sessions per week for 8 Participation Rate 24%; PORPUS, FACT- Within group improvements for PT 
et al, receiving ADT or non-controlled weeks; supervised (group- Adherence Rate= 91 % and P, FACT-F, group included: resting systolic BP 
2012(26) within 3 months of trial; GBE (n=6) based leader or personal 88% in the PT and GBE directly measured (p=0.033), body fat percentage 
completing ADT, vs. PT (n=7). trainer). 60 minute sessions groups, respectively; V02 peak, grip (p=0.001), lower extremity lRM 
GBE group mean with 5 minute warm-up, 25 Attrition Rate= 23% (all strength, maximal (p=0.002); 
age = years, PT minute RET, 25 minute AET, 5 dropouts, n=3, were from upper and lower 
group mean age = minute cool-down. AET and the GBE group) body strength Between group differences were 
66.3 years RET exercises in both ( 1 RM), balance observed for upper body 1 RM 
intervention arms were selected (Functional Reach (GBE>PT, p=0.013) and lower body 
from a standardized list of Test), BMl, WC, lRM (PT>GBE, p=0.038) 
exercises. body fat 
percentage, BMD No adverse events related to exercise. 
(quantitative 
ultrasound of 
calcaneus) 
.. Legend: 6MWT-6-mmute walk test, 7D-PARQ = 7-day Physical Activity Recall Questionnaire, ADT =androgen depnvat1on therapy, AET =aerobic exercise trammg, BDI =Beck 
Depression Inventory, BFI =Brief Fatigue Inventory, BMI =body mass index, BP= blood pressure, BPI= Brief Pain Inventory, DEXA =dual energy x-ray absorptiometry, CES-D =Centre 
for Epidemiological Studies - Depression Scale, EBR =external beam radiation, EORTC-QLQ C30 =European Organization for the Research and Treatment of Cancer - Quality of Life 
Study Group, EPIC= Expanded Prostate Cancer Index, F ACT-F =Functional Assessment of Cancer Therapy - Fatigue, F ACT-G =Functional Assessment of Cancer Therapy - General; 
F ACT-P =Functional Assessment of Cancer Therapy - Prostate, FSS =Fatigue Severity Scale, GH =growth hormone, GBE =group-based exercise, GL TEQ =Godin Leisure Time Exercise 
Questionnaire, Hb = hemaglobin, HC =hip circumference, HDL =high density lipoprotein, HR= heart rate, HRQOL =health-related quality of life, HRM =heart rate max, HRR =heart rate 
reserve, ISEL =Interpersonal Support Evaluation List, LDL =low density lipoprotein, m =meters, mCAFT (modified Canadian Aerobic Fitness Test), MSR =modified sit and reach, PA= 
physical activity, PFS =Piper's Fatigues Scale, PORPUS =Patient-Oriented Prostate Utility Scale, PSA =Prostate-specific antigen, PT= personal training, RCT = randomized controlled 
trial, RHR =resting heart rate, RM= repetition maximum, RP =radical prostatectomy, SF-36 = Short Forrn-36 Health Survey, SHBG =sex hormone binding globulin, STAI = State Trait 
Anxiety Index, WC = waist circumference, WHR = waist to hip rati 

Table 2. Baseline Characteristics of Study Participants 
Variable AET (n=32) RET (n=34) P-value 
Continuous Variables 
Age (years) 72.1 (8.9) 70.6 (9.5) 0.501 
Charlson Comorbidity Score 0.31 (0.59) 0.41 (0.78) 0.565 
Psychosocial Measures 
Fatigue -FACT-F 42.0 (8.4) 38.1 (12.1) 0.147 
HRQOL- FACT-P 123.9 (17.3) 119.3 (19.6) 0.346 
HRQOL - PORPUS 67.3 (11.5) 62.2 (10.4) 0.085 
Physical Fitness 
Weight (kg) 88.6 (9.9) 87.0 (12.8) 0.557 
WC (cm) 105.2 (9.6) 105.4 (11.0) 0.951 
BMI (kg/m2) 29.1 (3.4) 29.0 (4.0) 0.922 
Chest Skinfold (mm) 35.6 (9.9) 35.3 (11.9) 0.895 
Body Fat% 28.5 (5.6) 28.0 (7.4) 0.744 
V02 - Relative (ml/kg/min) 25.0 (10.3) 28.4 (9.3) 0.169 
Grip Strength (kg) 63.9 (14.3) 69.9 (11.9) 0.081 
Physical Activity Volume (MET-hrs/wk) 19.5(19.4) 24.0 (36.1) 0.541 
Psychosocial Correlates of Activity 
Self-Efficacy* 4.05 (0.21) 3.99 (0.21) 0.825 
Social Support - Family 2.09 (0.17) 1.78 (0.16) 0.199 
Social Support - Friends 1.8 (0.20) 1.5 (0.11) 0.192 
Social Support-Total 1.97 (0.16) 1.71 (0.14) 0.236 
Exercise-Induced Feelings 3.39 (0.16) 3.19 (0.20) 0.440 
Biomarker Outcomes 
Leptin (µg/mL) 19.9 (13.2) 12.8 (9.3) 0.133 
Adiponectin (µg/mL) 16.6 (6.1) 21.6 (10.0) 0.162 
Leptin:Adiponectin l.2 (0.87) 0.78 (0.81) 0.982 
lGF-1 (ng/mL) 159.6 (55.2) 159.1 (51.2) 0.201 
lGFBP-3 (ng/mL) 5582.7 (1514.3) 4360.5 (1370.9) 0.050 
lGF-1: IGFBP-3 0.03 (0.002) 0.04 (0.005) 0.078 
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Table 2 (continued). Baseline Characteristics of Study Participants 
Variable AET (n=32) RET (n=34) P-value 
Cate~orical Variables 
Caucasian 22 (69) 25 (74) 0.707 
Married 19 (59) 26 (76) 0.412 
Post-High School Education 22 (69) 22 (65) 0.528 
Retired 18 (56) 24 (71) 0.562 
Currently Smoking (no) 30 (94) 33 (97) 0.298 
Gleason Score 
6-7 14 (44) 16 (47) 
8-10 14 (44) 13 (38) 0.308 
Not Available 4 (13) 5 (15) 
T-Stage 
Tl 4 (13) 6 (18) 
T2 12 (38) 11 (32) 
T3 6 (19) 8 (24) 0.881 
T4 6 (19) 4 (12) 
Not Available 4 (13) 5 (15) 
Treatment 
LHRH-a alone 19(59) 19 (56) 
LHRH-a + anti-androgen 11 (34) 12 (35) 0.767 
Anti-androgen alone 2 (6) 3 (9) 
Data for continuous variables are presented as Mean (SD); p-value for between-group differences using 
independent sample t-test. Data for categorical variables are presented as Frequency (% of group); p-value 
for x2; LHRH-a = luteinizing hormone-releasing hormone agonist, ADT =androgen deprivation therapy; 
*the measure of self-efficacy for exercise was not implemented until partway through the study, thus not all 
participants have data at each time point and these data represent n = 21 from the AET group and n = 22 
from the RET group. 
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Table 3. Baseline Characteristics of Dropouts and Non-Dropouts 
Variable Dropouts Non-Dropouts P-value 
(n=22) (n=44) 
Continuous Variables 
Age (years) 74.2 (9.2) 69.8 (8.9) 0.067 
Charlson Comorbidity Score 0.32 (0.65) 0.39 (0.72) 0.710 
Psychosocial Measures 
Fatigue - FACT- F 40.9 (9.8) 39.6 (11.0) 0.650 
HRQOL-FACT-P 122.8 (8.5) 121.1 (20.0) 0.746 
HRQOL - PORPUS 64.4 (8.5) 65.2 (12.2) 0.806 
Physical Measures 
Weight (kg) 91.3 (10.7) 86.0 (11.5) 0.077 
WC (cm) 107.2 (9.8) 104.4 (10.5) 0.312 
BMI (kg/m2) 29.8 (3.1) 28.7 (3.9) 0.273 
Chest Skinfold (mm) 34.3 (11.4) 36.0 (10.7) 0.564 
Body Fat% 27.9 (5.9) 28.4 (6.9) 0.753 
V02 - Relative (ml/kg/min) 23.5 (10.0) 28.5 (9.5) 0.052 
Grip Strength (kg) 66.6 (16.3) 67.0 (11.6) 0.907 
Physical Activity Volume (MET-hrs/wk) 29.1 (43.3) 18.6 (19.5) 0.181 
Psychosocial Correlates of Activity 
Self-Efficacy* 4.08 (0.23) 3.99 (0.19) 0.734 
Social Support - Family 2.09 (0.20) 1.87 (0.15) 0.400 
Social Support - Friends 1.66 (0.20) 1.64 (0.14) 0.945 
Social Support-Total 1.98 (0.18) 1.77 (0.13) 0.371 
Exercise-Induced Fee 1 in gs 3.45 (0.18) 3.24 (0.17) 0.457 
Cate~orical Variables 
Caucasian 17 (77.2) 30 (68.2) 0.148 
Married 16 (72.7) 29 (65.9) 0.239 
Post-High School Education 15 (68.2) 41 (93.2) 0.277 
Retired 13(59.1) 29 (65.9) 0.169 
Currently Smoking (no) 21 (95.5) 42 (95.5) 0.481 
Gleason Score 
6-7 10 (45.5) 20 (45.5) 
8-10 7 (31.8) 20 (45.5) 0.334 
Not Available 5 (22.7) 4 (9.1) 
T-Stage 
Tl 2 (9.1) 8 (18.2) 
T2 7 (31.8) 16 (36.4) 
T3 5 (22.7) 9 (20.5) 0.805 
T4 4 (18.2) 6 (13.6) 
Not Available 4 (18.2 5 (11.4) 
Treatment 
LHRH-a alone 13(59.1) 24 (54.5) 
LHRH-a + anti-androgen 6 (27.3) 17 (38.6) 0.644 
Anti-androgen alone 3 (13.6) 3 (6.8) 
Data for continuous variables are presented as Mean (SD); p-value for between-group differences using independent 
sample t-test. Data for categorical variables are presented as Frequency(% of group); p-value for x2; LHRH-a = 
luteinizing hormone-releasing hormone agonist, ADT =androgen deprivation therapy; *the measure of self-efficacy for 
exercise was not implemented until partway through the study, thus not all participants have data at each time point and 
these data represent n = 16 dropouts and n = 25 non-dropouts. 
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Table 4. Intention To Treat Analysis of the Effects of Aerobic Exercise Training and Resistance Exercise Training on 
Fatigue and Health-Related Quality of Life Outcomes in Prostate Cancer Patients Receiving ADT 
Main Effects 
(RM-ANOVA) Group X Time Baseline 3 Months 6 Months 12 Months Interaction 
Group Time 
Variable AET RET AET RET AET RET AET RET F (di) F (di) F (di) p p p 
FACT-F 42.0 38.1 41.4 38.7 42.2 35.6 42.4 37.9 2.86 (1,60) 0.149 (2.2,132.26) 0.98 (2.2, 132.26) (1.5) (2.1) (1.4) (1.7) (1.3) (2.2) (1.4) (2.2) 0.096 0.880§ 0.385§ 
FACT-P 123.9 119.3 124.4 118.6 124.2 117.4 125.5 119.0 0.970 (1,049) 0.196 (1.831, 89.72) 0.255 (1.83, 89.72) (3.2) (3.6) (3.1) (3.4) (3.2) (4.1) (3.0) (4.4) 0.330 0.804§ 0.756§ 
FACT-P-PWB 24.5 23.3 24.3 23.5 23.8 23.0 24.2 22.8 0.951 (1, 58) 1.513 (3.0, 133.27) 0.644 (3.0, 133.27) (0.86) (0.94) (0.86) (0.83) (0.77) (0.95) (0.74) (1.01) 0.333 0.222§ 0.548 
FACT-P-SWB 22.9 20.7 22.7 20.6 22.6 20.2 22.9 20.9 3.65 (1,58) 0.203 (2.0, 116.19) 0.532 (2.0, 116.19 (0.93) (0.98) (0.86) (0.98) (0.85) (1.01) (0.76) (0.95)* 0.06 0.817§ 0.589§ 
FACT-P-EWB 21.1 18.5 21.0 18.5 20.8 18.6 21.0 18.4 7.30 (1,58) 0.055(2.48, 143.97) 0.036 (2.48, 143.97) (0.53) (0.84) (0.53) (0.71) (0.59) (0.78) (0.56) (0.87) 0.009 0.983§ 0.985§ 
FACT-P-FWB 22.7 20.2 22.3 20.6 22.4 20.9 23.0 20.2 2.557 (1,54) 0.537 (1.96, 105.65) 0.674 (91.96, 105.65) (0.77) (1.1) (0.85) (0.83) (0.87) (0.92) (0.71) (1.12) 0.116 0.582§ 0.509§ 
FACT-P- PSC 34.4 33.7 33.5 35.0 33.9 34.4 34.1 34.2 0.271(1,56) 0.055(2.23, 124.77) 1.056 (2.23, 124.77) (1.1) (1.1) (1.01) (0.72) (0.99) (1.0) (1.1) (1.05) 0.605 0.983§ 0.357§ 
PO RP US 67.3 62.2 67.0 63.1 65.8 62.3 67.2 64.5 1.518(1,50) 1.345(2.51, 125.37) 0.752 (2.51, 125.37) (2.0) (2.0) (1.2) (1.9) (2.1) (2.2) (2.0)* (2.8) 0.224 0.265§ 0.501§ 
Intention-to-treat analysis (AET: n=32; RET: n=34); Data are presented as mean (standard error); PWB =physical wellbeing, SWB =social wellbeing; EWB = 
emotional wellbeing; FWB =functional wellbeing; PSC =prostate cancer-specific concerns; F (degrees of freedom) and p-values for between-factor, within-factor, and 
interaction analyses are reported for RM-ANOVA; *trend towards within-group change from 6 months (p < 0.1), tsignificant within-group change from baseline (p ~ 
0.05); tsignificant within-group change from baseline (p ~0.01). Scales oriented to indicate improvement in wellbeing with increased score; §=analysis was conducted 
using Greenhouse Geisser's Correction for F-Statistic due to violation ofMauchley's test of sphericity. 
Table 5. Intention to Treat Analysis of the Effects of Aerobic Exercise Training and Resistance Exercise Training on 
Physical Outcomes in Prostate Cancer Patients Receiving ADT 
Main Effects 
(RM-ANOVA) Group X 
Baseline 3 Months 6 Months 12 Months Time 
Interaction 
Group Time 
Variable AET RET AET RET AET RET AET RET F (df) F (df) F (df) (p) (p) (p) 
Wt (kg) 88.6 87.0 87.0 87.2 87.7 87.0 88.2 87.5 0.056 (I, 63) 1.489 (2.45, 189) 1.489 (2.45, 189) (1.7) (2.2) (1.7)t (2.3) (1.8) (2.3) (1.9) (2.4) 0.814 0.225§ 0.225§ 
WC (cm) 105.2 105.4 103.9 105.5 104.3 104.8 103.9 104.6 0.081 (1, 62) 2.565 (3, 186) 1.373 (3, 186) (1.7) (1.9) (1.7)t (1.9) (1.7) (1.8) ( 1. 7)t (1.9) 0.776 0.056 0.252 
BMI (kg/m2) 29.2 29.0 28.7 29.1 28.9 29.1 29.1 29.2 0.025 (1, 63) 1.421 (2.41, 151.52) 
1.027 (2.41, 
(0.6) (0.7) (0.6)t (0.7) (0.6) (0.7) (0.7) (0.7) 0.874 0.243§ 151.52) 
f\ 'H'.Ol: 
Chest Skinfold 35.6 35.3 32.5 34.2 33.5 33.7 33.2 32.7 0.015 (I, 62) 4.813 (1.99, 123.08) 0.838 (1.99, 
(mm) (1.8) (2.0) (1. 7)t (1.8) (1.8) (1.8) (2.0)** (1.9)** 0.901 § 0.010§ 123.08) 
I\ A_., A<' 
28.5 28.0 27.1 27.4 27.3 27.3 26.6 26.1 O.Ql 8 (I, 61) 5.554 (2.07, 126.36) 0.512 (2.07, Body Fat% (0.1) (0.1) (1.0)t (1.2) (1.0) (1.2) (1.1 )t (1.3)** 0.895 0.004§ 126.36) 
. (\ l",.(\'7~ 
25.1 28.4 28.1 29.1 27.9 30.5 28.2 29.0 0.640 (I, 55) 2.655 (2.32, 127.65) 0.669 (2.32, V02 - (ml/kg/min) (1.8) (1.6) (2.0) (1.5) (2.0) (l.6)t (2.0)** (1.8) 0.427 0.066§ 127.65) () i:;'.21"..~ 
63.9 69.6 64.2 68.1 64.5 68.9 65.0 68.5 1.658 (I, 61) 0.196 (2.62, 159.97) 0.270 (2.62, Grip Strength (kg) (2.6) (2.0) (2.6) (2.1) (2.7) (2.3) (2.9) (2.5) 0.203 0.876§ 159.97) 0.821§ 
PA Volume (MET- 19.5 24.9 33.3 24.7 36.3 26.7 33.4 26.5 0.462 (1, 61) 5.491 (2.51, 152.89) 3.122 (2.51, 
hrs/wk) (3.5) (6.4) (6.6)t (6.5) (7.7)t (6.4) (5.9)t (6.3) 0.499 0.003§ 152.89) 0.036§ 
Intention-to-treat analysis (AET: n=32; RET: n=34); Data are presented as mean (standard error); F (degrees of freedom) and p-values for between-factor, w1thm-factor, 
and interaction analyses are reported for RM-ANOV A; * trend towards within-group change from 6 months (p < 0.1 ), tsignificant within-group change from baseline (p 
S 0.05); tsignificant within-group change from baseline (p S 0.01); •significant change from 6 months (p S 0.01); §=analysis was conducted using Greenhouse 
Geisser's Correction for F-Statistic due to violation of Mauchley's test of sphericity 
Table 6. Per Protocol Analysis of Fatigue and Health-Related Quality of Life Outcomes in Prostate Cancer Patients 
Receiving ADT 
Main Effects 
Baseline 3 Months 6 Months 12 Months (RM-ANOVA) Group X Time Interaction 
Group Time 
Variable AET RET AET RET AET RET AET RET F (di) F (di) F (di) (n=32) (n=34) (n=28) (n=29) (n=24) (n=20) (n=19) (n=l2) (p) (p) (p) 
FACT-F 41.07 41.53 40.21 43.95 40.89 44.21 41.42 44.37 0.471 (1, 27) 1.387 (3, 81} 0.925 (3, 81) (1.95) (2.86) (1.95) (1.73) (1.81) (1.99) (1.91) (2.25) (0.498) (0.253) (0.418) 
FACT-P 124.66 126.12 124.20 128.63 123.8 129.30 126.65 133.35 0.469 (1, 19) 0.742 (1.59, 28.85) 0.360 (1.59, 28.85) (4.77) (3.78) (4.90) (3.15) (4.78) (3.65) (4.21) (2.82) (0.502) (0.450) § (0.643) § 
FACT-P-PWB 23.78 (1.28) 25.14 26.66 25.23 23.31 25.33 23.94 25.44 0.377 (1,24) 0.006 (3,72) 0.048 (3,72) (1.02) (1.35) (0.62) (1.09) (0.87) (1.04) (1.00) (0.545) (0.999) (0.979) 
FACT-P-SWB 23.01 22.65 22.60 22.89 22.49 22.31 22.94 23.69 0.466 (1, 25) 0.095 (1.64,40.98) 0.882 (1.64,40.98) (1.31) (1.13) (1.12) (0.79) (1.18) (1.22) (1.00) (0.71) (0.501) (0.874) § (0.403) § 
FACT-P-EWB 21.16 19.87 21.29 19.73 20.89 20.33 21.18 20.46 1.006 (1,24) 0.244 (3,72) 0.501 (3,72) (0.64) (1.10) (0.64) (1.08) (0.72) (1.10) (0.64) (1.24) (0.326) (0.865) (0.683) 
FACT-P-FWB 22.06 21.02 21.88 22.07 22.17 22.20 23.05 22.81 0.506 (1, 23) 1.020 (1.78, 40.87) 0.536 (1.78, 40.87) (0.98) (1.69) (1.21) (1.16) (1.21) (1.35) (0.94) (1.45) (0.484) (0.362) § (0.659) § 
FACT-P - PSC 34.2 33.31 34.89 35.5 34.93 35.49 35.32 35.73 0.064 (1, 24) 1.936 (3, 72) 0.325 (3, 72) (1.26) (1.89) (1.26) (1.06) (1.35) (1.52) (1.55) (1.43) (0.803) (0.131) (0.808) 
PORPUS 68.57 (3.13) 64.23 67.44 (2.71) 64.83 65.63 64.25 67.93 12.ost* 0.018(1,23) 4.184 (3, 69) 3 .431 (3, 63) (2.83) (3.46) (3.28) (3.67) (2.96) (3.61) (0.894) (0.009) (0.022) 
Per-protocol analysis; sample sizes for each within group analysis are presented; data are presented as mean (standard error); PWB =physical 
wellbeing, SWB =social wellbeing; EWB =emotional wellbeing; FWB =functional wellbeing; PSC =prostate cancer-specific concerns; F (degrees of 
freedom) and p-values for between-factor, within-factor, and interaction analyses are reported for RM-ANOVA; *trend towards a within-group change 
from 6 months (p < 0.1), twithin-group change from baseline (p S 0.05); iwithin-group change from baseline (p :::_0.01). Scales oriented to indicate 
improvement in wellbeing with increased score;§= analysis was conducted using Greenhouse Geisser's Correction for F-Statistic due to violation of 
Mauchley's test of sphericity. 
Table 7. Per Protocol Analysis of Physical Fitness Outcomes in Prostate Cancer Patients Receiving ADT 
Main Effects Group X 
Baseline 3 Months 6 Months 12 Months (RM-ANOVA) Time 
Group Time Interaction 
Variable AET RET AET RET AET RET AET RET F (df) F (df) F (df) (n=32) (n=34) (n=28) (n=29) (n=24) (n=20) (n=19) (n=12) (p) (p) (p) 
88.5 86.5 86.7 86.8 87.8 83.0 88.5 88.3 0.01 (1,32) 2.05 (2.3, 73.63) 1.143 (2.3, 73.63) Wt(kg) (2.0) (2.4) (l.9)t (2.6) (2.2) (3.0) (2.4) (3.7) 0.921§ 0.129§ 0.336 
WC (cm) 104.8 105.9 103.1 106.1 104.3 102.4 103.6 105.3 0.15(1,32) 2.894 (3, 96) 1.022 (3, 96) (1.9) (2.2) (l.8)t (2.1) (2.2) (2.3) (2.4)t (3.0) 0.701 0.039 0.387 
BMI (kg/m2) 29.0 28.8 28.4 28.9 28.9 28.3 29.1 28.9 
0.061 (1, 2.152 (2.3, 1.052 (2.3, 73.57) 
(0.7) (0.8) (0.7)t (0.8) (0.8) (1.1) (0.9) (1.1) 32) 73.57) 0.362§ 
r\ --- " ' ' .r" 
35.7 35.2 32.1 34.0 34.0 36.8 32.2 33.7 0.467 (1, 2.461 (3, 93) 0.232 (3, 93) Chest Skinfold (mm) (2.0) (2.2) (1.9)t (1.9) (2.4) (32.9)t (3.0) (2.3) 31) 0.087 0.818 0.499 
28.7 28.5 26.9 27.8 27.3 26.2 25.1 25.3 0.082(1, 5 .483 (3, 90) 0.731 (3,90) Body Fat% (1.2) (1.4) (I. l)t (1.4) (1.4)** (1.7)** (1.5)t (1.7)** 30) 0.001 0.536 
,..... ---
V02 - (ml/kg/min) 28.1 27.5 30.4 28.3 
31.1 33.1 30.0 30.1 0.11(1,26) 2.876 (3, 78) 0.741 (3, 78) 
(1.9) (1.8) (1.9) (1.7) (2.3)t (2.0)t (2.6) (3.6) 0.743 0.041 0.531 
67.4 68.3 67.0 66.4 67.0 68.1 65.8 69.7 1.406 (1, 0.605(2.26, 7.2) 0.155 (2.26, 7.2) Grip Strength (kg) (2.6) (2.1) (2.8) (2.1) (3.4) (2.8) (3.6) (4.0) 31) 0.569§ 0.881§ 0.245 
PA Volume (MET- 22.3 17.5 38.3 18.3 43.5 23.9 34.3 21.3 1.392 (1, 2.714 (3, 96) 1.2 (3, 96) 
hrs/wk) (4.0) (3.2) (7.4)t (83.3.8) (10.7)t (4.7) (8.3)t (4.5) 32) 0.049 0.314 0.247 
Per-protocol analysis; sample sizes for each within group analysis are presented; data are presented as mean (standard error); F (degrees of freedom) and 
p-values for between-factor, within-factor, and interaction analyses are reported for RM-ANOVA; *trend towards a within-group change from 6 
months (p < 0.1), twithin-group change from baseline (p.:::: 0.05); iwithin-group change from baseline (p s_0.01); •significant change from 6 months 
(p.:S0.01); scales oriented to indicate improvement in wellbeing with increased score;§= analysis was conducted using Greenhouse Geisser's Correction 
for F-Statistic due to violation of Mauchley's test of sphericity. 
Table 8. Subgroup Analysis of the Effects of Aerobic Exercise Training and Resistance Exercise Training on 
Bio markers of Tumour Progression 
Main Effects 
(RM-ANOVA) 
Baseline 3 Months 6 Months Group X Time Interaction 
Group Time 
Variable AET RET AET RET AET RET F (df) F (df) F (df) p p p 
Leptin 19.9 12.8 14.9 13.6 20.6 12.1 1. 797 (I, 23) 0.821 /92, 46) 2.154 /92, 46) 
(µg/mL) (3.8) (2.6) (2.6) (3.5) (4.1) (3.1) 0.446 0.446 0.128 
Adiponectin 16.6 21.6 16.1 21.1 16.1 20.5 2.341 (I, 22) 0.620 (2, 44) 0.032 (2, 44) 
(µg/mL) (1.8) (2.8) (2.2) (3.3) (2.5) (2.6) 0.140 0.538 0.969 
Leptin:Adiponectin 1.2 0.78 1.08 1.04 1.6 0.88 0.992 (I, 22) 1.185 (2, 44) 2.12 (2, 44) (0.26) (0.22) (0.21) (0.42) (0.4) (0.35) 0.330 0.315 0.132 
IGF-1 159.6 159.1 169.7 138.3 161.9 146.4 0. 796 (I, 24) 0.221 (1.53, 36.64) 1.422 (1.53, 36.64) 
(ng/mL) (15.3) (14.2) (18.7) (11.8)t (12.7) (13.7) 0.381 0.743§ 0.252§ 
IGFBP-3 5582.7 4360.5 4770.4 4321.3 4259.8 4887.9 0.424 (I, 22) 0.877 (2, 44) 3.338 (2, 44) 
(ng/mL) (456.6) (380.2) (777.8) (334.3) (406.8)t (454.8)t 0.522 0.423 0.045 
IGF-1: IGFBP-3 0.03 0.04 0.13 0.03 0.04 0.03 1.188 (1, 22) 1.084 (1.01, 22.2) 1.148 (1.01, 22.2) (0.002) (0.005) (0.09) (0.005) (O.Ol)t (0.003)t 0.288 0.310 0.296 
Subgroup analysis (AET: n=13; RET: n=13); data are presented as mean (standard error); F (degrees of freedom) and p-values for between-
factor, within-factor, and interaction analyses are reported for RM-ANOVA; twithin-group change from baseline (p _:::: 0.05); twithin-group 
change from baseline (p .:s_0.01); §=analysis was conducted using Greenhouse Geisser's Correction for F-Statistic due to violation of 
Mauchley' s test of sphericity. 
Table 9. Correlation Matrix for Physical Fitness Outcomes and Biomarkers at Baseline 
Weight BMI WC BF% PA V02 GS IGF-1 IGFBP Adiponectin Leptin Leptin: IGF-1: Volume -3 Adiponectin IGFBP-3 
Age (years) -0.145 -0.157 0.000 -0.188 -0.076 
-0.641:1: -0.556:1: 0.047 0.196 0.316 -0.204 -0.146 -0.126 
n 66 66 65 65 64 66 65 26 24 24 25 24 24 
Weight (kg) 1 0.809:1: 0.856:1: 0.609:1: -0.137 -0.234* 0.089 0.027 -0.029 -0.471 ** 0.446** 0.531 ** 0.055 
n 66 65 65 64 66 65 26 24 24 24 24 24 
BMI (kg/m2) 1 0.787:1: 0.639:1: -0.122 -0.238* 0.036 -0.177 -0.214 -0.476** 0.480** 0.610t -0.055 
n 65 65 64 66 65 26 24 24 25 24 24 
WC (cm) 1 0.654:1: -0.268** -0.360t -0.110 0.069 -0.154 -0.556t 0.480** 0.667:1: 0.250 
n 64 63 65 64 26 24 24 25 24 24 
BF% 1 -0.262** -0.029 -0.124 -0.121 -0.261 
-0.523t 0.523t 0.606t 0.131 
n 63 65 64 26 24 24 25 24 24 
PA Volume 1 0.292** 0.250** 0.210 0.277 -0.098 -0.065 -0.010 -0.162 (MET-hrs/wk) 
n 64 63 26 24 24 25 24 24 
V02 1 0.474i -0.022 -0.192 -0.162 -0.182 -0.134 0.162 (ml02/kg/min) 
n 65 26 24 24 25 24 24 
GS (kg) 1 -0.176 -0.394* -0.029 -0.415** -0.381 * 0.134 
n 26 24 24 25 24 24 
IGF-1 1 0.517t 0.349* -0.118 -0.109 0.462** 
n 24 24 25 24 24 
IGFBP-3 1 0.245 -0.065 -0.231 -0.450** 
n 23 24 23 24 
Adiponectin 1 -0.301 
-0.598t 0.029 
n 24 24 23 
Leptin 1 0.833:1: -0.015 
n 24 24 
Leptin: 1 0.235 Adiponectin 
n 23 
Pearson r correlations; n refers to number of participants in bivariate correlation analysis, BMI = body mass index, WC = waist circumference, BF%= body fat 
%, V02 = V02 peak; GS= grip strength; *p:S0.1; **p:S0.05; tp:S0.01; ip:s0.001 
Table 10. Correlation Matrix for Change in Physical Outcomes from Baseline to 3 months 
~BMI ~WC ~BF% ~PA ~V02 ~GS MGF- ~IGFBP- ~Adiponectin ~Leptin ~Leptin: ~IGF-1: Volume 1 3 Adiponectin IGFBP-3 
~Weight (kg) 0.999t 0.441t 0.183 --0.187 -0.110 0.130 -0.223 0.073 0.140 0.602i 0.334 -0.452** 
n 65 64 64 62 63 63 26 24 24 25 24 24 
~BMI (kg/m2) 1 0.425t 0.171 -0.181 -0.119 - -0.211 0.057 0.132 0.610t 0.358* -0.444** 0.145 
n 64 64 62 63 63 26 24 24 25 24 24 
~WC (cm) 1 0.243* 
-0.372t -0.024 0.051 -0.046 0.292 -0.087 0.411 ** 0.189 -0.456** 
n 63 61 62 62 26 24 24 25 24 24 
~BF% 1 -0.176 0.091 0.140 -0.311 -0.313 0.139 -0.109 -0.060 -0.067 
n 61 62 62 26 24 24 25 24 24 
~PA Volume (MET- 1 0.340t 0.032 0.119 -0.017 0.139 -0.026 -0.040 0.117 hrs/wk) 
n 61 60 26 24 24 25 24 24 
~ V02 (ml02/kg/min) 1 0.128 0.052 -0.087 0.154 -0.406** -0.159 0.379* 
n 61 26 24 24 25 24 24 
~GS (kg) 1 0.138 -0.062 -0.093 -0.213 -0.253 0.043 
n 26 24 24 25 24 24 
MGF-1 (ng/mL) 1 -0.161 -0.067 -0.048 0.175 0.573t 
n 24 24 25 24 24 
MGFBP-3 (ng/mL) 1 -0.122 0.296 -0.029 -0.444** 
n 23 24 23 24 
~Adiponectin 
1 0.135 -0.250 0.052 (ug/mL) 
n 24 24 24 
~Leptin 
1 0.734i -0.565t (µg/mL) 
n 24 24 
~Leptin: I 0.099 Adiponectin 
n 23 
Pearson r correlations; n refers to number of participants in bivariate correlation analysis, BMI = body mass index, WC = waist circumference, BF%= body fat 
%, V02 = V02 peak; GS= grip strength; *p:S0.1; **p:S0.05; tp:S0.01; tp_:s0.001 
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~BMI ~WC ~BF% ~PA ~V02 ~GS ~IGF- ~IGFBP- ~Adiponectin ~Leptin ~Leptin: MGF-1: Volume 1 3 Adiponectin IGFBP-3 
~Weight (kg) 0.997t 0.549t 0.109 -0.156 -0.341 t -0.019 0.098 -0.179 -0.146 0.529t 0.526t 0.316 
n 65 64 64 63 62 63 26 24 24 25 24 24 
~BMI (kg/m2) 1 0.532t 0.095 -0.145 -0.35t -0.035 0.078 -0.175 -0.142 0.517t 0.524t 0.297 
n 64 64 63 62 63 26 24 24 25 24 24 
~WC (cm) 1 0.339t -0.178 -0.433t -0.052 0.228 -0.163 -0.044 0.267 0.226 0.432** 
n 63 62 61 62 26 24 24 25 24 24 
~BF% 1 -0.124 -0.034 -0.055 0.155 0.032 0.365* -0.252 
-0.529t 0.198 
n 62 61 62 26 24 24 25 24 24 
~PA Volume 1 0.318t -0.002 0.240 -0.075 -0.155 -0.132 -0.001 0.135 (MET-hrs/wk) 
n 61 61 26 24 24 25 24 24 
~V02 1 0.044 0.142 0.045 0.087 -0.471 ** -0.275 -0.133 (ml02/kg/min) 
n 60 25 23 23 24 23 23 
~GS (kg) 1 0.156 -0.008 -0.065 0.323 0.249 0.090 
n 26 24 24 25 24 24 
MGF-1 1 0.170 0.340 0.173 0.150 0.246 (ng/mL) 
N 24 24 25 24 24 
MGFBP-3 1 0.200 -0.141 -0.024 
-0.787t (ng/mL) 
n 23 24 23 24 
~Adiponectin 1 -0.164 -0.292 -0.022 (µg/mL) 
n 24 24 23 
~Leptin 1 0.773t 0.311 (µg/mL) 
n 24 24 
~Leptin: 1 0.198 Adiponectin 
n 23 
Pearson r correlations; n refers to number of participants in bivariate correlation analysis, BMI =body mass index, WC = waist circumference, 
BF%= body fat%, V02 = V02 peak; GS= grip strength; *p_:SO.l; **p_::::0.05; tp:S0.01; tp_::::0.001. 
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Table 12. Correlation Matrix for Determinants of Exercise Outcomes at Baseline 
Charlson EIF SUP SUPF SUPFR SE PA V02 
Age -0.015 0.073 0.011 -0.046 0.105 0.005 -0.076 -0.641:1: 
66 59 62 63 62 41 64 66 
Charlson 1 0.043 .043 -.043 -.069 -.30* -.172 .07 
59 62 63 62 41 64 66 
EIF 1 .273** .248* .257* .534t .143 .235* 
58 59 58 37 58 59 
SUP 1 .979t .787t .339** .056 .095 
62 62 41 61 62 
SUPF 1 .644t .335** .042 .068 
62 41 62 63 
SUPFR 1 .258 .089 .164 
41 61 62 
SE 1 .272* .341 ** 
41 41 
PA 1 .292** 
64 
EIF =exercise-induced feelings; SUP= social support (total); SUPF =social support (family); SUPFR = 
social support (friends); SE= self-efficacy; PA= physical activity volume; V02 = V02 peak; *p<O.l; 
**p<0.05; tp<0.01; tp<0.001 
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Table 13. Correlation Matrix for Determinants of Exercise Outcomes at 3 Months 
Charlson EIF SUP SUPF SUP FR SE PA V02 
Age -0.101 0.107 0.034 0.057 -0.011 -0.130 -0.096 -0.608t 
55 48 51 52 52 51 52 52 
Charlson 1 .055 -.104 -.164 .070 . .151 -.238* .075 
48 51 52 52 51 52 52 
EIF 1 .415t .404t .331 ** .490t .165 .243 
46 47 47 46 47 46 
SUP 1 .978t .839t .294** .021 .112 
51 51 49 50 49 
SUPF 1 .709t .261 * -.007 .114 
51 50 51 50 
SUP FR 1 .296** .092 .093 
50 51 50 
SE 1 .127 .303** 
51 49 
PA 1 .383t 
50 
EIF =exercise-induced feelings; SUP= social support (total); SUPF =social support (family); SUPFR = 
social support (friends); SE= self-efficacy; PA= physical activity volume; V02 = V02 peak; *p<O. l; 
**p<0.05; tp<0.01; tp<0.001. 
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Table 14. Correlation Matrix for Determinants of Exercise Outcomes at 6 Months 
Charlson EIF SUP SUPF SUP FR SE PA V02 
Age -0.024 0.161 -0.022 -0.050 0.057 0.055 -0.199 -0.644t 
41 39 41 40 41 37 41 40 
Charlson 1 -.147 -.169 -.233 .059 .233 -.188 .103 
39 41 41 41 37 41 40 
EIF 1 .195 .236 .015 .480t .083 .205 
39 39 39 36 39 38 
SUP 1 .961t .712t .221 .132 0.098 
41 41 37 41 40 
SUPF 1 .489t .224 .137 .114 
41 37 41 40 
SUP FR 1 .125 .068 .020 
37 41 40 
SE 1 .165 .130 
37 36 
PA 1 .389** 
40 
EIF =exercise-induced feelings; SUP= social support (total); SUPF =social support (family); 
SUPFR =social support (friends); SE= self-efficacy; PA= physical activity volume; V02 = V02 
peak; *p<0.1; **p<0.05; tp<0.01; tp<0.001. 
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Table 15. Correlation Matrix for Determinants of Exercise Outcomes at 12 Months 
Charlson EIF SUP SUPF SUP FR SE PA V02 
Age -0.135 -0.084 -0.216 -0.125 -0.338 -0.130 -0.233 -0.699t 
34 33 33 33 34 33 34 29 
Charlson 1 .061 -.078 -.119 .038 -.065 -.054 -.164 
33 33 33 34 33 34 29 
EIF 1 .092 .030 .184 .312* .153 .130 
32 32 33 32 33 28 
SUP 1 .956l .751l .334* .017 .109 
33 33 32 33 28 
SUPF 1 .523t .303* .033 .097 
33 32 33 28 
SUP FR 1 .314* -.026 .105 
33 34 29 
SE 1 -.258 .029 
33 28 
PA 1 .530t 
29 
EIF =exercise-induced feelings; SUP= social support (total); SUPF =social support (family); SUPFR = 
social support (friends); SE= self-efficacy; PA= physical activity volume; V02 = V02 peak; *p<0.1; 
**p<0.05; tp<0.01; tp<0.001. 
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Table 16. Explained Variance in Regression Models for Determinants of Exercise 
and Control Variables at Each Time Point 
Dependent Time point R R2 Adjusted F Coefficient Variable n R1 p Table 
Physical 
Baseline 41 0.417 0.174 0.041 1.309 0.286 17 
3 months 48. 0.415 0.173 0.064 1.585 0.188 18 Activity 6 months 39 0.305 0.093 -0.058 0.615 0.690 19 Volume 
12 months 29 0.445 0.198 0.037 1.232 0.324 20 
Baseline 41 0.685 0.470 0.384 5.494 0.001 21 
V02 peak 3 months 48 0.753 0.568 0.507 9.448 <0.001 22 6 months 39 0.726 0.528 0.446 6.476 <0.001 23 
12 months 29 0.713 0.508 0.385 4.132 0.01 24 
Independent variables= social support, self-efficacy, exercise-induced feelings; Control 
Variables = age, exercise group; 
Table 17. Model Coefficients for Physical Activity Volume at Baseline 
Unstandardized Standardized 
Coefficients Coefficients 
Model B Std. Error Beta t Sig. 
Self-Efficacy 4.178 4.293 .197 .973 .338 
Social-Support .673 4.405 .029 .153 .880 
Exercise-Induced Feelings 3.621 3.927 .183 .922 .364 
Age -.519 .343 -.258 -1.513 .140 
Exercise Group -1.621 6.768 -.041 -.239 .812 
Table 18. Model Coefficients for Physical Activity Volume at 3 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy -1.391 4.853 -.050 -.287 .776 
Social-Support -8.162 7.589 -.180 -1.075 .289 
Exercise-Induced Feel in gs 7.563 6.419 .219 1.178 .246 
Age -.446 .548 -.125 -.813 .421 
Exercise Group -22.818 9.748 -.362 -2.341 .025 
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Table 19. Model Coefficients for Physical Activity Volume at 6 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy 6.571 6.924 .190 .949 .350 
Social-Support 5.062 11.150 .089 .454 .653 
Exercise-Induced Feelings -2.654 7.540 -.071 -.352 .727 
Age -.635 .765 -.147 -.830 .413 
Exercise Group -12.469 14.292 -.164 -.872 .390 
Table 20. Model Coefficients for Physical Activity Volume at 12 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy -8.597 4.983 -.356 -1.725 .097 
Social-Support -1.793 8.207 -.048 -.219 .829 
Exercise-Induced Feelings 10.746 7.402 .299 1.452 .159 
Age -.910 .691 -.245 -1.317 .200 
Exercise Group -14.850 12.893 -.251 -1.152 .260 
Table 21. Model Coefficients for V02 peak at Baseline 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy 2.012 1.664 .196 1.209 .236 
Social-Support 1.234 1.707 .109 .723 .475 
Exercise-Induced Feelings 1.749 1.522 .183 1.149 .259 
Age -.542 .133 -.558 -4.077 .000 
Exercise Group 2.721 2.623 .143 1.038 .308 
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Table 22. Model Coefficients for V02 peak at 3 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy .448 1.098 .051 .408 .686 
Social-Support .469 1.756 .034 .267 .791 
Exercise-Induced Feelings 4.488 1.696 .374 2.646 .012 
Age -.796 .128 -.726 -6.206 .000 
Exercise Group 1.001 2.332 .051 .430 .670 
Table 23. Model Coefficients for V02 peak at 6 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy .132 1.223 .016 .108 .915 
Social-Support 2.134 1.969 .154 1.084 .287 
Exercise-Induced Feelings 2.254 1.331 .252 1.694 .101 
Age -.666 .135 -.642 -4.938 .000 
Exercise Group 3.713 2.549 .200 1.456 .156 
Table 24. Model Coefficients for V02 peak at 12 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Self-Efficacy -.724 1.601 -.078 -.452 .656 
Social-Support -1.272 2.562 -.092 -.496 .625 
Exercise-Induced Feelings 1.641 2.423 .120 .677 .506 
Age -.998 .226 -.726 -4.416 .000 
Exercise Group 1.713 4.013 .079 .427 .674 
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Table 25. Explained Variance in Regression Models for Determinants of Exercise 
and Control Variables for Program Adherence from Baseline to 24 weeks 
Dependent Variable n R R2 Adjusted R2 F p 
Physical Activity Volume 
33 0.339 0.115 0.021 0.843 0.510 (,1 from baseline to 6 months) 
V02 Peak 33 0.393 0.154 0.019 1.141 0.360 (,1 from baseline to 24 weeks) 
Independent variables= social support, exercise-induced feelings; Control Variables= age, exercise group 
Table 26. Model Coefficients for Change in Physical Activity Volume from Baseline 
to 6 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Social-Support -5.267 6.389 -.156 -.824 .417 
Exercise-Induced Feelings 3.035 5.841 .101 .520 .608 
Age -.490 .737 -.126 -.665 .512 
Exercise Group -17.941 11.843 -.284 -1.515 .142 
Table 27. Model Coefficients for Change in V02 Peak from Baseline to 6 Months 
Unstandardized Standardized 
Coefficients Coefficients t Sig. 
Model B Std. Error Beta 
Social-Support -1.269 1.216 -.197 -1.044 .307 
Exercise-Induced Feelings -.015 1.111 -.003 -.014 .989 
Age .007 .141 .010 .052 .959 
Exercise Group 4.017 2.306 .325 1.742 .094 
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Table 28. Power and Sample Size Calculations for Fatigue and HRQOL Outcomes 
Observed Observed Observed Sample Size Standard Hypothesized Sample Size for Primary Effect Size Effect Size Power Calculation for Deviation MCID Effect Size Hypothesized Outcome (partial 112) (j) Observed Effect Used (j) Effectt 
3.5 
Fatigue 0.046 0.220 0.384 N=l72 5.8 points 0.30 N=78 (FACT-F) (120, 413) (120, 
413) 
5 
HRQOL 0.019 0.139 0.162 N=348 9.1 points 0.15 N=92 (FACT-P) (120, 514) (120, 
514) 
HRQOL 11.1 5 0.029 0.173 0.227 N=226 points 0.23 N=l34 (PORPUS) (425) (425) 
Power and sample size calculations are based on a RM-ANOV A for between-groups analysis from baseline to 6 months using intention-to-treat 
approach; Observed Effect Size was derived from statistical output of SPSS; Observed Power reflects the power of the sample size of current analysis 
(AET: n = 32; RET: n = 34); t refers to sample size calculation using alpha= 0.05, Power= 0.80; a medium effect size was used as a conservative 
default when an MCID was not available, when the MCID and SD of the were available, they were used to calculate Cohen's d (d = MCID/SD) which 
was converted to Cohen's/ using a reference table of effect sizes(515); Referent values for effect sizes using Cohen's! 0.1=small,0.25 =medium, 
0.4 =large. 
Table 29. Power and Sample Size Calculations for Physical Fitness Outcomes 
Observed Observed Sample Size Standard Hypothesized Sample Size for Primary Effect Size Effect Size Observed Calculation for Deviation MCID Effect Size Hypothesized Outcome (partial 112) (j) Power Observed Effect Used (j) Effectt 
Chest Skinfold 0.001 0.032 0.052 N=6668 NA NA 0.25 N=llO (mm) 
Body Fat 0.001 0.032 0.052 N=6668 7.1§ 3%** 0.25 N=llO (%) (21) 
V02 peak 0.110 0.123 N=552 6.6§ 3.5 0.25 N=llO ( ml02/kg/min) 0.012 (26) ml02/kg/min! 
Grip Strength 0.026 0.163 0.245 N=252 14.2 7kg 0.25 N=llO (combined - kg) (26) 
Physical Activity 9 MET-hrs/wk Volume 0.008 0.09 0.103 N=830 NA (110) 0.25 N=llO (MET-hrs/wk) 
Power and sample size calculations are based on a RM-ANOV A for a between-groups analysis from baseline to 12 months using intention-to-treat 
approach; Observed Effect Size was derived from statistical output of SPSS; Observed Power reflects the power of the sample size of current analysis 
(AET: n = 32; RET: n = 34); t refers to sample size calculation using alpha= 0.05, Power= 0.80; a medium effect size was used as a conservative 
default when an MCID was not available, when the MCID was available and SD were available, they were used to calculate Cohen's d (d = MCID/SD) 
which was converted to Cohen's! using a reference table of effect sizes(515); §Segal et al's (21) previous assessment of RET effects over 6 months 
were used to provide SDs for a small-moderate effect size; **3% represents an approximate 10% reduction in total body fat percentage for someone 
overweight/obese (-30% body fat); t MCID for relative V02 peak (ml02/kg/min) is generally understood to be 1 metabolic equivalent or 3.5 
ml02/kg/min; Referent values for effect sizes using Cohen's! 0.1 =small, 0.25 =medium, 0.4 =large. 
Table 30. Power and Sample Size Calculations for Biomarker Outcomes 
Observed Observed Observed Sample Size Calculation for Hypothesized Sample Size for Primary Outcome Effect Size Effect Size Power Effect Size 
(partial 112) (/) (n) Observed Effect (f) Hypothesized Effectt 
Leptin (µg/mL) 0.072 0.28 0.250 N=88 0.25 N=llO 
Adiponectin 0.096 0.33 0.310 N=66 0.25 N=llO (µg/mL) 
Leptin:Adiponectin 0.043 0.21 0.159 N=l52 0.25 N=llO 
IGF-1 (ng/mL) 0.032 0.18 0.137 N=204 0.25 N=llO 
IGFBP-3 (ng/mL) 0.019 0.14 0.096 N=348 0.25 N=llO 
IGF-1: IGFBP-3 0.051 0.23 0.181 N=l28 0.25 N=llO 
Power and sample size calculations are based on a RM-ANOVA for between-groups analysis from baseline to 12 months using intention-to-treat 
approach; Observed Effect Size was derived from statistical output of SPSS; Observed Power reflects the power of the sample size of current analysis 
(AET: n = 13; RET: n = 13); t refers to sample size calculation using alpha= 0.05, Power= 0.80; for all biomarker assay sample size analyses, a 
medium effect size was used as a conservative default when an MCID because MCIDs have not yet been established; Referent values for effect sizes 
using Cohen's! 0.1 =small, 0.25 =medium, 0.4 =large. 
Assessed for eligibility: 
(N=712) Excluded: (n=507} 
Refused to participate: (n=139} 
No time (n=33) Eligible patients approached: (n= 205) 
Distance (n=123) 
Medical contraindication (n=126) 
Psychological contraindication (n=10) 
Currently receiving chemotherapy 
or radiation (n=22) 
Language barrier (n=54) 
Deceased (n=15) 
Intermittent ADT (currently off)(n=157) 
Lacks transportation or too far 
travel for assessments (n=8) 
Traveling during !ntervention 
period (n=12) 
Not interested/no reason (n=27) 
unable (self-determined) (n=35) 
Already exercising (n=24) 
I 
Agreed to participate and 
randomly allocated: 
(n=66) 
I 
Allocated to aerobic exercise training group: 
(n=32) 
I 
Dropped out before 3 months: (n=4) 
I 
Dropped out between 3-6 months: . ( n=4) 
I 
Dropped out between 6-12 months: (n=5) 
I 
Missing data: 
Baseline FACT-P (n=2) 
Baseline FACT-F & GS (n=1) 
3 months PORPUS (n=2) 
3 months FACT-P (n=4) 
3 months FACT-F, Wt. WC, Chest SKF! 
& GS (n=1) 
3 months V02 (ri=3) 
3 months GL TEO (n=2) 
6 months PORPUS & V02 (n=3) 
6 months FACT-P (n=2) 
6 months GLTEO, Wt, BMI, WC, Chest SKF, 
& GS (n=1) 
12 months POR PUS (n=4) 
12 months FACT-P (n=3) 
12 months FACT-F, GLTEQ, Wt, BMI, WC, 
Chest SKF, & GS (n=1) 
12 months V02 (n=6) 
Figure 1. CONSORT Diagram 
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6months GLTEQ, WC, V02 & GS 
12 months PORPUS 
12 months FACT-P 
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12 months V02 
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Legend: Time point 1 = Baseline; Time point 2 = 3 months; Time point 3 = 6 months; 
Time point 4 = 12 Months; main effect of Group: F(2.s1, 152.89) = 7.302, p = 0.009); 
tbetween-group difference, p:::; 0.02. 
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Figure 7. Intention to Treat Analysis of Change in Physical Activity Volume 
Legend: Time point 1 =Baseline; Time point 2 = 3 months; Time point 3 = 6 months; 
Time point 4 = 12 Months; main effect of Time: F(2.s1, 152.89) = 5.491, p = 0.003); twithin-
group change from baseline, p .:S 0.01; twithin-group change from baseline, p .:S 0.001; 
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Figure 8. Per Protocol Analysis of Change in PORPUS Scores 
Legend: PORPUS = Patient-Oriented Prostate Utility Scale; Time point 1 = Baseline; 
Time point 2 = 3 months; Time point 3 = 6 months; Time point 4 = 12 months; main 
effect of Time: F(3,69) = 4.184, p = 0.009; Group X Time interaction: F(3, 69) = 3.431, p = 
0.022; twithin-group change from baseline, p = 0.002; t =within-groups change from 3 
months, p = 0.014; *within-group change from baseline, p = 0.014. 
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Figure 9. Change in Mean Self-Efficacy For Exercise Score Over Time 
Legend: Time point 1 = Baseline; Time point 2 = 3 months; Time point 3 = 6 months; 
Time point 4 = 12 Months; t within-group difference from baseline (p = 0.014) 
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Figure 11. Change in Mean Score for Friend Social Support For Exercise Score 
Over Time 
Legend: Time point 1 = Baseline; Time point 2 = 3 months; Time point 3 = 6 months; 
Time point 4 = 12 Months; twithin-group difference from baseline (p = 0.043). 
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Figure 12. Change in Mean Score for Total (Friend +Family) Social Support For 
Exercise Score Over Time 
Legend: Time point 1 = Baseline; Time point 2 = 3 months; Time point 3 = 6 months; 
Time point 4 = 12 Months; t within-group difference from 3 months (p = 0.027); t 
within-group difference from 6 months (p = 0.03). 
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Appendix A: Physical Activity Screening Form (P AR-Q) 
PAR-Q & YOU 
(A Questionnaire for People Aged 15 to 69) 
Regular p!Tfsicai activity i's ru111 !?ltd healt~ and increasing•/ more people are starmg to become mOle active every day. Being more ac:iive is 'teJY safe for most 
people. HO'll'f\•er, some people should check •lfflh their ooctor be.fore they start becoming much more plr)•skaltf acti•re. 
lf you are planning to bemne moch more phys[<alty am•e than 'JOO are now, start by answering me se•i'f!ll quesnoos in the. bo>: bebw. If 'fG:J are between !'le 
ages of i5 and 69, me PAR-Q will tell you if you 500.rld check with your doctor before you start. If you are over 69 yeats of age, and you are oot used to being 
•tery active. check •mil )OUr doctor. 
Commoo sense is 'fOOl best guide when 'JOO answer these questions. Please read the questions carefully and answer each one honestly: er.eek YES or NO. 
YES NO 
D D 
D D 
D D 
D D 
D D 
D D 
D D 
If 
you 
answered 
1. 
z. 
J. 
4. 
s. 
6. 
7. 
Hu your doctor eve1 :aid that you have a heart condition and that you should only do phpical activity 
recommended by a doctor? 
Do you feel pain in your chest when you do physical activity? 
In the past month, have you had me.st pain when you were not doing phy:ical activity? 
Do JOU lo:e your balance because of dizzine:: or do you ever lose con:ciou:ne::? 
Do you have a bone or joint problem (for enmple, back, knee or h~p) that could be made worse by a 
change in your plly:ical activity? 
I: your doctor curreat1J pre:cril>ing drugs (for enmple, water pill:) for rour blood preuure or beart con-
dition? 
Do JOU know of any other reason why JOU should not do plly:ical activity? 
YES to one or more questions 
T slk with )"OIK doct« ht phor;g or ii perso11 B.ff()Rf you start becoming rooch mors physically actM! or BEFORE you fmie a fitn&ss ~prais:al. Tell 
)'01.lr doctor about tli9 ~'t-0 and vAtich questiorn you aM'Nered YES. 
• You may be able to do any activity )'OU want- as lor119 as you start slowly and b!Md up gradual!}\ ~. 'JOO CM/ nsed to rl!Strict )'OIJr actr1iti9s lo 
those v.tiidi ere safe for you. Tall with }'OUr docror abM the kincis c4 aclit.rilies yoo •isb to participate m and fclalt' his/h&r e.dvioa. 
• Find ·Cl.Ii which commooity progi-ams are s.;.4e; and hslpful for yoo. 
D!LAY Bl!<OHHK HUCH HOR! ACTIVI!: 
If }'OU aRSwef"ed NO honesltj to fill 1¥.R-Q qu!:Stioos. )'OU cai be reasorobl,· sin thai you can: 
• if 'JOO are oot f*ing wel 0©3ir..a of a temporary ilness. such as 
a cd::I or a fBWlr - wait until Y!l'l feel better; or 
• start becorr~ng ITllJch mOC"& physicaltj a.ctMi - begin slowly and biill up grsduaft.;. This is the 
sales.! and ea.siesi ""JtJ to ~-
• take part i11 a fitr19ss a~raisal -ihis is an e.~c'6llent way to detsrmiie }OOr basic litn&Ss so 
that )'OU CSill pliii ihe best way for 'JOU to 11.'9 actrl6t,: II is also hight/ reccmrMnded that you 
h-3Ve }OOr blood pressuni euski,;ted. If )'OUt reacf11g is cter 144J'~4. tel 111ith ;-our doctor 
before 'JOO slor1 b5comir;g much rr.ore plrr..icz.tn1ctr..a. 
• if }'JU a.ra or may be pre.gram - tall lo 1•oor doctor before you 
start bsc!'.('lling more acfue.. 
PL!A.SI! HOT!: l! 'JOOr health charq~s so that )'OU ir~n aiswer 'l'ES to 
art/ .ti th~ ebove q.iesiions. tsD 'JOOr fitne.ss or heallh pro~al. 
Ask whe1her }'OU mid chani;e )\)Ur pir)-sical activir1 plan. 
htnne.1 Ike •4 W Pils.Q- fngCsnacimSociSfyk>r &.enise Ftr_r;illogy, Hsili!Csnsds, lilldth:irag:ra:s asrums ro bbiit/k>r pec-sons 11ro ;in:femlei;i'rJSic.;.f aanify. and if ill cbubtaoarccmp5li11; 
1his q-J!!Skmsira, COll5iJt :fOUT OO:tcc 17i:rto ~ actil.tt; 
No change: permitted. You are encouraged to photocopy the PAR·Q but only if you u:e the entire form. 
HCTE: !l lhs f'll.<i-Q is beil)Q !jt1En ro spec-son t:Efcre i"e or sh9 participaes in a i;i'rJSic.;.f actT.itoJ praqam or a fF.nass appr<.iscl, this s9dico fil?J b6 t<sad ~legal er ac'minist-<:liw purpJSes. 
"I hEt\le read, understood and completed this questionnaire. lmy questions r had were fil!:swered to my f'JIM satisfaction." 
Sm\.~.fCf?AA!NT _____________________ _ 
OI C-0\l[JWl jl::r p~~..-.:o •.ndor d!o "SI' cf m,itrlY.i 
Note: TM: ph:r:lcal actMty dearance l: valld few a maxlm111m of 1Z month: from the date HI: completed and 
become: lnwaHd If your condition change: :o that :rou wo111ld an.:wer Yl!S to any or the :even qve:tlon:. 
•.t.1 Health Sance 51
-"?Jr':9d LY- II""" Can:xla Canada contil'.l-ued on other side ... 
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Title: 
Appendix C: Consent to Participate in a Research Study 
A Pilot Study of a Home-Based Exercise Intervention for Prostate 
Cancer Patients on Androgen Deprivation Therapy 
Principal Investigators: P. Ritvo, Ph.D.; S.MH, Alibhai, MD (416-340-4800 ext 3203) 
Co-Investigators: A. Matthew, Ph.D; J Trachtenberg MD, N Fleshner; MD, M 
Connor Ph.D.; & D. Santa Mina, Ph.D (Cand.)/CEP 
24-Hour Phone Number: 416-937-4567 
You are being asked to take part in a research study. Before agreeing to take part in this 
study, it is important that you read and understand the following explanation of the 
proposed study procedures. The following information describes the purpose, 
procedures, benefits, discomforts, risks, and precautions associated with this study. It 
also describes your right to refuse to participate or withdraw from the study at any time. 
In order to decide whether you want to participate in this research study, you should 
understand enough about its risks and benefits to be able to make an informed decision. 
This is known as the informed consent process. Please ask the study doctor and/or study 
staff to explain any words you do not understand before signing this consent form. Make 
sure all your questions have been answered to satisfaction before signing this document. 
The principal investigators of this research study are Dr. Paul Ritvo and Dr. Andrew. 
Matthew. Mr. Daniel Santa Mina is the research coordinator and is also a graduate 
student at York University. 
Background 
Currently the standard of care for prostate cancer does not usually include exercise 
programming. However, recent studies have shown that exercise can help reduce some of 
the negative side-effects related to prostate cancer treatment, including hormone therapy. 
Specifically, some patients receiving hormone therapy (androgen deprivation), resistance 
training and/or aerobic exercise have demonstrated benefits throughout treatment. It is 
now important to compare the effects of different types of exercise to the standard care 
usually provided which does not include exercise programming. Thus, this study 
compares resistance training, aerobic exercise, and standard care (no exercise). 
Understanding the positive effects of exercise and the best approaches to exercise will 
assist in developing programs for patients in the future aimed at reducing the potential 
side-effects of hormone therapy. 
Purpose 
Several questions remain with respect to the appropriate type, intensity, duration, and 
frequency of exercise. This study aims to evaluate the effectiveness of two types of 
exercise, namely resistance training and aerobic exercise (e.g. walking, jogging, walking 
briskly), compared to standard care for patients undergoing hormone therapy for prostate 
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cancer. This study has a randomized controlled trial design in which 3 groups are 
compared: resistance exercise, aerobic exercise, and patients undergoing standard care 
(i.e. wait-list controls). Randomized means that the group you will be assigned to will be 
decided by chance, neither you nor the study doctor can choose which study group you 
will join. The patients in the standard care group will receive exercise information but no 
specific exercise instruction. 
Study Visits and Procedures 
We are recruiting 60 prostate cancer patients to take part in this study that will last 24-30 
months. Should you agree to participate, you will be required to complete questionnaires, 
fitness and body composition assessments, and provide blood samples at 4 time points 
(baseline, at 12 weeks, and at 24 weeks). 
Screening: The first study visit will be a screening visit and this will occur after your 
doctor explains this study to you (this may take place over the phone). You may contact 
the study coordinator immediately to discuss the study or the study coordinator may 
contact you if you tell your doctor you wish to participate. This screening visit will 
involve questions to help determine whether you can take part in this study. 
Participation: Should you decide to participate, the study coordinator will schedule a 
time to conduct the baseline assessment. If you choose not to participate, we would ask 
you for your permission to collect information about your reason(s) for refusal. Refusing 
to be in the study will not affect your care in anyway. 
Procedures: The study team needs to find out about your prostate cancer and your health 
history so they can see how well the exercise programs work. A baseline fitness 
assessment will be scheduled at the time of your screening visit to review your current 
levels of fitness and health. We will try to schedule these visits on the same dates as your 
other clinic appointments. You may be excluded from the study if your fitness level is 
found to be low. 
The fitness assessments will be conducted by a certified exercise physiologist in a study 
office. The remaining questionnaires will be answered independently and will be mailed 
to the study centre (postage provided) or returned during clinic visits with your doctor. 
All information gathered during the assessments will be kept strictly confidential. 
The measurements included in this study are: 
Prostate Specific Quality of Life Questionnaires ( 5 min) 
Fatigue Questionnaire (5 min) 
Anxiety and Depression Questionnaire ( 10 min) 
Body Composition (height, weight, waist girth, & skinfolds) (10 min) 
Treadmill Test (15 min) 
A Grip Strength Test (5 min) 
10 ml blood sample (10 min) 
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Sample Questions: The type of questions you will be answering in the questionnaires: 
• Please rate how often you experience a lack of energy 
• Please rate your level of urinary frequency and urgency 
• Using a list of descriptive statements, please describe the communication between 
yourself and your doctor. 
• How often have worrying thoughts on your mind? 
This baseline assessment will require you to complete a package of 5 questionnaires 
assessing prostate cancer and treatment related symptoms, a brief body composition 
assessment, a fitness test (treadmill walking test and/or step test), and a grip strength test. 
This visit will last approximately 60 minutes. 
Semi-Structured Interview 
To further understand your experience within this trial, we will be conducting a semi-
structured telephone interview with you. During this interview you will be asked about 
your preference for your assigned group, factors that affected your participation and 
adherence, and your general experiences throughout the exercise program. The interview 
will be conducted at end of24 weeks. The interview will take approximately 20-30 
minutes. 
Randomization: After your first assessment, you will be grouped into a resistance 
training exercise program or an aerobic exercise program for 24 weeks. 
Exercise Program: Participants in the resistance and aerobic exercise groups will have a 
personalized, moderate intensity exercise program to be completed 3-5 times per week, 
for 60 minutes. Each exercise program is individually tailored to your current fitness 
level based on the fitness assessment. All exercise equipment will be provided to you free 
of charge, with no requirements to return any equipment at the end of the study. 
Participants in the exercise groups will receive instruction and demonstration of the 
exercises, intensity monitoring, completion of logbooks, and safety measures during 
exercise. 
Booster Sessions: You will be required to attend 90 minute group-based 'booster 
sessions' every 2 weeks. Booster sessions include 60 minutes of group-based exercise 
and 30 minutes of group-based discussion to address motivation, barriers, and other 
issues related to your exercise program. 
Follow-up Visits: You will be required to return to the study centre at the hospital 3 
additional times after the baseline visit to complete the same measures as in your baseline 
visit. Your first follow-up visit will occur 12 weeks into the exercise program, the second 
visit will occur at the end of the exercise program (24 weeks), and the third visit will 
occur 24 weeks after the end of your exercise program. 
Reminders: 
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• You should not conduct heavy physical activity on the day of your assessment 
• You should not drink a caffeinated beverage before your visit 
• You should not smoke before your visit 
• You should not eat within 2 hours of your visit 
• Tell your study team about anything that worries you 
• Tell your study team about any changes to your treatments or medications 
• Tell your study team if you change your mind about being in the study 
• Ask your study team any questions related to the study and/or exercise program 
Risks 
The risks of experiencing a cardiac incident (heart attack, chest pain, etc.) involved in 
completing the physical assessments, questionnaires, and exercise program are extremely 
minimal (approximately 1/20000 or 0.00005%). All physical assessments will be 
conducted by a certified exercise physiologist using standardized protocols and clean 
equipment. 
The fitness programs employed in this study are within the guidelines of recommended 
exercise frequency, duration, and intensity during prostate cancer and treatment, and have 
been used in previous studies. You will receive an information and education session on 
the appropriate exercise technique, intensity monitoring practice, and safety guidelines 
for your exercise program. You will be contacted by the exercise physiologist on a 
monthly basis to ensure that your program is being successfully maintained and so that 
any limitations, barriers, or problems may be addressed. 
You will also be responding to questionnaires that have been used in numerous studies. 
There are minimal risks associated with answering these questions. You may refuse to 
answer any questions that you do not feel comfortable with. 
Possible side effects of drawing blood include: faintness, inflammation of the vein, pain, 
bruising, or bleeding at the site of puncture. There is also a slight possibility of infection. 
A second attempt may be necessary to obtain blood if enough was not obtained the first 
time. 
Skinfold measurements to assess body fat percentage have minimal risks. You may 
experience slight discomfort (like a pinch) while the skinfold is being measured. 
Benefits 
You may or may not receive any medical benefit from your participation in this study, 
although previous studies have shown some benefit for prostate cancer patients 
undergoing exercise treatment. Also, you may be interested in an exercise test to rate 
your own fitness level and body composition which may be an incentive for participation. 
This information will be provided to you. Additionally, information learned from this 
study may benefit other patients who are facing similar circumstances to your own. 
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Confidentiality 
If you agree to join this study, the study doctor and his/her study team will look at your 
personal health information and collect only the information they need for the study. 
Personal health information is any information that could be used to identify you and 
includes your: 
• name, address, date of birth 
• new or existing medical records, that includes types, dates and results of medical 
tests or procedures. 
The information that is collected for the study will be kept in a locked and secure area by 
the study doctor for 7 years. Only the study team or the people or groups listed in this 
document will be allowed to look at your records. Your participation in this study also 
may be recorded in your medical record at this hospital. 
Representatives of the University Health Network Research Ethics Board may look at the 
study records and at your personal health information to check that the information 
collected for the study is correct and to make sure the study followed proper laws and 
guidelines. 
All information collected during this study, including your personal health information, 
will be kept confidential and will not be shared with anyone outside the study unless 
required by law. You will not be named in any reports, publications, or presentations that 
may come from this study. 
If you decide to leave the study, the information about you that was collected before you 
left the study will still be used. No new information will be collected without your 
perm1ss1on. 
Presentation of Study Results 
The final study research paper will be written without the use of any identifiable 
information to maintain the anonymity and confidentiality of the participants. Any 
publications (e.g. academic journals or media) arising from this study will also maintain 
the anonymity and confidentiality of the participants. 
Participation 
Your decision to participate is voluntary. You may decide not to be in this study, or to be 
in the study now, and then change your mind later. You may leave the study at any time 
without affecting your care. If you decide to participate, you can refuse to answer any 
questions you do not want to answer, or not answer and questionnaire question by saying 
"pass". 
We will give you new information that is learned during the study that might affect your 
decision to stay in the study. You may also have access to the exercise physiologist if you 
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have any questions or concerns about your current physical activity and exercise 
programs. 
This research study has been reviewed and approved for compliance with research ethics 
protocols by the Human Participants Review Subcommittee (HPRC) of York University 
and the Research Ethics Board at The University Health Network. 
In Case You are Harmed in the Study (Compensation for Injury) 
If you become ill or are physically injured as a result of participation in this study, 
medical treatment will be provided. The reasonable costs of such treatment will be 
covered by your health insurance for any injury or illness that is directly a result of 
participation in this study. In no way does signing this consent form waive your legal 
rights nor does it relieve the investigators, sponsors, or involved institutions from their 
legal and professional responsibilities. You do not give up any of your legal rights by 
signing this consent form. 
Expenses Associated with Participating in the Study 
You will not have to pay for any of the procedures or exercise equipment/programming 
involved in this study. The exercise equipment that you will receive may remain with you 
permanently. You will not be reimbursed for any transportation, meals, time, or 
inconvenience related to this study, although we will try to schedule your visits you're 
your appointments to limit your trips to the hospital. 
Questions 
If you suffer any side effects or other injuries during the study, or you have general 
questions about the study, you may contact the Principal Investigators, Dr. Paul Ritvo at 
(416) 971-5100 extension 3203, Dr. Andrew Matthew at (416)-946-2332, or Daniel Santa 
Mina (Ph.D. candidate) at (416) 340-4800 extension 3957. 
If you have any questions about your rights as a research participant, please call the Chair 
of the University Health Network Ethics Board or the Research Ethics Office at ( 416) 
581-7849 or the Manager of the Office of Research Ethics at York University, 5th Floor, 
York Research Tower: (416) 736-5914. Contact with either of these offices will not affect 
your participation in this study. 
Consent 
I have had the opportunity to discuss this study and my questions have been answered to 
my satisfaction. I consent to take part in the study with the understanding that I may 
withdraw at any time without affecting my medical care. I have received a signed copy 
of this consent form. I voluntarily consent to participate in this study. 
Participant's Name (print) Participants Signature Date 
Name of person obtaining consent Signature Date 
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Appendix D: Reasons for Non-Participation Questionnaire 
We are interested in understanding the reasons why you decided not to participate in the study so that 
we can improve the study protocol and increase future participation. There may be many reasons why 
you decided not to participate in the study. Please share with me which of these reasons apply to you. 
1. You do not believe in participating in any research studies. 
Please explain: 
2. You are too tired/fatigued to participate. 
Please explain: 
3. The length of this study (12 weeks) is too long. 
Please explain: 
4. The number of assessments is too many. 
Please explain: 
5. The length of the assessments is too long. 
Please explain: 
6. You do not see any personal benefit from participating in this study. 
Please explain: 
7. You do not like to exercise. 
Please explain: 
8. You find it difficult to exercise. 
Please explain: 
9. Your physician (either family physician or leukemia doctor) 
discouraged you from participating in this study. 
Please explain: 
10. A family member or friend discouraged you from participating 
in this study. 
Please explain: 
11. Are there any other factors that influenced your decision not to 
participate in this study? 
Please explain: 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
Yes D No D 
12. Now that we have discussed the various reasons that may have contributed to your decision 
not to participate in this study, can you please tell me which of these reasons had the biggest 
influence on your decision to not participate in this study? 
Please explain: 
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Appendix E: Booster Session Outline 
Week 1: Maintaining an Active Lifestyle after Program Completion 
• Logbook 
• Plan of action 
Week 2: Exercise in General 
• Components of exercise 
• Exercise guidelines (current national guidelines) 
• FITT principle 
• Monitoring intensity 
• How to use the physical activity log: handout weekly activity log 
Week 3: Goal Setting 
• Specific, measurable, action, realistic, time: (SMART) 
• Goal setting guidelines 
• Planning for activity 
• Set goals 
Week 4: Behaviour Change 
• Steps to change behaviour: awareness, management, reinforcement 
• Steps in learning a new behaviour 
• Personal plan of action 
Week 5: Barriers & Relapse Prevention 
• Identifying barriers 
• Overcoming barriers 
• Dealing with relapse 
• Relapse planner 
Week 6: Social Support 
• Developing/maintaining support 
• Spouse or partner support 
• Children 
• Friends or neighbours 
Week 7: Monitoring Behaviour/Review 
• Review weekly logs 
• Check in on goals/discipline 
• Activity variety 
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Week 8: Maintaining Motivation 
• What is motivation? 
• What motivates you? 
• Who is a great motivator in your life? 
• How are you similar/different to that person? 
• How are you going to maintain motivation? 
• Motivation tools 
Week 9: Adapting your Fitness Program 
• Guidelines for assessing and designing programs 
• Review FITT 
• Safe exercise techniques 
• Common exercise concerns 
• Warm up and cool down tips 
Week 10: Personal Control 
• What is control? 
• Ways to maintain control 
• Ways to let go 
• Exercise control 
Week 11: Self-Reward/Discipline & Attitude 
• Self-esteem, self-talk, self-worth, positive attitude 
• Types of rewards 
• Principles of reinforcement 
• Self-reward 
Week 12: Home-based Exercise 
• At home exercising 
• How to maintain an at home exercise program 
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Appendix F: Functional Assessment of Cancer Therapy-Fatigue (FACT-F) 
By circling one (1) number per line, please indicate how true each statement 
has been for you during the past 7 days. 
ADDITIONAL CONCERNS Not A Some- Quite Very 
at all little what a bit much 
bit 
1. I feel fatigued. 0 1 2 3 4 
2. I feel weak all over. 0 1 2 3 4 
3. I feel listless ("washed out"). 0 1 2 3 4 
4. I feel tired. 0 1 2 3 4 
5. I have trouble starting things because I am 0 1 2 3 4 
tired. 
6. I have trouble finishing things because I 0 1 2 3 4 
am tired. 
7. I have energy. 0 1 2 3 4 
8. I am able to do my usual activities. 0 1 2 3 4 
9. I need to sleep during the day. 0 1 2 3 4 
10. I am too tired to eat. 0 1 2 3 4 
11. I need help doing my usual activities. 0 1 2 3 4 
12. I am frustrated by being too tired to do 0 1 2 3 4 
the things I want to do. 
13. I have to limit my social activity because 0 1 2 3 4 
I am tired. 
* These items comprise the 13-item fatigue scale 
261 
Appendix G: Functional Assessment of Cancer Therapy - Prostate (FACT-P) 
Below is a list of statements that other people with your illness have said are 
important. By Circling One (1) number per line, please indicate how true each 
statement has been for you during the past 7 days. 
PHYSICAL WELL BEING Not A Somewhat Quite Very 
at all little a bit much 
bit 
1. I have a lack of energy. 0 1 2 3 4 
2. I have nausea. 0 1 2 3 4 
3. Because of my physical condition I have 0 1 2 3 4 
trouble meeting the needs of my family. 
4. I have pain. 0 1 2 3 4 
5. I am bothered by side effects of treatments. 0 1 2 3 4 
6. I feel ill 0 1 2 3 4 
7. I am forced to spend time in bed. 0 1 2 3 4 
SOCIAL/FAMILY WELL BEING Not A Somewhat Quite Very 
at all little a bit much 
bit 
1. I feel close to my friends. 0 1 2 3 4 
2. I get emotional support from my family. 0 1 2 3 4 
3. I get support from my friends. 0 1 2 3 4 
4. My family has accepted my illness. 0 1 2 3 4 
5. I am satisfied with family communication 0 1 2 3 4 
about my illness. 
6. I feel close to my partner (or the person who 0 1 2 3 4 
is my main support.) 
Regardless of your current level of sexual activity, 
please answer the following question. If you prefer 
not to answer it, please check this boxD and go to the 
next section. 
7. I am satisfied with my sex life. 0 1 2 3 4 
EMOTIONAL WELL BEING Not A Somewhat Quite Very 
at all little a bit much 
bit 
1. I feel sad. 0 1 2 3 4 
2. I am satisfied with how I am coping with 0 1 2 3 4 
my illness. 
3. I am losing hope in the fight against my 0 1 2 3 4 
illness. 
4. I feel nervous. 0 1 2 3 4 
5. I worry about dying. 0 1 2 3 4 
6. I worry that my condition will get worse. 0 1 2 3 4 
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By Circling one (1) number per line, please indicate how true each statement 
has been for you during the past 7 days. 
FUNCTIONAL WELL BEING Not at A Somewhat Quite Very 
all little a bit much 
bit 
1. I am able to work (Include work at home). 0 1 2 3 4 
2. My work (Include work at home) is fulfilling. 0 1 2 3 4 
3. I am able to enjoy life. 0 1 2 3 4 
4. I have accepted my illness. 0 1 2 3 4 
5. I am sleeping well. 0 1 2 3 4 
6. I am enjoying the things I usually do for fun. 0 1 2 3 4 
7. I am content with the quality of my life right 0 1 2 3 4 
now. 
ADDITIONAL CONCERNS Not at A Somewhat Quite Very 
all little a bit much 
bit 
1. I am losing weight. 0 1 2 3 4 
2. I have a good appetite. 0 1 2 3 4 
3. I have aches and pains that bother me. 0 1 2 3 4 
4. I have certain parts of my body where I 0 1 2 3 4 
experience significant pain. 
5. My pain keeps me from doing things I want to 0 1 2 3 4 
do. 
6. I am satisfied with my present comfort level. 0 1 2 3 4 
7. I am able to feel like a man. 0 1 2 3 4 
8. I have trouble moving my bowels. 0 1 2 3 4 
9. I have difficulty urinating. 0 1 2 3 4 
10. I urinate more frequently than usual. 0 1 2 3 4 
11. My problems with urinating limit my activities. 0 1 2 3 4 
12. I am able to have and maintain an erection. 0 1 2 3 4 
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Appendix H: Prostate Outcomes Record of Psychometric and Utility Self-Report 
(PO RP US) 
Please circle the statement that comes closest to describing you in the last two weeks. 
I. Pain and Disturbing Body Sensations (e.g. hot flashes, painful swelling of breasts, 
nausea) 
1. No pain and no disturbing body sensations. 
2. Mild pain or disturbing body sensations that do not limit any activities (e.g. work, 
social, sexual, sleep). 
3. Moderate pain or disturbing body sensations that limit a few activities. 
4. Moderate to severe pain or disturbing body sensations that limit some activities. 
5. Severe pain or disturbing body sensations that limit many activities. 
II. Energy 
1. Very full of energy, lots of pep. 
2. Fairly energetic, no limitation of activities (for example: work, social, sexual). 
3. Moderate reduction in energy or pep that limits a few activities. 
4. Generally low energy or pep that limits some activities. 
5. No energy or pep at all. I feel drained, and many activities are limited. 
III. Support From Family and Friends 
1. Most of the time feel supported by my spouse, family and friends. 
2. A fair amount of the time feel supported by my spouse, family and friends. 
3. Occasionally feel supported by my spouse, family and friends. 
4. Rarely feel supported by my spouse, family, and friends. 
IV. Communication With Doctor (primary caregiver for prostate cancer, may be 
specialist or family doctor) Please check the statement that comes closest to describing 
you in the last two scheduled appointments 
1. Always able to express my concerns to my Doctor and get all the information or advice 
I need. 
2. Most the time, able to express my concerns to my Doctor and get all the information or 
advice I need. 
3. Some of the time, able to express my concerns to my Doctor and get all the 
information or advice I need. 
4. Rarely able to express my concerns to my Doctor and get all the information or advice 
I need. 
Please circle the statement that comes closest to describing you in the last two weeks. 
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V. Emotional Wellbeing 
1. Generally happy and free from worry, sadness, or frustration. 
2. A little worry, sadness, or frustration. 
3. Moderate worry, sadness, or frustration. 
4. Quite a bit of worry, sadness, or frustration. 
5. Extreme worry, sadness, or frustration. 
VI. Urinary Frequency (need to pass urine frequently during the day or night) and 
Urgency (difficulty delaying urination after the urge is felt to urinate, ability to "hold it") 
1. No urinary frequency or urgency. 
2. A little urinary frequency or urgency does not interfere with sleep or other activities 
(for example: work, social); no need to plan ahead. 
3. Some urinary frequency or urgency interferes with sleep or other activities; may need 
to plan ahead. 
4. Quite a bit of urinary frequency or urgency; need to be near a bathroom most of the 
time. 
5. Extreme urinary frequency or urgency; need to be near a bathroom always. 
VII. Leaking Urine/ Poor Bladder Control 
I. Never, under any circumstances leak urine or lose bladder control. 
2. On rare occasions, leak urine or lose bladder control, does not interfere with any 
activities (for example: work, social, sexual, sleep). 
3. Occasionally leak urine or lose bladder control, interferes with a few activities. 
4. A moderate amount of the time, leak urine or lose bladder control, interferes with some 
activities. 
5. Most of the time, leak urine or have poor bladder control, interferes with many 
activities. 
6. Require a clamp, catheter, or collecting bag because of leaking urine or poor bladder 
control. 
VIII. Sexual Function (problems with achieving I maintaining an erection) 
1. Full erections sufficient for intercourse. 
2. Erections sufficient for intercourse, but some reduction in firmness. 
3. Erections sufficient for masturbation or foreplay only. 
4. Erections, but not firm enough for any sexual activity. 
5. No erections at all. 
Please circle the statement that comes closest to describing you in the last two weeks. 
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IX. Sexual Interest I Drive 
1. Normal amount of sexual drive and interest for you. 
2. A little decrease of sexual drive or interest for you. 
3. Moderate decrease of sexual drive or interest for you. 
4. Substantial decrease of sexual drive or interest for you. 
5. No sexual drive or interest. 
X. Bowel problems: diarrhea, rectal discomfort (pain, burning or irritation) or 
constipation. 
1. No diarrhea, rectal discomfort, or constipation. 
2. Occasionally have diarrhea, rectal discomfort, or constipation. 
3. Frequently have diarrhea, rectal discomfort, or constipation 
4. Nearly always have diarrhea, rectal discomfort, or constipation. 
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Appendix I: Godin Leisure Time Exercise Questionnaire (GL TEQ) 
For this next question, we would like you to recall your average weekly 
exercise over the past month. How many times per week on average did you 
do the following kinds of exercise over the past month? 
When answering these questions please: 
• Consider your average over the past month. 
• Only count exercise sessions that lasted 15 minutes or longer in duration. 
• Only count exercise that was done during free time (i.e., not occupation or 
housework). 
• Note that the main difference between the three categories is the intensity of 
the exercise. 
• Please write the times per weekly on the first line and the average duration on 
the second line. 
a. STRENUOUS EXERCISE 
(LE.HEART BEATS RAPIDLY, SWEATING) 
(e.g., running, jogging, hockey, soccer, squash, cross country skiing, judo, roller 
skating, vigorous swimming, vig9rous long distance bicycling, vigorous aerobic 
dance classes, heavy weight training) 
___ Times/week Avg. Duration (minutes) 
b. MODERATE EXERCISE 
(NOT EXHAUSTING, LIGHT SWEATING) 
(e.g., fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy 
swimming, alpine skiing, popular and folk dancing. 
Times/week 
-----
_____ Avg. Duration (minutes) 
c. MILD EXERCISE 
(MINIMAL EFFORT, NO SWEATING) 
(e.g., easy walking, yoga, archery, fishing, bowling, lawn bowling, shuffleboard, 
horseshoes, golf, 
snowmobiling) 
_____ Times/week _____ Avg. Duration (minutes) 
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Appendix J: Modified Exercise Induced Feeling Inventory-Chronic (mEIFI-C) 
Thinking back over the past week, please describe how much you 
experienced the following feelings during physical activity/exercise, using the 
scale provided (none of the time ~ all of the time): 
Feeling None of A little of Some of A good Most of All of the 
the time the time the time bit of the the time time 
time 
1 Refreshed 0 2 3 4 5 
2 Calm 0 2 3 4 5 
3 Fatigued 0 2 3 4 5 
4 Enthusiastic 0 l 2 3 4 5 
5 Relaxed 0 1 2 3 4 5 
6 Energetic 0 2 3 4 5 
7 Happy 0 2 3 4 5 
8 Tired 0 2 3 4 5 
9 Revived 0 2 3 4 5 
10 Peaceful 0 1 2 3 4 5 
11 Worn-out 0 1 2 3 4 5 
12 Upbeat 0 2 3 4 5 
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Appendix K: Self-Efficacy for Physical Activity Survey (SEP AS) 
Whether you exercise or not, please rate how I know Maybe I know Does 
confident you are that you could really I I I Not 
motivate yourself to do things like these Cannot Can Can Apply 
consistently,for at least 6 months 
(1) (2) (3) (4) (5) (6) 
1. Get up early, even on weekends to 1 2 3 4 5 6 
exercise. 
2. Stick to your exercise program after a 1 2 3 4 5 6 
long, tiring day. 
3. Exercise even though you are feeling 1 2 3 4 5 6 
de2ressed. 
4. Set aside time for a physical activity 1 2 3 4 5 6 
program; such as, walking, swimming, 
biking, resistance training or other 
continuous activities for at least 30 
minutes, 3 times Qer week. 
5. Continue to exercise with others even 1 2 3 4 5 6 
though they seem too fast or too slow for 
OU. 
6. Stick to your exercise with others even 1 2 3 4 5 6 
though they seem too fast or too slow for 
OU. 
7. Attend a Qarty only after exercising 1 2 3 4 5 6 
8. Stick to your exercise program when 1 2 3 4 5 6 
your family is demanding more time 
from you. 
9. Stick to your exercise program when 1 2 3 4 5 6 
you have household chores to do. 
10. Stick to your exercise program even 1 2 3 4 5 6 
when you have excess demands at work. 
11. Stick to your exercise program when 1 2 3 4 5 6 
social obligations are very time 
consuming. 
12. Read or study les in order to exercise 2 3 4 5 6 
more. 
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Appendix L: Social Support for Physical Activity Questionnaire (SSP AQ) 
Please indicate, by circling the appropriate number, whether your family has done or said the 
following: 
None Very 
Often 
Exercised with me 2 3 4 
2 Gave me encouragement to stick with my exercise 2 3 4 
program 
3 Changed their schedule so we could exercise together 2 3 4 
4 Offered to exercise with me 2 3 4 
5 Gave me helpful reminders to exercise 2 3 4 
6 Planned for exercise on recreational outings 2 3 4 
7 Discussed exercise with me 2 3 4 
8 Talked about how much they like to exercise 2 3 4 
9 Helped plan activities around my exercise 2 3 4 
10 Asked me for ideas on how they can get more exercise 2 3 4 
11 Took over chores so I had more time to exercise 2 3 4 
12 Made positive comments about my physical appearance 2 3 4 
13 Got angry at me for exercising 2 3 4 
14 Criticized me or made fun of me for exercising 2 3 4 
15 Gave me rewards for exercising 2 3 4 
Please indicate, by circling the appropriate number, whether your friend has done or said the 
following: 
None 
Exercised with me 2 3 4 
2 Offered to exercise with me 2 3 4 
3 Gave me helpful reminders to exercise 2 3 4 
4 Gave me encouragement to stick with my exercise program 2 3 4 
5 Changed their schedule so we could exercise together 2 3 4 
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5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
Very 
Often 
5 
5 
5 
5 
5 
Appendix M: Demographic Questionnaire 
ID# Today's date: __ 
Month Day Year 
Please provide the following information: 
(Please answer the question in the space provided or place a check in the appropriate 
box) 
1. Address: 
2. Telephone Number: 
(Home) _______ (Altemate) ______ _ 
3. E-mail: 
4. Your Date of Birth: 
Month Day Year 
5. Your Age: 
6. Your Ancestry/Ethnicity: 
D White/Caucasian 
D Black/ Afro-Caribbean/ African 
D Latino/Hispanic 
D Arabic (e.g. Lebanon, Palestine) 
D Ashkenazi Jewish 
D South Asian (e.g. India, Pakistan) 
D East Asian (e.g. China, Korea, Japan) 
D South East Asian (e.g. Philippines, Vietnam) 
Other: Please Specify: __________ _ 
7. What is your annual household income? 
D less than $40,000 
D $40,000-$80,000 
D more than $80,000 
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8. What is your current marital status? 
D Single (never married) 
D Married (including common law) 
D Widowed 
D Separated 
D Divorced 
9. What is your highest level of education? 
D Less than high school 
D High school graduate 
D Community college/ trade school graduate 
D University graduate 
D Graduate university degree 
D Other 
~~~~~~~~-
9. Are you now working? 
D No, retired 
D No, but looking for job 
D Yes, part-time 
D Yes, Full-time 
10. Do you currently smoke cigarettes? 
D No 
D Yes (Please specify frequency: __ /day) 
11. Are you presently taking any medication? 
D No 
D Yes (Please specify type and dose) 
12. When were you first diagnosed with prostate cancer? I 
(month) (year) 
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13. What treatment(s) did you receive? (Please check all that apply) 
D Radical Prostatectomy (Surgery) 
D Radiation Therapy I Brachytherapy 
D Hormone Therapy 
D Watchful waiting 
D Other: (Please specify) 
14. What is your current hormone therapy treatment regimen? 
(Please check as many as apply) 
Medication(s) ________ frequency: ____ ; planned duration: __ _ 
Medication(s) ________ frequency: ____ ; planned duration: __ _ 
Thank you for completing this questionnaire. 
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Appendix N: Semi-Structured Qualitative Interview 
Goal: To develop an improved exercise program and to get a representation of participant 
experiences and perspectives. Specifically, we want to know about their: a) level and reasons for 
adherence (or non-adherence); b) their general enjoyment/satisfaction with the program (i.e. 
strengths and weaknesses); and c) the benefits/setbacks associated with the program. ALWAYS 
ASK IF THERE IS ANYTHING ELSE YOU WANT TO ADD. 
Survey Questions (short answer; yes/no): 
• Were you assigned to resistance exercise training or aerobic exercise training? 
• Was this your preference? Please explain why. 
• On average, how many days per week did you exercise (frequency)? (days/week) 
• On average, how intense (hard) did you exercise on a scale of 0-10 (to being maximal 
effort)? 
• On average, how long were your exercise sessions? (minutes) 
• Depending on what exercise program you were assigned to, did you or did you not add 
other forms of exercise? (If yes, what did you do? why did you take up other forms of 
exercise?) 
"Now I want to ask you about your adherence or compliance to the exercise program" 
• We know that people exercise for many different reasons. Can you tell us why you like to 
exercise? 
• Some things make exercise easy to do. 
o What helped you to exercise using our exercise program (adherence)? 
• Some things make exercise difficult to do. What prevented you from exercising in our 
program? 
• Group-based exercise classes can be useful for teaching exercise, and improving 
motivation and adherence. 
o Did you attend the group-based booster sessions? Why/why not? 
o What would make you more likely to attend a booster session? Or Continue 
attending? 
• The benefits of exercise are only maintained with consistent/routine exercise. As a 
program, how can we support adherence to exercise? (I.e. what would you suggest we do 
to keep people exercising?) 
• Are you continuing to exercise? What has helped you continue to exercise after the 
program? 
• Do you intend to keep exercising? Please explain why? How? 
"Now I want to ask you about the strengths and weaknesses of the exercise 
program" 
• As a new program offered at the Prostate Centre, we are continually trying to improve the 
patient experience. The exercise program is a new component of the Prostate Centre and 
we would like your feedback on how to improve the program. 
• Can you identify some strengths and weaknesses of the program for promoting and 
maintaining exercise. (Allow for respondent to provide answers, then use the prompts 
below). 
o Location/office setting? (professional? Appropriate?) 
o Convenience (home-exercise, facility-based boosters, equipment, manual, staff) 
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o Did you understand the manual (did you read it? Was it helpful? Use the 
logbook? How often did you refer to the manual?) 
o E-mails/ calls (did you prefer emails or telephone calls? Frequency? Timing?) 
o Exercise technique (did you feel prepared to conduct your exercises? Were you 
comfortable increasing the intensity on your own? Did you have enough support 
from the manual/staff to address any concerns?) 
o Booster sessions (did you like the format? How would you improve?) 
• If you were to design the program ... 
o What would you do to make it better? 
o What did you not like? 
"Now I want to ask you about some of the outcomes of the study, in terms of any 
benefits or setbacks that you may have experienced" 
• How do you feel physically after participating in the exercise program? (strength 
changes, body weight? Body image? Fat? Energy? Endurance?, etc.) 
• How do you feel mentally after participating in the exercise program? (attention, mental 
clarity, etc.) 
• How do you feel emotionally after participating in the exercise program? 
(positive/negative mood, anxiety, depression, happiness, sadness) 
• How would you compare your overall quality of life from the beginning to the end of the 
exercise program? 
How has your lifestyle changed as a result of participating in this program? (has your diet 
changed? More time outdoors? More/ease-of daily activity? Sleeping habits? 
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